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ABSTRACT
The main objective of this thesis was to estimate the sensitivity and 
specificity of four screening tests: visual inspection after the application of 
acetic acid (VIA), VIA_M: combined VIA and VIAM (magnified VIA 
using an AviScope™ performed by a doctor), liquid-based cytology (LBC 
using the AutoCyte-Prep® manual system) and HPV testing (using Hybrid 
Capture H); to detect histologically confirmed high-grade squamous intra- 
epithelial lesions (HSIL). Participants of the “Tamizaje y Tratamiento 
Inmediato de lesiones cervico-uterinas” (TATI) project, who signed an 
informed consent for additional cervical samples, were included in this 
study. Separate cervical samples for conventional cytology (CC), LBC and 
Hybrid Capture II (HC-II), were collected by a midwife before applying 
acetic acid (5%) to the cervix and performing VIA. Women testing positive 
on VIA were referred to VIAM performed by a doctor who confirmed the 
midwife diagnosis, and treated lesions with cryotherapy if appropriate, or 
referred women to colposcopy. Negative women on VIA_M; underwent 
colposcopy if  they had HSIL on CC or LBC; or had second screening if 
they had any lesser abnormality on LBC or were positive only on HC-II. 
Of 5565 participants, 104 had histologically confirmed HSIL and an 
estimated 112 had undetected/unconfirmed HSIL. Sensitivities of VIA, 
VIA_M, LBC (any abnormality), LBC (high-grade abnormality) and HC-II 
were 44% (95% confidence interval (Cl): 34,59), 31% (Cl: 20,50), 69% 
(Cl: 61,78), 35% (Cl: 23,56) and 72% (Cl: 65,79), respectively. VIA had 
the lowest specificity among all tests: 77% (Cl: 74,77). LBC ^ISIL had the 
highest PPV: 44% (Cl: 34,53). HC-II was more sensitive than the other 
tests in our study. LBC3ISIL was more specific than the other tests. VIA 
had low sensitivity and specificity. VIA could still be an option for 
developing countries if implemented with regular quality assurance.
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GLOSSARY
AAIR: Age-adjusted incidence rate.
ASCUS: Atypical squamous cells of undetermined significance.
AGUS: Atypical glandular cells of undetermined significance.
Cl: 95% Confidence Interval.
CIN: Cervical intraepithelial neoplasia.
CR: Cumulative rate up to age 74.
C.S.: Centro de Salud. Health centre.
DIRES: Direccion Regional de Salud San Martin. Health Directive Office 
of the San Martin region of Peru.
HPV: Human papillomavirus
H.R.: Hospital Rural. Rural hospital.
HSIL: High-grade squamous intraepithelial lesion.
INEN: Instituto de Enfermedades Neoplasicas. Cancer hospital in Lima.
LEEP: Loop electrosurgical excision procedure, sometimes used as 
LLETZ: Large loop electrosurgical excision of the transformation zone.
LBC: Liquid-based cytology
LSIL: Low-grade squamous intraepithelial lesion.
NICE: National Institute for Clinical Excellence.
PPV: Positive predictive value.
P.S.: Puesto de salud. Health post (small health centre).
RLU: Relative lights units.
SIL: Squamous intraepithelial neoplasia.
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VIA: Visual inspection of the cervix after the application of acetic acid 
(nominally 5%).
VIAM: Magnified VIA or aided VIA using a magnification device.
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1. INTRODUCTION
Cervical cancer is the second most common cancer among women 
worldwide \  with almost half a million new cases and quarter of a million 
deaths each year l . The aetiology of cervical cancer is not fully understood 
but it is now accepted that Human Papillomavirus (HPV), most frequently 
HPV 16, is the most important etiological agent for cervical cancer 2. The 
overall prevalence of HPV infection was estimated as 99.7% among 
cervical cancers worldwide, this gave HPV the highest attributable fraction 
ever identified for a specific cause of a major human cancer3.
In terms of cervical cancer control, it has been well established that 
organised cytology screening programmes can substantially reduce the 
incidence and mortality from cervical carcinoma in developed countries. 
However, such programmes have not been successful in developing 
countries.
Study setting
The study is based in Peru, a country well suited to study cervical cancer 
and its control. Cervical cancer is the most common cancer among women 
in Peru, as reported by the only two cancer registries in the country: 
Trujillo and Lima. The incidence rate (age-standardise rate per 105 women) 
of cervical cancer for women in Trujillo was of 53.5 for the period 1988- 
90, while in Lima, it was 26.1 between 1990-1991 4. Data on cervical 
cancer aetiology in Peru are consistent with studies elsewhere. In a case- 
control study in Peru, the prevalence of HPV infection among cases was 
94.9% and 17.7% among controls, indicating that HPV is the most 
important and probably a necessary cause of cervical cancer among 
Peruvian women 5. Several attempts to establish a national screening 
programme in Peru have failed, but in 1998 the Ministry of Health 
formulated a National Plan for Gynaecological Cancer Prevention: Cervix 
and Breast and in 1999 declared cervical cancer a national priority.
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Peru has special geographic characteristics. It is composed of three marked 
regions: coastal desert, mountains (the Andes) and rainforest (Amazon 
jungle), with extremely diverse climates, altitudes and cultures. These 
characteristics make the country propitious for research on cancer risk 
factors since life-styles and accessibility to health and other facilities differ 
greatly but at the same time a real challenge to establish any national 
screening programme.
Rationale fo r  this study
Given the prominence of cervical cancer for women’s health worldwide 
and in Peru, it is crucial to investigate strategies to control this disease. 
Screening has been found to be effective in western countries but much 
less so in developing countries. This project seeks to fill this gap. This 
study intends to evaluate the effectiveness of four different screening 
techniques, or a combination of them, in a province of the Amazonia of 
Peru. These techniques are (i) unaided visual inspection of the cervix after 
application of 5% acetic acid (VIA), (ii) a combination (VIA_M) of 
unaided VIA with aided visual inspection using a magnification device 
(VIAM), (iii) HPV DNA testing using Hybrid Capture II (HC-II), and 
liquid-based cytology (LBC) using the AutoCyte-Prep® manual system. 
The study is nested within a larger project called “Tamizaje y Tratamiento 
Inmediato de Lesiones Cervico-uterinas” (TATI), which aims to screen 
80% of women in the region over three years. The success of the TATI 
intervention will be measured in terms of the number of women with 
successfully treated histologically confirmed high-grade disease.
Structure o f  the thesis
The next chapter of this thesis presents the background to the problem of 
cervical screening and the suggested strategy for its solution. It is divided 
upon three parts. The first part presents a brief description of the cervix and 
its clinical features, a short introduction into cervical cancer precursors and
19
invasive cancer, some epidemiological facts, risk factors starting with 
human papillomavirus infection (HPV) and its relationship to cervical 
neoplasia. The second part deals with prevention and control of cervical 
cancer. Screening is defined and the three screening tests used in this 
project are reviewed. The potential for new preventive and therapeutical 
cervical cancer vaccines is introduced. The last part of the chapter 
describes the problem of cervical cancer in Peru, i.e. the rates of disease 
and the efforts to control the burden of cervical cancer in the country. It 
also gives details of the “Tamizaje y Tratamiento Inmediato de Lesiones 
Cervico-uterinas” (TATI) project with which the current project is 
associated.
The third chapter presents the aim, the objectives and the hypothesis of the 
project. The objectives are divided in main and secondary objectives. As 
mentioned above, the aim of the project was to evaluate the sensitivity, 
specificity, acceptability and feasibility of various combinations of the 
screening techniques.
The fourth chapter describes the methodology. It presents the design of the 
study, divided into two parts, the statistical analysis and briefly the ethical 
considerations. In the first part, the details of screening procedures are 
listed and clinical management of VIA or VIAM positive women is 
explained. The second part deals with follow-up of initial screening and the 
management of untreated women who tested positive on HC-II or LBC. 
Laboratory techniques, sample handling and data management are also 
summarised. The statistical analysis starts with the definition of disease 
status. The statistical methods are then divided in descriptive statistics, 
estimation of missing screening test results, and estimation of sensitivity 
and specificity of screening tests or of combinations of them. Multinomial 
logistic modelling was used to estimate incomplete information regarding 
screening tests. Empirical imputation and logistic regression modelling 
were used to estimate disease status among those women who were not 
fully evaluated and weighted measures of efficacy were estimated.
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Bootstrapping was used to estimate 95% confidence intervals (Cl). Finally, 
sample size considerations and ethical considerations are addressed.
The fifth chapter presents the results. First, the numbers of women and the 
inclusion/exclusion criteria are presented. Demographic data such as age, 
education and screening centre distributions are tabulated. Reproductive 
and sexual factors are summarised and data on previous cytology are 
presented. Positivity rates of screening tests are also presented. Women are 
grouped into 6 different clinical management strata, which are summarised 
in six flowcharts. The number of women receiving different treatments, 
and their histology results are also summarised. Finally, estimates of 
sensitivity, specificity and positive predictive value, together with 95% Cl 
are tabulated.
The fifth chapter is dedicated to discussion of the design and the results of 
the study. Topics covered include: participants, health providers and 
screening techniques used; the advantages and problems encountered with 
each screening test, and their positivity rates are compared to those of 
similar studies. Before examining sensitivity and specificity of each 
screening test and of some combinations of tests, the histology results 
obtained during the study are evaluated; a correspondent quality 
assessment is summarised. Then, the advantages of using a special 
information system and a basic cost-analysis are presented. Finally, but no 
less important, the future of cervical screening and the evaluation of new 
techniques, in Peru and worldwide are presented.
The seventh chapter presents the conclusions and recommendations based 
on the thesis.
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2. BACKGROUND
2.1. Cervical cancer
2.1.1. Introduction
Cervical cancer is an important public health problem worldwide. It is the 
second most common cancer among women, ranking first in many 
developing countries Of 468,000 new cases and 233,000 deaths of 
invasive cervical cancer estimated for year 2000 6, 80% occur in less 
developed countries where it disproportionately affects poor women who 
are the least likely to receive effective treatment, and so very prone to die 
of the disease.
It has been shown that effective screening can prevent cervical cancer, by 
detecting preinvasive lesions, which can be treated before becoming 
cancer.
In most developed countries, well-organised screening programmes have 
succeeded in reducing incidence and mortality from cervical cancer. A 
clear example is Finland, where there has been a significant reduction in 
incidence of cervical cancer: age-adjusted incidence rates of cervical 
cancer (AAIR per 100,000 women) fell from 15 to 5 (67% reduction) from 
1961 to 1985 7.
Unfortunately, in developing countries, where most of the burden of 
cervical cancer is concentrated, screening for cervical cancer is mainly 
opportunistic. Very few cervical lesions are detected, and they are usually 
in advanced incurable stages 8. Women will not be informed of their results 
and detected lesions will not be treated 9,10.
2.1.2. Clinical Features
To understand the clinical features of cervical cancer, some basic 
knowledge about anatomy and physiology is necessary. The uterus is 
divided into two parts. The upper part, or body of the uterus is where a
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fetus grows. The cervix is the part of the uterus below the internal os. The 
cervix connects the body of the uterus to the vagina (birth canal). The part 
of the cervix closest to the uterus is called the endocervix. The part next to 
the vagina is the ectocervix or portio. The endocervix is lined with mucous 
columnar epithelium, the ectocervix, with squamous epithelium. The 
transition zone between the two: the squamocolumnar junction (SCJ) is 
the area that is predisposed to malignant change.
2.1.2.1. The transformation zone
The SCJ of the cervix is the point at which the endocervical columnar 
epithelium meets the ectocervical stratified squamous epithelium. This 
junction is not at a fixed point on the cervix throughout life.
Figure 2.1.2.1.1. Diagram of the uterus and cervix.
Fallopian
Tube
Uterine
Cavity
Squamoculumnar Junction 
(Transformation Zone)
Vagina
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At birth, the SCJ is said to be located at, or close to, the external os of the 
cervix. This point is often called the “original” SCJ. During puberty, 
because of ovarian hormonal production there is an increase in the size of 
both the corpus and cervix uterine. This leads to eversion of the cervix. As 
a consequence, the endocervical epithelium then lies on the vaginal portion 
of the cervix and is exposed to the acidic environment of the vagina. It 
seems to be mainly this stimulus that leads to squamous metaplasia, a 
physiologic process in which a series of cell changes culminate in 
replacement of the everted endocervical columnar epithelium into matured 
squamous epithelium. The zone where the change of epithelium has 
occurred is called the transformation zone (see Figure 2.1.2.1.1).
When ovarian hormonal stimulation decreases at menopause, the eversion 
of the cervix is reversed and the SCJ passes into the endocervical canal n .
As the majority of cervical cancers arise in this transformation zone,
cryotherapy, laser surgery or loop electrical excision (LEEP) over it are the
well-established treatment procedures when preinvasive lesions are found 
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2.1.3. Intra-epithelial precursors of cancers
It has been generally recognised and accepted that precursors lesions to 
invasive squamous cervical cancer, comprise a morphologic and biologic 
spectrum of changes, from mild, moderate and severe dysplasia to 
carcinoma in situ (CIS). These four non-invasive categories are part of a 
single neoplastic continuum and have been conventionally graded 
according to progressive epithelial differentiation or “atypia o f epithelial 
cells” and progressive involvement of the full thickness of the epithelium, 
from the basal layers in milder lesions, to the increasingly mature 
squamous cells as the mucosal surface is approached. Thus, in CIS, the full 
thickness of the epithelium is involved by undifferentiated cells, and 
indeed, any of these categories may coexist at different sites within the 
same cervix.
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Mild dysplasia is also called cervical intraepithelial neoplasia one (CIN I), 
terminology introduced by Richart in 1973 12, or as low-grade squamous 
intraepithelial (low-grade SIL) according to the Bethesda system 
developed in 1988 13 and reviewed recently 14. Table 2.1.3.1 presents the 
different terminology used for squamous cervical lesions.
The category low-grade SIL also includes the cytological diagnosis of 
koilocytotic atypia, which corresponds to cytological changes 
characteristic of infection with HPV 15.
Each of the preinvasive lesions has three options for further development: 
(i) regression, (ii) progression to the next higher step in the sequence of 
dysplasia until CIS, or (iii) development into invasive cancer. Several 
follow-up studies aiming to estimate rates of regression and progression 
have shown that the majority of low-grade lesions will regress to norm al15 
and that the worse the abnormalities, the higher the likelihood of 
progression into higher lesions or invasive cancer 16,17. Hence, the 
likelihood of development into invasive cancer is particularly high in 
severe dysplasia and CIS 18, and furthermore, 10 to 15% of untreated CIS 
will progress into invasive cancer within 3 to 5 years 19.
Table 2.1.3.1 Common classification of Cervical Squamous Neoplasia
CIN Scale BSCC Scale1 Bethesda system
Koilocytotic or 
condylomatous atypia
Koilocytotic or 
condylomatous atypia
Low-grade SIL 
including koilocytosis
CIN I Mild dysplasia Low-grade SIL
CIN II Moderate dysplasia High-grade SIL
CIN III
Severe dysplasia/ 
carcinoma in situ
High-grade SIL
Invasive cancer Invasive cancer Invasive cancer
1: Advocated by the British Society for Clinical Cytology
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2.1.4. Histopathology of invasive cervical cancer
There are three main histological types of cervical carcinomas: squamous, 
adeno- and adenosquamous carcinomas. The distribution of them has 
changed in recent years. In the past, between 85% and 90% of cervical 
carcinomas were squamous and most of the rest were adenocarcinomas. 
According to data from “Cancer Incidence in Five Continents Volume
90  i •VIII” , m well-screened populations the percentage of adenocarcinomas 
has increased up to 28%, while in areas with no screening programmes, 
squamous carcinomas still account for about 80% to 90% of all cervical 
cancers. Other histological types, such as melanomas, sarcomas, and 
metastasic tumours, are very rare.
Several studies have reported increasing incidence rates of cervical 
adenocarcinomas over time, especially in young women in the United 
States 21,22,23,24, England and Wales 25,26, Norway 27 and Sweden 28. 
Reasons for the increase are such as the increase in the prevalence of HPV 
infection and the improvement in screening, however, they are not definite
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Most epidemiological studies have focused on squamous carcinomas or 
have ignored histologic distinctions altogether n .
2.1.5. Descriptive Epidemiology
Cervical cancer is the second most frequent cancer in women all over the 
world, after cancer of the breast and the most common in developing 
countries \  When men and women are considered together, cancer of the 
cervix is the seventh most common cancer worldwide, after cancers of the 
lung, breast, colon/rectum, stomach, liver and prostate, accounting for an 
estimated 4.7% of all cancers.
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Table 2.1.6.1 Estimated number of cases and age standardised- 
incidence rates of cervical cancer by region of the world (2000).
Region
Cervical cancer 
New cases AAIR
Eastern Africa 30,206 44.3
Central America 21,596 40.3
The Caribbean 6,670 35.8
South America 49,025 30.9
Southern Africa 5,541 30.3
South Central Asia 151,297 26.5
Middle Africa 6,947 25.1
Western Africa 13,903 20.3
South Eastern Asia 39,648 18.3
Eastern Europe 35,482 16.8
Northern Africa 10,479 16.8
Western Europe 13,282 10.4
Southern Europe 10,116 10.2
Northern Europe 6,049 9.8
US/Canada 14,845 7.9
Australia/New Zealand 1,077 7.7
Eastern Asia 51,266 6.4
Western Asia (the Middle East) 3,458 4.8
World 470,606 16.1
AAIR = Age-adjusted incidence rates per 100,000 women.
Almost 80% of the cases of cervical cancer occur in developing countries. 
Incidence and mortality rates vary greatly within region of the world and 
within countries. Table 2.1.6.1 shows the number of new cases and the 
age-adjusted incidence rates per 100,000 women (AAIR) by region as 
estimated by GLOBOCAN 30 for the year 2000. The highest rates are 
observed in most of Africa, Latin America and South Central Asia.
27
Intermediate rates are observed South Eastern Asia, Northern Africa, and 
Eastern Europe, while the lowest rates are seen in the rest of Europe, the 
United States and Canada, Australia and New Zealand, Eastern Asia 
(mainly China) and the Middle East.
Table 2.1.6.2. shows the estimated incidence rates of some countries in 
Latin America and Africa. Haiti has the highest and most striking rate. 
Also Nicaragua and Bolivia have very high rates, and not much lower are 
those of most South American countries (AAIR over 30), higher than that 
of Romania (AAIR 31.5), ranking number one in Europe. The variation 
within Africa is also great, rates range from 61 in Tanzania to less than 7 in 
Tunisia.
Table 2.I.6.2. Incidence rates of cervical cancer in Latin America and 
Africa (2000)
Latin America Cervical cancer Africa Cervical Cancer
Country AAIR CR (%) Country AAIR CR (%)
Haiti 93.9 4.9 Tanzania 61.4 4.6
Nicaragua 61.1 4.3 Zimbabwe 52.1 3.5
Bolivia 58.1 4.1 Rwanda 48.1 3.7
Ecuador 44.2 3.1 Gabon 31.7 2.2
Costa Rica 40.6 1.7 South Africa 28.9 2.0
Peru 40.0 2.9 The Gambia 26.0 2.0
Colombia 32.9 2.4 Algeria 23.4 2.0
Brazil 31.3 2.2 Sudan 19.0 1.3
Cuba 23.9 1.7 Cameroon 16.6 1.2
Uruguay 13.9 1.1 Egypt 14.0 1.1
Puerto Rico 10.3 0.7 Tunisia 6.8 0.5
AAIR = age-adjusted incidence rates. CR = cumulative rate to age 74.
There is also a lot of variation of incidence rates of cervical cancer both 
within and between regions and within and between countries, shown by
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cancer registry reports. For instance, incidence rates among different ethnic 
groups in the United States vary from 7.3 (among white women) to 11.7 
(among black women). This variation has been explained by socio- 
economical and education levels within developed countries.
It has been suggested that variations in the prevalence of HPV could 
explain part of the between and within countries variation of cervical 
cancer. Also, social factors, sexual behaviour and the impact of screening 
programmes have been proposed as potential reasons, but consistent results 
have not been achieved.
2.1.6. Risk factors for cervical cancer
The relationship between sexual behaviour and cervical cancer was 
postulated for the first time in 1842, when it was observed that frequency 
of cervical cancer among virgins and nuns was low 31. Sexual transmitted 
diseases like Neisseria gonorrhoe, Trichomonas and Treponema species, 
Chlamydia and genital herpes, were then suggested as possible causes of 
cervical cancer but the main etiologic factor was yet to be discovered. Zur 
Hausen was the first to relate human papillomaviruses (HPV) to cervical 
cancer. Since then, evidence coming from several studies has established 
that high-risk HPV types are the main causal factor of cervical cancer.
2.1.7. Human Papillomavirus infection
The Human Papillomavirus (HPV), is a member of the papovirus group, 
which typically causes benign, regressive squamous cell papillomata in the 
skin or mucosa in a large number of animal species 33 including human 
beings.
Genital infection with HPV is one of the most common sexually 
transmitted diseases, its prevalence in young women ranging from 20% to 
46% in various countries 34>35j36>37>38j39
Studies in Zur Hausen’s laboratory were the first to relate HPV 6 and HPV 
11 to human genital warts 32,40 and HPV 16 to cervical cancer 41, but it was
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not until 1987 that Zur Hausen pointed out that HPV had a possible role in 
human genital cancer 42,43. Since then, more than 35 distinct types of HPV 
have been recognized to infect the genital tract44. Twenty or more of these 
HPV types are cancer associated. Types 16 and 18 are strongly associated 
with cervical cancer; types 31, 33, 35, 39, 45, 51, 52, 56, and 58 are 
associated with a moderate elevated risk; and others, most commonly 6 and 
11, are associated with genital warts, but not with cervical cancer 45.
The association of HPV infection and cervical cancer fulfils the criterion 
for causality proposed by Hill in 1965 46. In 1995, Walboomers et al 47 
using archival negative cervical smears of 18 women who were later 
diagnosed with cervical cancer; concluded that HPV infection was present 
(up to six years) before development of disease. This has been confirmed 
by similar archival smears studies 48, and nested case-control or cohort 
studies using serology in blood samples 49>50j51>52j53> Molecular studies 
have identified protein products of HPV early genes (E6, E7), which 
interact with growth-regulatory proteins of the human cell (p53, pRb), 
providing a possible mechanism for an HPV oncogenic effect 54,55. 
Multiple epidemiologic studies have shown that the association of genital 
HPV with cervical cancer is strong (HPV infection was present in over 
95% of cases) independent of other risk factors, and consistent in several 
countries Moreover, in 1999, Walboomers et al
reported that the HPV prevalence in cervical carcinomas was of 99.7% in a 
worldwide series 3,67. As a consequence, HPV is now widely recognised 
as the major causal factor of cervical cancer in the world.
HPV prevalence is age-dependent. Several studies have found a peak of 
infection before 25 years of age, and a decreasing prevalence afterwards 
68,69,70,71,72,73,74. However, a study by Cuzick et al 75 in women older than 
35 years of age, showed that the prevalence of infection increases again in 
women older than 50. This pattern has been also observed in two more 
recent studies, with a clear second peak of HPV infection in women, with 
normal cytology (or ASCUS), aged 45 or older. Lazcano et a l76 in Mexico 
and Herrero et a l 11 in Costa Rica; reported HPV prevalences in women
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aged 18-25 of 17% or 20%, respectively, which rapidly decline into 4 to 
5% in women 35-44 and start increasing again after 45 years of age. 
Possible explanations for this later infection peak include a cohort effect: 
longer exposure to HPV of these women when they were younger, or 
reactivation of latent HPV infections by reduction of immune surveillance 
or hormonal factors associated with older age.
Among sexually active asymptomatic women, 15% can have HPV 
infections, most of which are transient and will disappear spontaneously
*70  7 Q  o n  o r  Q i
and are not important , , , , . But recent evidence suggests that a 
subset of women will have persistent infections and therefore be at higher 
risk of developing cervical lesions. Median duration of persistence of 
infections varies between 8 to 14 months, depending on oncogenic types of 
HPV; 70% of infections will clear within one year, and less than 10% of 
women will continue to be infected after 2 years 82>83#84j85>86j87>88< Factors 
determining persistence of HPV infection have not been established yet, 
though older age (>30 years), use of oral contraceptives (> 2 years), high 
viral load (RLU: relative light units>10) and presence of an oncogenic type 
in the first specimen have been suggested as potential ones in different 
studies 81,80,89,85,90.
Case series from many areas of the world have established that a high 
proportion (approximately 50%) of cervical cancers and high-grade CIN 
lesions contain HPV-16 DNA 2. In a meta-analysis of longitudinal studies 
of unselected and low HPV prevalence populations, with follow-up for 
HSIL and cervical cancer in women tested for HPV antibodies, the authors 
estimated that vaccination against HPV 16 infection would prevent up to 
44% of cervical carcinoma 91.
2.I.7.I. Other risk factors
Both descriptive and analytic studies have demonstrated that cervical 
cancer predominantly affects women in lower social classes, as defined by 
levels of income and education. Several studies have tried to established 
relationships between cervical cancer and age at first sexual intercourse,
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lifetime number of sexual partners, sexual transmitted diseases (STDs), use 
of oral contraceptives, sexual behaviour of male partners, parity and 
smoking. Yet, to what extent, these are risk factors for cervical cancer, or 
are correlates of HPV infection, or are HPV cofactors operating only in the 
presence of the infection, or are independent risk factors is not entirely 
clear.
Recent studies have attempted to establish a role of Chlamydia 
Trachomatis infection as a cofactor of HPV on cervical carcinogenesis but 
still they have not shown consistent results 92, 93,94,95.
Latest reports from the IARC multicentric Cervical Cancer Study Group of 
a pooled-analysis of HPV DNA positive women of ten case-control studies 
(8 on invasive cervical cancer and 2 on in-situ carcinoma) done in Thailand 
60, the Philippines 61, Morocco 62, Brazil 63, Peru 5, Paraguay 64, Colombia 
and Spain 65,66, conclude that long-term use (5 years or more) of oral 
contraceptives 96 and high parity 97 increase the risk of cervical cancer, 
independently, after restricting analysis to HPV positive women. Women 
taking oral contraceptives for more than 5 years were 1.5 times more at 
risk than those not using them (Odds Ratio, OR: 4.01, Cl: 2.01-8.02), and 
the risk doubles after 10 years of use (OR: 2.82, Cl: 1.46-5.42 for 5-9 
years, OR: 4.03, Cl: 2.09-4.82 for 10 years or more), so the longer the use 
the higher the risk, and those who stop taking oral contraceptives at least 6 
years before the study had risks almost similar to never users. These 
suggest that the risk and benefits from oral contraceptives, especially on 
women from countries with high incidence, needs to be re-evaluated. 
Treating the relative risk as a floating absolute risk to estimate CIs, 
nulliparous women were at less risk of squamous-cell carcinoma than 
parous ones, and the risk is increased with increasing number of full-term 
pregnancies; odds ratios of 3.8 (Cl: 2.7-5.5) for women with seven or more 
full-term pregnancies compared with nulliparous ones and 2.3 (Cl: 1.6-2.3) 
compared with women with one or two full-term pregnancies. No parity 
effect was found on risk of adeno- or adenosquamous carcinomas; odds 
ratio of 3.0 (Cl: 0.6-14.6) for parous women compared with nulliparous.
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Another report from the same group suggest that Herpes Simplex Virus 
Type 2 (HSV-2) may act in conjunction with HPV infection to modestly 
increase the risk of invasive cervical carcinoma and that this association is
QO
seen with both squamous-cell, and adeno- or adenosquamous carcinoma .
Smoking has also been independently associated with an increased risk of 
cervical cancer, a dose-dependent effect has been shown by different 
studies 99}100j101>102 Nevertheless, some studies have reported no effect 
after adjusting for other HPV related life-style factors such as number of 
sexual partners and alcohol consumption , , , .
More conclusive evidence comes from a systematic review (including 11 
cohorts and 32 case-controls) of the association between cervical cancer 
and smoking by Szarewski and Cuzick 104, who reported statistical 
significant odds ratios for various groups of studies between 1.5 and 2.2. 
Moreover, both cotinine and nicotine have been found in cervical mucus of 
smokers 105>106)107>108j smoking cessation has been associated with 
reversal of CIN. In a longitudinal study 109 in which 81 women with CIN 1 
or less were encouraged to quit smoking. After six months o f follow-up, 
the lesions in 40% of those who stopped smoking disappeared, while it 
grew in those who did not stopped.
2.2. Prevention of cervical cancer
2.2.1. Screening
Screening consists of examination of asymptomatic people in order to 
classify them as likely or unlikely to have the disease for which they are 
screened. The disease could be cancer (as is when using mammography) or 
non-invasive neoplasia (as is the aim of cervical screening). Those who 
seem likely to have the disease are investigated further to arrive at a final 
diagnosis, and if considered diseased are supposed to be treated. The goal 
of screening is to reduce morbidity or mortality from the disease among 
screened people; this goal is accomplished by early treatment of identified 
cases no.
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Cervical cancer is a disease that can be prevented by detecting and treating 
its precursors. The Papanicolaou (Pap) test, which detects cervical 
dysplasia, is the primary method of screening for cervical cancer and its 
precursors. The aim of screening for cervical cancer is to identify and treat 
preinvasive lesions, thus preventing the progression to invasive cancer. 
This has been achieved in industrialized countries with organized mass 
screening programmes based on cytology “ V 12,113 '“ i i s i w u t n i n s *  
However, substantial reduction in cervical cancer rates has been achieved 
only by numerous repeated tests over lifetime of women who undergo 
screening 121.
Age-adjusted incidence rates of cervical cancer (AAIR per 100,000 
women) were reduced substantially in Denmark, Sweden and Finland, 
where the AAIR fell from 15 to 5 (65% reduction) from 1966 to 1985 after 
the implementation of well-organised mass screening 7,122. The same has 
happened in the UK, where a 50% reduction in incidence rates during the 
last decade has been observed 123 and a possible similar reduction in 
mortality rates in women aged 20-69 years have been suggested 124 due to 
a well-organised screening programme with high coverage.
A collaborative study of screening programmes in eight countries: 
Scotland, Canada, Iceland, Denmark, Norway, Sweden, Switzerland and 
Italy; identified cancer cases (either from case-control or cohort studies) 
and selected previously screened healthy controls (or women in the cohort 
with an initial negative smear); and compared the relative protection 
acquired from cervical screening against developing cervical cancer. 
Women who had two or more negative smears were less likely to develop 
disease than those never screened, but the effect depended upon time from 
last negative smear. The relative “protection” was 15.3 for developing 
cervical cancer within one year of a negative screening in women with at 
least two negative screenings, and 1.6 within 10 years 113. Sasieni and 
colleagues 115 also compared the screening history of women with invasive 
cancer to those of healthy controls (matched by age and residence) in 
England, Wales and Scotland, and confirmed that the risk of developing
34
invasive cervical cancer was a function of the number of years since a 
negative smear result. They found that the relative protection against 
cervical cancer was reduced from 5.6 to 1.6 within one year or 4-5 years 
after a negative screening. Other studies have confirmed that two or more 
previous negative smears have a protective effect on the development of 
cervical cancer, but that such effect decreases as time since the last 
negative smear increases, suggesting that although cytology based well- 
organised mass screening programmes have been very successful, they
125 120 126 127depend on a technique which has large false negative rates , , , .A s
a consequence, women who are lesion-free at screening may experience 
the development of invasive cervical cancer within few years 48>128J 1291 130,
131 1329
These limitations have generated interest in the use of new alternative 
technologies such as liquid-based cytology and human papillomavirus 
(HPV) testing for more effective cervical cancer screening programmes; 
and other less-costly techniques for developing countries that so far, have 
failed to establish effective cervical screening programmes.
2.2.1.1. Cytology
The smear test (or Pap smear) consists of cells removed from the cervix; 
which are specially prepared for microscopic examination. A 
gynaecologist or other health care provider removes the cells by brushing 
or scraping the cervix during a pelvic examination. The removed cells are 
evenly spread on one or more glass slides. Pap smears are then stained, 
examined under a microscope, and interpreted.
As stated before, there is good evidence that smear tests can be used as part 
of an organised screening programme to effectively reduce the incidence of 
cervical cancer 113,115. However, the sensitivity is poor, and the accuracy of 
the test is subject to human error. Conventional cytology is limited by 
sampling error, in which the abnormal cells do not get placed on the slide, 
and reading error, whereby the few abnormal cells present are lost among 
the many normal cells that predominate. Sensitivities of 40% to 80% to
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detect high-grade cervical intraepithelial neoplasia have been reported 
i33,i34}7M35 ^  particular, the relative sensitivity of cytology (LSIL or
worse) for confirmed HSIL was reported to be 46% (Cl: 35,57), on women
n i
attending family practitioner clinics for routine screening . The second 
phase of the Zimbabwe study estimated a sensitivity of cytology of 44.3% 
(Cl: 37,51) for HSIL 135. These studies are consistent in finding that less 
than half of women with HSIL are identified by conventional cytology.
Furthermore, in a meta-analysis by Fahey et a l 136, the mean sensitivities of 
cytology for detecting CIN 1 and CIN 2 were 63%(95%CI:55-71) and 
61%(95%CI:52-70), and the specificities were 69% (95%CI:62-76) and 
65%(95%CI:57-74), respectively. But a more recent meta-analysis by
1 37Nanda and collaborators , reported sensitivities for cytology at LSIL 
threshold for detecting CIN 1 from 18% to 98%, and for detecting CIN 2-3 
from 23% to 99% in studies in which all women or a random sample with 
negative tests attended colposcopy. The correspondent specificities varied 
from 9% to 100% for CIN 1 and from 6% to 99% for CIN2-3, highlighting 
the variability of performance of conventional cytology.
Although established programmes in other parts of the world rely on 
cytology (Pap smears), recent research indicates that other technologies 
such as visual inspection after the application of acetic acid (VIA), HPV 
testing or liquid-based cytology (LBC) may be more efficient in detecting 
high-grade cervical lesions in developing countries 135j138j139>140>141j135.
Standards of cytology in Latin America are generally very poor 8. The 
main problems being the high number of false negative and false positive 
results due to poor specimen quality, and high intra- and inter-observer 
variability in cytological diagnosis. Also problems regarding deficient 
infrastructure, insufficient and inadequate personnel training, shortage of 
human resources and clinical information, lack of supervision and follow 
up in procedures at laboratories, different diagnostic criteria, and 
classification systems, lack or delay in reporting, and lack of internal and 
external quality control. Diverse technical problems occurred in and out of 
laboratories, starting at the smear taking stage, where availability of
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spatulas and slides may be scarce so slides are washed and reused. 
Papanicolaou smear providers do not take adequate samples, and slides get 
mixed up, lost or broken before they reach the laboratory.
The use of Liquid-based cytology (LBC) has been proposed as an 
alternative to conventional cytology in industrialised countries, and is 
being tested in less developed ones. LBC has been shown to be at least as 
sensitive as conventional cytology for detection of cervical lesions and is 
potentially more easily combined with (semi) automated reading of slides
142 143 >
LBC samples are collected using a plastic broom or a combination of 
plastic spatula and endocervical brush. Samplers are rinsed or the head of 
the brush is detached into a vial of liquid transport medium, creating a cell 
suspension. Once in the laboratory, slides are prepared either manually 
(labour-intensive) or in a semi- or fully-automated fashion using one of 
three devices approved by US Food and Drug Administration (FDA): two 
Thin-Prep® processors manufactured by Cytic Corporation and the 
SurePath® system previously known as AutoCyte-Prep® or CytoRich® 
manufactured by TriPath Imaging Inc.
Several split-sample or direct-to-vial studies have been carried to evaluate 
the performance of LBC either using ThinPrep or AutoCyte-Prep® 
systems; most of them showing consistent advantages of LBC over 
conventional cytology.
Liquid-based cytology reduces the number of inadequate samples and 
removes responsibility for slide preparation and fixation from the smear
t _ i _  144 145 146 147 148 149 150 151 152 153 154 idJvcr 9 9 9 9 9 9 9 9 9 9 .
LBC slides are uniformly well fixed, free of inflammatory exudates and 
blood making them easier to screen 155}156>157j158
A systematic review of LBC by Payne et a l 159, concluded that LBC might 
reduce the number of false negative test results, the number of 
unsatisfactory specimens and might decrease the time needed for specimen 
interpretation.
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In the UK, debate about the implementation of LBC massively is on going; 
among opinions against the change are those of Herbert and Johnson l55, 
Moseley and Paget 160, and the latest results of a study by Coste and 
colleagues 161. Herbert and Johnson re-evaluated the evidence in favour of 
LBC, and concluded that the cost of implementing LBC in a massive way 
would be overwhelming, especially because cytopathologists would need 
time to develop experience in reporting LBC and in assessing specimen 
adequacy; and LBC cytoscreeners would need constant training. In a more 
sophisticated review, Moseley and Paget 160 analysed published raw data 
using the National Health Service Cervical Screening Programme 
(NHSCSP) terminology to avoid differences due to nomenclature, 
especially regarding definition of inadequate samples. They also concluded 
that the benefits of LBC have not been sufficiently sustained to justify 
replacement of conventional cytology and more evidence in favour of LBC 
through multicentre trials is needed. A more recent study by Coste e ta l ]6\  
after screened 828 women referred for colposcopy because of previously 
detected cytological abnormalities and 1757 women attending for routine 
smears, with conventional cytology, liquid-based cytology and HPV 
testing; conclude that LBC was more likely to give false positive and false 
negative results than conventional cytology.
After considering these opinions and deeply evaluating the results of Coste 
and colleagues, as well as previous literature and new studies, the reviewed 
NICE Guideline 154 on the use of liquid-based cytology for cervical 
screening concluded: that the sensitivity may be up to 12% better with 
LBC (to detect low-grade disease or worse) compared with Pap smear 
(conclusions based on a meta-analysis of 14 studies); that there is no 
difference between the specificity of LBC and Pap smear (based on a meta­
analysis of six studies); that the rate of inadequate samples was reduced 
with LBC using data from a UK pilot study; which also gave evidence to 
support that the detection of glandular neoplasm with cytology is similar 
when using LBC or Pap smear. NICE recommended to use LBC as the 
primary means of processing samples in the cervical screening programme
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in England and Wales, but that there is not enough evidence to recommend 
one LBC product over another. This guideline is to be reviewed in 2006.
Overall, LBC appears to be more sensitive than CC for detection of LSIL 
or worse lesions, and that the number of inadequate samples is reduced; 
but still is an expensive technique and requires lots of training.
2.2.I.2. Human Papilloma Virus Testing
High-risk types of HPV cause at least 95% of cervical cancer 162,3, but the 
majority of women exposed to genital HPV will not develop cervical 
cancer 45.
It has been proposed that HPV testing can be used as an adjunctive to 
cytology or even as a primary screening test. HPV testing has poor 
specificity but it has higher sensitivity than cytology for detecting HSIL on 
histology. Both HPV testing and LBC reduce the inadequate rates, because 
of the collection devices and the transport media used and the reduced 
involvement of the smear takers. HPV testing of self-collected samples still 
has better sensitivity than cytology and could potentially be used for 
women who do not wish to attend screening in developed countries 163,164,
165
The use of HPV testing in the triage of ASCUS and low-grade disease and 
in the follow-up of treated women is under study in pilot centres in the UK. 
If HPV proves being efficient in either of these areas as has been suggested 
for ASCUS by two very large US studies 166,167,168, clinical management of 
minor lesions and of treated women could be substantially improved.
Several techniques have been used to detect HPV in cervical smears giving 
different results. In a systematic review of the role of HPV testing within a 
screening programme, Cuzick et al established that two consensus primer 
PCR systems (MY09/11 and GP5+/6+ pairs) and Hybrid Capture II (HC- 
II) using high-risk probes are the best methods so far because they have 
high sensitivity for detecting oncogenic viruses and could be automated 169.
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Most studies using HC-II have reported sensitivities over 80% and 
specificities between 62% and 98% to detect histologically confirmed 
high-grade lesions or worse 75j170>171j172 confin ing  HC-II is a
sensitive and robust test for oncogenic HPV that can be used to identify 
women with high-grade cervical lesions in a screening setting 169.
The test is currently expensive for a developing country and may also lack 
specificity. However, unlike earlier PCR based techniques, HC-II is 
relatively straightforward to implement in hospital laboratories. Aliquots of 
cells stored in a liquid-based medium may be analysed either by thin layer 
cytology or by Hybrid Capture for HPV DNA, creating the opportunity to 
triage the management of patients with cervical abnormalities.
2.2.I.3. Visual inspection after acetic acid application -  a systematic review
The naked-eye visualisation of the cervix after application of 3-5% acetic 
acid is termed cervicoscopy 175 or visual inspection of the cervix after 
acetic acid (VIA). The results are reported as negative (no acetowhite 
areas) and positive (evidence of acetowhite) areas, but other more detailed 
descriptions are possible.
VIA has been investigated as a low-cost alternative to cytological 
screening programmes in countries where skilled labour costs are low. VIA 
with or without magnification has shown very similar or better sensitivity 
to cytology in detecting pre-cancerous lesions. It does not require a 
cytological laboratory, it is cheaper than cytology and the outcome is 
immediately available.
After searching MEDLINE and the “Web of Science” electronic databases, 
all papers with “visual inspection”, “VIA”, “DVI”, “acetic acid test”, 
“AAT” “cervicoscopy” and “visual methods” in their title, abstract or 
keywords were selected and reviewed. Studies with colposcopy (and 
histology) used as reference standard to estimate sensitivity and specificity 
o f VIA for detecting intraepithelial lesions are presented in Table 2.2.1.3.1. 
As sensitivity and specificity are often biased by the design of the studies, 
the percentage of VIA positive tests in women with histologically
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confirmed HSIL or worse lesions (% VIA pos in HSIL pos) and in those 
with lesions no worse than LSIL are presented (% VIA pos in <HSIL) 
instead. The last two columns show the number of women who attended 
colposcopy, the corresponding percentage from all women in the study, 
and the criteria used for referral to colposcopy.
The first report indicating that a cervix at risk can be identified by 
recognising acetowhite areas with the naked eye; was that of Ottaviano and 
La Torre 176. The cervices of 2,400 unselected patients with normal or 
abnormal cervical cytology were examined in Florence, Italy, by both VIA 
and colposcopy; and their results were compared. VIA and colposcopy 
were considered positive if  the transformation zone was found atypical 
(ATZ). Punch biopsies were taken during examination if  appropriate. 
Histology results were reported in four categories: benign lesions, cervical 
intraepithelial neoplasia (CIN) grades I and II, CIN III and preclinical 
invasive carcinoma. An ATZ was found in 312 women with colposcopy. 
VIA gave the same result for 307 of these women but classified as 
“suspicious” 5 of them. Histologic examination of biopsies from the 312 
ATZ revealed 169 (54.2%) benign lesions, 81 CIN I-II, 56 CIN III and 6 
preclinical invasive carcinomas. The five cases classified as “suspicious” 
by VIA were histologic benign lesions. Based on the high percentage of 
agreement between colposcopy and VIA, the authors concluded that 
colposcopic magnification was not essential in clinical practice to identify 
the cervix at risk, but was useful to decide how to treat cases of CIN.
As this study intended to highlight the importance of the naked-eye 
inspection of the cervix by gynaecologists, results from Pap smears were 
not presented nor was their correlation with VIA or colposcopy 
commented upon.
Following Ottaviano et al conclusion, that the naked-eye visualisation of 
the cervix was enough to detect a cervix at risk, Ficsor et a l 177 carried out 
a study in rural clinics of Van Buren, Michigan, USA, to determine if 
additional women at risk for cervical cancer were identified when using 
VIA, ViraPap and ViraType tests. A Dacron swab and a wooden spatula
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were used to collect endocervical and cervical cells that were then spread 
into the same glass slide for conventional cytology evaluation. Cells 
remaining on the wooden spatula were collected on the Dacron swab, and 
then immersed in a transport media provided with the ViraPap kit, which 
was also used to test HPV DNA. Those found positive to HPV DNA were 
then analysed using the type-specific ViraType DNA test kits. They found 
that 30 of 145 (21%) women were VIA positive (abnormal acetowhitening 
of the cervix) as compared to 13 HPV DNA positive and 14 (10%) who 
had some cervical abnormality detected by conventional cytology. Twenty- 
two women were positive on VIA but had a negative Pap smear and a 
negative ViraPap test. In 6 of 14 (43%) patients with abnormal 
Papanicolaou tests no acetowhite lesions were detected. Positive Pap test 
results were 6.61 times more likely when VIA was positive and 5.41 times 
more likely when HPV DNA was detected in cervical cells. Based on these 
results and on the fact that the Pap test is considered an effective screen for 
early cervical cancer and its precursors, the authors suggested that VIA and 
the ViraPap test also detect women who are at risk for cervical cancer. 
Unfortunately, no definition of positivity on each test was stated clearly 
and since colposcopy was not performed, and hence histology was not 
available, true disease was not determined and sensitivity and specificity 
were not estimated. These results are not included on Table 2.2.1.3.1.
Conventional cytology and VIA were used to screen 2827 women less than 
46 years of age in the HARNET study area in Pennsylvania, USA, by
1 78Slawson and associates . Cytology was considered positive if 
ASCUS/AGUS or worse lesions were found. VIA was considered positive 
if acetowhite areas were detected “outside the transformation zone (sic)”. 
Women with Papanicolaou smears showing squamous intraepithelial 
lesions underwent immediate colposcopy, while those with a positive VIA 
(cytology less than SIL) had colposcopy within a 6-month period. 
Specially qualified doctors performed colposcopy and directed biopsies. 
Endocervical curettage was performed on all subjects. Of the 2827 women 
screened, 358 (13%) were found to have an abnormal result on VIA or 
cytology, 74 of these did not meet the inclusion criteria (47 older than 45
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years of age, 20 had previous cryotherapy, 7 were pregnant); and 63 
eligible women refused colposcopy. VIA correctly identified 43, found 14 
additional CIN I lesions and 4 additional CIN II or III lesions that were 
missed by cytology, representing a 27.3% increase in the detection of 
cervical lesions. However, in almost 50% of positive VIA cases, 
colposcopic findings were normal.
In the study of Van Le et al 179, 85 women positive on VIA but with 
normal cytology, were subjected to colposcopy. Of them, 34 (40%) had 
normal colposcopic examinations, and the rest were subjected to biopsy. 
Thirteen (15%) CIN lesions (nine CIN I and four CIN II) were detected by 
VIA and missed by cytology, but 34 false-positive women underwent 
unnecessary colposcopy. Because women with VIA negative, were not 
referred for colposcopy a false-negative rate could not be estimated.
Cecchini et al in Florence, Italy 180 screened 2105 women using VIA, 
Cervicography (projected magnified inspection of pictures of acetic acid 
impregnated cervix), and cytology. VIA was reported positive if  there was 
evidence of acetowhite areas. Cytology was considered abnormal if 
ASCUS/AGUS or more severe lesions were reported. Any woman with 
abnormal cytology, suspicious Cervicography or positive VIA was invited 
for colposcopy. Negative colposcopy or histologic diagnosis at 
colposcopically guided biopsy, were considered as the gold standard for 
the determination of sensitivity, specificity and positive predictive value 
for CIN II-III (HPV morphology or CIN I were considered negative). 
Among 486 women with at least one positive test who underwent 
colposcopy, directed biopsies were performed in 281. VIA, cervicography, 
and cytology detected 7, 5, and 5 of the 8 high-grade lesions (4 CIN II and 
4 CIN III) histologically confirmed. VIA was found to be more sensitive 
than cytology in detecting lesions, but because of being less specific 
resulted in a recall of 25% of 2,105 subjects for further investigations, as 
opposed to 4% with cytology. Because colposcopy was performed only in 
23% and biopsies were taken only on 13% of screened women, the 
definition of specificity was limited.
43
Frisch et al 181, reported a significantly augment on the ability of screening 
to identify normal women when adding VIA to cytologic screening in a 
selected population of college students with a high prevalence of low-grade 
squamous lesions. The negative predictive value for detecting HPV 
infection or cervical intraepithelial neoplasia (CIN) increased from 
67%[CI: 57-77] for cytology alone to 91%[CI: 83-99] when performing 
VIA as an adjunct. Unfortunately, this study did not have enough power to 
evaluate the performance of VIA in detecting HSIL.
Another study by Slawson and associates 182 on the HARNET population 
evaluated the use of VIA in the follow-up of Papanicolaou smears 
reporting ASCUS. They found that VIA increased the detection rate of 
CIN II or worse lesions from 67% to 93% and proposed a management 
scheme to minimise unnecessary colposcopy by performing it if  either 
repeated VIA or cytology after 4 or 6 months was positive. This study is 
not included in Table 2.2.3.1.1, because women participating in their first
178study are included to women recruited the next 10 months.
In a study in Cape Town, South Africa 183, the positive predictive value for 
detecting histologically confirmed LSIL of VIA was 72.4% as compared with 
89% of conventional cytology. Women, attending a mass free screening 
program at a mobile clinic, were screened by VIA and conventional cytology. 
Smears were processed immediately by a cytotechnologist aware of the 
study. Those being positive on either test underwent colposcopy and were 
treated with large loop excision of the transformation zone (LEEP) when 
necessary within three days of being screened. Unfortunately, those resulted 
negative on both tests were not further evaluated and so estimates of 
sensitivity and specificity were not possible to obtain. The authors concluded 
that the higher number of false negative tests with VIA than with cytology 
made VIA not useful as a screening method for premalignant cervical lesions. 
But since VIA detected 64% of HSIL on both cytology and histology, they 
suggested that it should be considered as a possible alternative to cytology in 
countries with limited resources or wherever cytology is not available.
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Five hundred sexually active, non-pregnant women attending a college 
hospital in Vellore, India 184, were screened with VIA and conventional 
cytology (sample collected immediately after VIA), and were asked to return 
for colposcopy. Of the 500, 372 underwent colposcopy, all information 
presented in the paper is based in this colposcopically examined women. 
Biopsies were collected during colposcopy if indicated and colposcopy 
diagnosis was used as the reference test (gold standard). VIA was positive in 
197 women (53%) while only 23 women (6.2%) were positive on 
conventional cytology (disease threshold not specified). Seventy-five women 
were colposcopically diagnosed with LSIL, 22 with HSIL and one had a 
histologically confirmed invasive cancer. The respective sensitivities were 
72.4% and 13.2% for VIA and conventional cytology, and the correspondent 
specificities were 54% and 96.3%. Using colposcopy as the standard test, 
VIA missed 5 HSIL while cytology failed to detect 17 HSIL and one invasive 
lesion, but the false positive rate of VIA was 91% to detect high-grade 
lesions, implying a large number of unnecessary colposcopies. Still based in 
the gain in sensitivity the authors concluded that VIA was a promising 
screening test for developing countries and that the high false positive rate 
could be decreased with adequate training of VIA examiners. It is noteworthy 
that smear samples in this study were taken after application of acetic acid 
and others have shown that this can adversely affect the results 185.
Sankaranarayanan et al 138, concluded that VIA and cytology had similar 
performance in detecting cervical lesions in a study in Kerala, India. 
Considering a low-threshold for cytology (defined positive if atypia or a 
worse lesion was present), detection rates were 15.7 and 15 per 1000, the 
specificities were 92.2 and 92.7 and positive predictive values were 17 and 
17.2 for VIA and cytology, respectively, to detect histologically confirmed 
HSIL or worse lesions. But negative predictive values were not possible to 
obtain, again, because only those testing positive and those with a 
macroscopically abnormal-looking cervix underwent colposcopy. However, 
the high specificity obtained for VIA as compared with previous studies was 
explained by prolonged training of those performing the exam and by the 
definition of VIA results, which were considered positive only if distinct
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acetowhite areas were present. In a selected population of 1,351 women from
1 QAthis Kerala study , the authors reported detection rates of HSIL and cancer 
of 53.6 and 34.7 per 1000 for VIA and cytology, and approximated 
specificities of 68% and 89.5%, respectively. Because these women were 
attending a cancer detection clinic, either for a routine exam or as referred to 
rule out cancer, VIA showed a significantly higher detection rate (p-value 
<0.01 for a ratio of sensitivities of 1.54) than cytology. But VIA specificity 
was lower than that of cytology (p-value<0.01) yielding a higher referral of 
women for colposcopy. This second study is not summarised in Table 
2.2.3.1.1 since study populations overlapped.
In a pilot study in Zimbabwe, Chirenje et al 187 screened 1000 women aged 
25-55 years coming into primary health clinics in Mashonaland with 
conventional cytology and VIA. Colposcopy was performed on any women 
with an abnormal result in either screening test and in a 10% random sample 
of those negative in both VIA and cytology. Using colposcopy as the gold 
standard, the sensitivity of VIA was 68% and the specificity 3.4%, despite 
this extremely low specificity the authors concluded that VIA was a practical 
alternative to cervical cytology in countries with limited resources.
The second-phase study in Zimbabwe 135 tried to overcome the lack of the 
false-negative rate. In the first phase, women testing positive on either VIA or 
cytology, as well as a random sample of those negatives on both tests were 
scheduled for colposcopy. In the second phase of the study all women 
regardless of results were called for colposcopy.
A total of 8,731 women were enrolled on phase I, of them 1,584 had 
colposcopy and biopsy as indicated. Positivity rates for VIA and cytology 
were 20.2% and 14.6%, and the predictive positive values were 25.9% and 
43.9% for detecting colposcopically or biopsied confirmed HSIL or worse 
(assumed as tme disease), for VIA and cytology, respectively.
During the second phase of the study, 2,203 women participated and 2,147 of 
them underwent colposcopy. Also, an additional sample for HPV testing was 
collected to determine if feasible as a single screening test in a less-developed
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country and to assess its use as an adjunct to VIA. Sensitivity and specificity 
of VIA were 76.7% and 64.1%, as compared to 44.3% and 90.6% of 
cytology, to detect HSIL or worse. The authors concluded that their results 
confirmed once more that VIA is more sensitive but less specific than 
cytology, but still VIA could be used as a screening test in difficult settings 
even though the expected large number of referrals. However, the different 
rate of high-grade disease found in both phases is of concern (4.7% in Phase I 
and 9.5% in Phase II), since the sensitivity of VIA was only increased in 
10%.
Denny and colleagues carried out two studies in South Africa: one in Cape
1 -JQ
Town (2944 participants) between January 1996 and September 1997 and 
a second one in the periurban area of Cape Town (2754 participants) between 
January 1998 and November 1999 188. In both studies women were screened 
with four tests: VIA, conventional cytology, HPV testing and Cervicography. 
As in the Zimbabwe study, the rate of high-grade disease increases from 
2.9% to 4.2%, while the sensitivity of VIA only increases 5%. In both studies 
a magnified visual inspection was performed immediately after VIA, with the 
intention to increase the sensitivity of VIA, but made no significant 
improvement. The specificity of VIA was 83% in the first study and 78% in 
the second one. Once again, the authors conclude that VIA could be used as a 
primary screening test in low-resource settings.
1 80In another study in New Delhi, India , 402 symptomatic women attending 
a gynaecological clinic were examined with VIA, conventional cytology and 
underwent colposcopy. The sensitivity of VIA for HSIL was 87% and the 
specificity 82%, but as expected this population had an extremely high rate of 
HSIL (34%).
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Table 2.2.1.3.1. Summary of screening studies evaluating Visual Inspection after acetic acid (VIA).
Authors No.screened
%
with
HSIL
% VIA 
pos in 
HSIL pos
% VIA 
pos in 
LSIL pos
% VIA 
pos in 
<LSIL
% VIA 
pos in 
<HSIL
No. with 
Colp. (%)a
Criteria used for referral to 
colposcopy
Ottaviano M et al1 
Italy 1982
2400 2.6 100 10.5 2400 (100) All women.
Slawson DC et al 
USA 1992
2753 1.1 29 37.7 2.2 2.9 221 (8) VIA+ or cytology ^ \SCUS.
Van Le L et al1 
USA 1993
85 4.7 100 36.5 58.8 95.3 85 (100)
All women. But women VIA 
negative not described in the 
study.
Cecchini S et al 
Italy 1993
2105 0.4 87.5 16.5 486 (23) VIA+, cytology ^ ASCUS, or cervicophotography.
Frisch LE et al 
USA 1994
95 4.2 100 92.3 70.5 73.6 52 (55) VIA+, cytology ^ ASCUS, or cervicophotography.
Megevand E et al 
South Africa 1996
2426 1.3 64.5 13.8 1.0 2.3 330(14) VIA+ or cytology ^ S IL .
Londhe M et al 
India 1997
372* 6.2 78.3 70.7 46.0 51.3 372(100)
All women. Colposcopy 
results were used as reference 
test*.
Sankaranarayanan R et 
al, India 1998 3000 1.7 90.2 70.1 6.1 7.8 277 (9)
VIA+ or cytology ^ .SCUS, 
and those with abnormalities 
on speculum exam.
Continued on Page 49
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Table 2.2.1.3.1. Summary of screening studies evaluating Visual Inspection after acetic acid (VIA).
Authors No. screened % with HSIL
% VIA 
pos in 
HSIL pos
% VIA 
pos in 
LSIL pos
% VIA 
pos in 
<LSIL
% VIA 
pos in 
<HSIL
No. with 
Colp. (%)a
Criteria used for referral to 
colposcopy
Chirenje ZM et al 
Zimbabwe 1999
1000 3.8 68.4 23.3 213(21)
VIA+ or cytology ^ ISIL. 
Colposcopy was the reference 
test.
JHPIEGO 
Zimbabwe 1999
8731 
Phase I 4.7 65.5 17.9 1584(18)
VIA+ or cytology ^ LSIL, and a 
10% of negative or atypical VIA 
women.
JHPIEGO 
Zimbabwe 1999
2203 
Phase II 9.5 76.7 54.1 32.7 35.9 2147 (98) All women.
Denny L et al 
South Africa 2000
2944 2.9 67.4 49.5 18.3 16.7 760 (26)
VIA+, cytology sLSIL, HPV 
(viral load>10pg/mL), or 
cervigrams: “warranting 
colposcopy” or ^S IL .
Singh V et al 
India 2001
402 33.6 87.4 52.1 6.0 18.4 402 (100) All women. But selected women with gynaecological symptoms.
Belinson JL et al 
China 2001
1997 4.3 70.9 44.1 24.4 25.7 1997(100) All women.
Cronje HS et al 
South Africa 2001
6301 2.6 49.4 16.0 1747(28)
VIA+, cytology ^ LSIL, or 
cervigrams: “warranting 
colposcopy” or ^LSIL.
Continued on Page 50
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Table 2.2,1.3.1. Summary of screening studies evaluating Visual Inspection after acetic acid (VIA).
Authors No. screened % with HSIL
% VIA 
pos in 
HSIL pos
% VIA 
pos in 
LSIL pos
% VIA 
pos in 
<LSIL
% VIA 
pos in 
<HSIL
No. with 
Colp. (%)a
Criteria used for referral to 
colposcopy
Denny et al 
South Africa 2002
2754 Unaided 4.2 72.6 57.8 20,7 22.2
1156(42)
VIA+, cytology ^ S IL , HPV 
(viral load>lpg/mL), or 
cervigrams: “warranting 
colposcopy” or ^S IL .
Magnified 76.1 59.8 23.4 24.8
Rodriguez-Reyes E 
et al, Mexico 2002 376 13.6 92.2 100 40.3 41.2 376 (100) All women.
Claeys et al 
Nicaragua 2003
1076 4.7 88.2 84.4 22.4 27.0 307 (29) VIA+ or cytology ^ \SCUS.
Sankaranarayanan 
R et al, India 2003
4444
low-threshold 3.3 88.6 22.0 4444 (100) All women.
high-threshold 82.6 13.5
HSIL=HSIL or worse lesions.
a : percentage of women who underwent colposcopy in the study.
1: HSIL not including CINII or moderate dysplasia.
2: HSIL including only CIN II. LSIL including koilocytosis.
* Originally 500 women, no data on 128 assumed without colposcopy.
50
172A comparative trial of multiple cervical screening techniques in China 
examined 1997 women aged 35-45 with HPV testing, fluorescence 
spectroscopy, liquid based cytology, VIA and Colposcopy. All women had 
multiple cervical punch biopsies. The sensitivity and specificity of VIA were 
71% and 74%, respectively. These estimates were free of verification bias as 
each woman had histology. These results were not as good as those from 
Zimbabwe or India. Furthermore, VIA was performed by gynaecologic 
oncologists, who missed one third of the cancers identified during the study.
• t onCronje et al screened 6301 women with conventional cytology, 
cervicography and VIA in the Free State Province of South Africa. They 
reported a sensitivity of 49% and a specificity of 84% of VIA for detecting 
CIN I or worse lesions. VIA results by histology are not presented limiting 
the calculation of measures of performance to detect HSIL.
The first study published in Latin America has been that of Rodriguez-Reyes 
and colleagues in Mexico 191. They examined 376 women with VIA and 
colposcopy (and directed cervical biopsy) attending an early cancer detection 
program in Durango, Mexico. Because of being a selected population the rate 
of high-grade disease was high (14%), nevertheless, VIA had a sensitivity of 
92% but a low specificity of 60%.
• 1Q9A recent study in Nicaragua screened 1076 women with VIA and 
conventional cytology. VIA was performed by six medical doctors and 14 
trained nurses. Women testing positive in either test were referred to 
colposcopy and had biopsy if indicated. VIA had a sensitivity of 88% and a 
specificity of 73% but only 29% of the participants underwent colposcopy. 
The authors concluded that VIA increases the detection of HSIL significantly 
as compared with conventional cytology (positive if ASCUS or worse); 
which had a sensitivity of 45%; and that uniform criteria on test positivity 
should be established in order to improve VIA performance in field 
conditions.
Another recent study in Kerala, India 193 evaluated 4444 women with 
conventional cytology, VIA and visual inspection after the application of 
Lugol’s iodine (VELI). VIA test positivity had a low and a high threshold
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definition. The later including well-defined opaque acetowhite lesions close 
to or touching the squamocolumnar junction. They reported a rate of high- 
grade disease of 3%, sensitivities of 89% and 83% and specificities of 78% 
and 87% for low and high VIA thresholds, respectively. This results are 
unbiased as every woman underwent colposcopy and are more realistic than 
those of the previous study in 1998 where sensitivity and specificity of VIA 
were over 90%.
It should be stated that only three studies were free of selection and 
verification bias: the second phase of the JHPEEGO study in Zimbabwe, the 
study by Belinson and colleagues in China, and the recent one of 
Sankaranarayanan in India. The sensitivity of VIA could then be assumed to 
vary between 70% and 89%, and the specificity between 64% and 78% for 
detecting histologically confirmed high-grade lesions.
Soler et a l194, in a review of the new technologies for the detection of cancer 
precursors, stated that despite the higher rates for referral or an offer to 
treatment obtained with VIA, the gain with increasing coverage, diminishing 
losses to follow-up and immediate results, are to be considered. They 
suggested that implementing two-step approaches using adjunctive HPV self­
sampling or sequential screening with HPV or cytology may improve the 
specificity of VIA alone.
There are several studies on going in order to evaluate the efficacy of 
combined cervical screening tests in India, South Africa and in Peru, results 
of which are to be available in the following years. However, so far, despite 
its poor specificity, VIA has been shown to be a potential alternative for 
cervical screening in developing countries.
2.2.2. Vaccination
The objective of vaccination is to prevent cervical cancer, by immunizing 
against HPV infection or eliminating persistent infections (prophylactic 
vaccines) or treating women already infected with HPV (therapeutic 
vaccines).
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In 1991, Zhou and colleagues created the first papillomavirus-like particles 
in the laboratory 195. Virus-like particles are non infectious as they contain 
no DNA or RNA, but they imitate the natural structure of the virion and 
generate a potent immune response. Vaccines derived from species- 
specific virus-like particles protected animals from wart viruses. The next 
step was then to determine if such vaccines will indeed protect cervical 
epithelium from high-risk HPV infections 1%. A recent study by Koutsky 
and collaborators 197 evaluated the protective effect of a virus-like particle 
vaccine against HPV 16. A total of 2,392 American women aged 16-23 
years were randomised to receive three doses of placebo or HPV-16 virus- 
like-particle vaccine intravenously (40 /ig per dose). In a first analysis of 
765 placebo women and 768 vaccinated women followed-up for a median 
of 17.4 months, they reported an incidence of persistent HPV-16 infection 
of 3.8 per 100 woman-years at risk in the placebo group and zero in the 
vaccine group; and the only nine cases of HPV-16-related cervical 
intraepithelial neoplasia were all in women receiving placebo. The authors 
conclude that this prophylactic vaccine against HPV-16 infection is highly 
efficacious, but long-term follow up studies are needed to determine the 
actual duration of its protective effect. Also, “multivalent vaccines”, those 
that can prevent more than one HPV type, are already under study and 
could prevent more cancer cases. Therapeutic vaccines are at a much 
earlier stage of development198.
Although, vaccination is indeed a promising alternative to cervical 
screening, the availability and introduction of them in a massive scale in 
developing countries could take many years, and cost-effective analysis are 
needed before deciding large interventions.
2.3. Peru
Peru is located in west central South America, bounded on the north by 
Ecuador and Colombia, on the east by Brazil and Bolivia, on the south by 
Chile, and on the west by the Pacific Ocean. The area of the country,
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including several offshore islands, is 1,285,216 sq. km, making it third in 
size (after Brazil and Argentina) of South American countries.
Peru may be divided into three main topographical regions: the coastal 
plain, the sierra (highlands) and the Amazon forest. Its climate varies 
widely, ranging from tropical in the Amazon forest to arctic in the highest 
mountains of the Andes.
The population of Peru is estimated to be 25,661,700 with 50.4% females, 
33.4% children (under 15 years of age) and only 4.8% people over 64 
years (estimates based on the National Census of 19933. About 45% of 
Peru’s inhabitants are Indians, some of whom are descended from the Inca 
civilisation of the 15th century. Some 37% of Peruvians are mestizos, 
mixed white (mainly Spanish) and Indian background, 15% are of unmixed 
white descent and many of the remainder are of black African extraction, 
or Asian (Japanese, Chinese and Korean).
The overall population density of Peru is about 20 persons per sq. km. The 
distribution, however, is uneven, the coast is only ten percent of the 
territory but 40% of Peruvians inhabit it, the Sierra (31.8% of Peruvian 
land) holds 37% of Peruvians, and only 10% live in the Amazon forest, 
which is the largest region (739,672 sq. km, 58% of Peruvian territory). 
Around 72% of Peruvians live in urban areas, with 29% living in 
Metropolitan Lima, 22% in other major cities, and 21% in other urban 
areas.
Metropolitan Lima is the capital city of the country. It is situated in the 
central part of the Pacific coast. It is by far the most populated city, with
7,497,000 inhabitants follow by Arequipa with 762,000 inhabitants, 
Trujillo (652,000), Chiclayo (517,000) and Iquitos (367,000). During the 
last five decades, there have been internal migrations, from deprived parts of 
Peru to more developed areas, mainly to coastal cities such as Lima, which 
has been the favourite target. Most people migrate from rural areas, 
expecting better opportunities and life improvement (housing, employment 
and education); instead, they usually experience a lot of deprivation while 
adapting. Accommodation and education are expensive, the unemployment
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and sub-employment rates are very high, and social discrimination is a 
huge problem.
Spanish, the only official language until 1975, is spoken by 70% of the 
population. Quechua, one of the main languages of the Incas, was made 
official in 1975. Aymara, another Incas language, is also spoken in some 
parts of the country.
Peru is a catholic country, more than 90% of Peruvians profess this 
religion. In 1915, Roman Catholicism was established, as the official 
religion of the country, however few aborigens still practice customs of 
their inherited religions. There are also a small number of Jews and 
Muslims, and a larger number are becoming Protestants.
The estimated Peruvian birth and mortality rates are of 23.7 and 6.3 per 
1000, respectively. The average annual growth rate is 1.7% and life 
expectancy is 69.1 years.
2.3.1. Health system in Peru
The health system of Peru is composed of public, social security, army 
forces and private facilities, all of them under the regulation and 
monitoring of the Ministry of Health, the highest authority.
The country is divided into health regions composed of health networks 
that include hospitals, clinics, health centres and health posts. There are 
more than 7,800 health facilities all over the country. Most of them are 
concentrated in Lima and other urban areas, despite an effort for 
decentralization that started in the nineties. Primary care is not free except 
in some deprived areas of the country where family planning and 
reproductive health clinics, as well as children vaccination are covered by 
the health region budget. But in most places, patients are to pay their cost 
for hospitalisation and basic medication.
Only those with a permanent job are covered by the social security system, 
and those enrolled or with family working in the army forces can access 
the army forces facilities.
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Private hospitals and clinics are expensive and so only available to a small 
sector of the population.
2.3.2. Cervical cancer in Peru
Cervical cancer is the most common cancer in women in Peru, as shown by 
figures from the only two existing cancer registries in the country the 
Trujillo Cancer Registry (TCR) and the Metropolitan Lima Cancer 
Registry (MLCR).
In 1994, 880 new cases o f invasive cancer were diagnosed at, the Instituto 
de Enfermedades Neoplasicas “Dr. Eduardo Caceres” (INEN), the national 
cancer hospital in Lima. Most of these cancers were on late stages with no 
possibility of therapeutic treatment.
In 1998, the Ministry of Health of Peru (MOH) formulated a National Plan 
for Gynaecological Cancer Prevention: Cervix and Breast 1998-2000, in 
which activities to be carried out at each health level to implement a 
national screening programme, were detailed.
In 1999, once the plan was revised and approved, cervical cancer was 
declared a health priority in the country.
2.3.2.I. Mortality and incidence, rates and trends, importance in Peru
The incidence rates of cervical cancer in Peru are high. In Volume VII of 
Cancer Incidence in Five Countries 199, the TCR reported 53.5 new cases 
per 100,000 women, the second highest rate in Latin America after that of 
Belem, Brazil (64.8 new cases per 100,000).
Trujillo is located in the La Libertad region, and its cancer registry covers 
five districts in the province of Trujillo with approximately 613,000 
inhabitants, representing 2.3% of the Peruvian population 20°. Data from 
Lima are available from the Metropolitan Lima Cancer Registry, which 
covers the provinces of Lima and Callao with more than 8 million 
inhabitants, 32% of the Peruvian population 201.
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In Metropolitan Lima, the annual age-standardised incidence rates of 
cervical cancer per 100,000 women were 45 between 1968-1970 and 27.3 
between 1990-1991 while the crude mortality rates were 12.7 and 9.3 per
100.000 women in the same periods. Both, incidence and mortality have 
experienced a substantial decrease over 25 years in Lima, where cytology 
screening has been available since 1953, in a small scale from both public 
and private health services.
This has not happened in Trujillo, where rates have experienced a very 
small (non-significant) decrease over a decade (1984 to 1995), the 
incidence rate was 56.6 per 100,000 in 1984 and still there are more than 
50 new cases per 100,000 women each year. Mortality rates were 20 per
100.000 women in Trujillo in 1984 and remained the same in 1995.
Unpublished data from the only specialised cancer hospital of the country, 
the Instituto de Enfermedades Neoplasicas “Dr. Eduardo Caceres G.” 
(INEN) based in Lima, reported a total of 880 new cases of invasive 
cervical cancer, 139 in situ carcinomas and 111 cervical dysplasias 
admitted in 1994. Most of the invasive cases presented at late stages with 
no possibility of therapeutic treatment. Sixty percent of those occurred in 
women from other parts of the country. It is expected then that a larger 
number of cases are presenting all over the country and only those who can 
afford it would reach the cancer hospital.
Apart from INEN, there exist other cancer treatment units, but radiotherapy 
is available only in Trujillo and Arequipa, where the number of cases of 
cervical cancer is again large, and most cancers are diagnosed in very late 
not curable stages.
There is no doubt then that cervical cancer is not only the most frequent 
cancer in Peruvian women but also the major cause of cancer death.
2.3.2.2. Possible reasons for the high rates
Cervical cancer usually strikes poor non-educated women. That is the case 
in Peru where most cervical cancers occurs in women living in very 
deprived semi-urban and rural areas. Age is also to be considered, cervical
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cancer incidence increases with age, and women between 35 and 50 years 
are at high risk, 35% of women in Peru are in this age group.
Since some high-risk HPV types are necessary to cause cervical cancer, 
although affected by age, the prevalence of HPV DNA infection is to be 
accounted. Unfortunately only two studies in Lima (one unpublished) have 
reported data regarding this. The first one carried out in a deprived area in 
Lima between 1993-1995, reported a prevalence of 20% of HPV DNA 
infection detected by PCR (unpublished data). The second one, a hospital- 
based case-control study in INEN, reported a prevalence of 17.7% of HPV 
infection among 175 hospital controls 5. Both prevalences are within the 
range of similar studies. However, the prevalence of HPV 52 in cancer 
cases was 8.1% (14 of 173 squamous cell carcinomas), suggesting that 
HPV 52, now consider a high-risk type 202, is particularly confined to 
Peruvian women.
There exist national statistics on potential cofactors such as age of first 
intercourse, estimated to be 19.3 years, use of contraception methods, and 
other sexual behaviour data. None of them seem to explain the high 
incidence of cervical cancer, nor does smoking, since very few women 
smoke in Peru.
Because cervical cancer is a preventable disease, one reason for having 
high incidence and mortality rates in Peru is the lack of a prevention 
programme of cancer of the cervix uteri.
2.3.3. Efforts to control cervical cancer in Peru
Tables 2.3.3.1 and 2.3.3.2 show unpublished data presented by the 
Ministry of Health personnel in a working meeting in 1997. They reported 
a total of 401,155 cervical smears among 8,087,875 Peruvian women older 
than 14 years of age (5% coverage), 75% of those were screened for the 
first time. Forty one percent of those smears (163,381) were taken on non­
pregnant women between 30 and 49 years of age.
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Table 2.3.3.I. Number of Peruvian women screened with cytology in 
1997.
Number of screened women by age-group 
15-29 30-49 >50
Previously unscreened 174,952 113,612 13,918
Previously screened 46,541 49,769 5,729
Total number screened 221,493 163,381 19,647
Women to be covered * 3,550,394 2,862,847 1,674,634
Coverage 6.2% 5.7% 1.2%
Projected female population for 1997 according to the 1993 Nationa 
Census.
The cytology positivity rate was of 8% for mild dysplasia or worse. A total 
o f 8,713 (27%) low-grade lesions, 6,138 (19%) moderate dysplasias, 5,383 
(16%) severe dysplasias, 5,534 (17%) in situ carcinomas and 6,833 (21%) 
invasive cancers were cytological detected. Forty eight percent of high 
grade lesions were on young women (15 to 29 years of age), 31% in those 
between 30 and 49 years and 41% in those older than 49. Despite these 
large figures, information regarding treatment and follow up of these cases 
is not available.
Table 2.3.3.2. Cytology results of Peruvian women in 1997.
Cervical lesions detected by 
Conventional Cytology 15-29
Age-group
30-49 >50
Low-grade lesions 3,988 3,942 781
High-grade lesions or worse 11,380 7,277 9,913
- Moderate Dysplasia 2,999 2,636 502
- Severe Dysplasia 2,777 2,185 421
- In situ carcinoma 2,759 2,232 540
- Invasive cancer 2,845 2,860 1,127
Total detected lesions 15,368 13,855 3,371
Albujar reported that in 1993, the region cytology screening coverage in 
women aged 15-49 years was 9.4%, 16.3% for the province of Trujillo, and
203zero for the highland and Amazonian areas of La Libertad region 
According to unpublished local statistics, the annual cytology coverage for 
2000 was of 16% of women aged 15-49 in La Libertad, of them, only 39% 
were previously unscreened.
Jeronimo et al 204 evaluated Pap smear results of 61,846 screened in the 
gynaecological department of a general hospital in Lima, Peru, between 
1994 and 1996, and found a positivity rate (for LSIL or worse) of just
0.47%. Given the very high rates of cervical cancer in Lima, these data 
suggest a very low quality of cytology. By comparison, approximately 
3.5% of women screened in England have LSIL or worse on cytology.
2.3.3.I. General governmental efforts
In 1998, the Ministry of Health of Peru formulated a National Plan for 
Gynaecological Cancer Prevention: Cervix and Breast 1998-2000, in 
which activities to be carried out at each health level to implement a 
national screening programme, were detailed.
In 1999, once the plan was revised and approved, cervical cancer was 
declared a health priority in the country.
In September 1999, we produced a draft protocol concerning cervical 
screening in Peru, incorporating the use of visual inspection of the cervix 
after the application of acetic acid (VIA) in combination with two 
laboratory-based tests: Hybrid Capture II to detect Human Papillomavirus 
(HPV) DNA and liquid-based cytology. In the same month, the Bill and 
Melinda Gates Foundation awarded $50 million to the Alliance for 
Cervical Cancer Prevention for a major new effort to prevent cervical 
cancer in developing countries. The Alliance is made up of five 
international organisations: AVSC International, IARC (International 
Agency for Research on Cancer), JHPIEGO Corporation, PAHO (Pan 
American Health Organisation), and PATH (Program for Appropriate 
Technology in Health). PAHO and PATH decided to start a screening
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programme in the region of San Martin, Peru, in collaboration with the 
Ministry of Health of Peru. The intervention would try to screen 80% of 
women aged 25-49 in the region, to detect cervical lesions using VIA and 
to immediate treat with cryotherapy. Results from the project should give 
recommendations regarding of how to set an organised cervical screening 
programme in the Peru.
2.4. San Martin
The department of San Martin is located in the Amazon forest of Peru. It 
has a warm and humid climate with average maximum and minimum 
temperatures of 36°C and 19°C, respectively.
The department is divided into ten provinces: Bellavista, El Dorado, 
Huallaga, Lamas, Mariscal Caceres, Moyobamba, Picota, Rioja, San 
Martin and Tocache.
The capital of the department is Moyobamba located in the province of the 
same name, however the main city is Tarapoto situated in the province of 
San Martin.
Tarapoto was founded later but has become one of the commercial centres 
in the Peruvian Amazonian region. It has an airport with daily flights to 
different cities of the coast and jungle. The Marginal Highway connects the 
city with the rest of the region and the rest of the country. This highway is 
not yet paved and rains usually make it a route of mud holes so journeys 
can become very tedious and long.
The population of the department of San Martin was estimated to be 
667400 in 1997, based on data from the 1993 National Census 205. The 
birth and mortality rates of the department were of 26.8 and 5.3 per 103 
with a density population of 13 inhabitants per square km. It is one of the 
few departments where the male/female rate is over one (1.14). Around 
61% of the population live in urban areas, however, after 1993 when the 
leaders of the two main terrorists groups were captured and control over 
drug traffic improved, migration into rural areas increased. Migrants move 
to work in agriculture (61.5% of employed population). It should be
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noticed that these migrants represent a seasonal mobile population. The 
illiteracy rate is 12.5%.
San Martin is one of the departments where important Peruvian ethnic 
groups live, either under their original lifestyle or with a mixture of a 
modem and aboriginal life. According to the Census of 1993, of 65 ethnic 
groups registered all over the country, three of them have communities 
living in the region of San Martin: the Aguarunas, the Lamas-Chachapoyas 
and the Chayahuitas and are among the ten largest ones in Peru. The 
Aguarunas population is estimated to be around 45,137 inhabitants. They 
are located in the departments of Amazonas, Cajamarca and Loreto and in 
the provinces of Rioja and Moyobamba in San Martin. There are 
approximately 22,513 Lamas-Chachapoyas, composed of 51 different 
communities distributed over the provinces of Bellavista, El Dorado, 
Huallaga, Lamas, Picota, San Martin and Tocache, all in the department of 
San Martin. The Chayahuitas do not communicate with any other group in 
the Amazonian region. According to the 1993 census, there were 13,717 
Chayahuitas mainly in the departments of Loreto and San Martin.
The health region of San Martin (Direccion Regional de Salud, DIRES), 
representative of the Ministry of Health, has headquarters in the city of 
Tarapoto. It has a very well structured and implemented network that 
offers services to inhabitants including vaccination against endemic 
diseases of the area. Health posts and centres refer cases and send collected 
specimens to larger hospitals using network facilities. One of the main 
problems of the area is transport. Heavy rains sometimes make it 
impossible to travel from one town to another either by river or by road. 
This causes serious delays on sending specimens and referring patients and 
on receiving laboratory materials and results. One reason for inhabitants 
neglecting referral and increasing complications and losses to follow up is 
the poor transport particularly in the rainy season.
Cytological screening has been on going for several years, but results have 
never been published. Women seeking attention at any health facility are
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educated about cervical cancer and offered cytological screening every 
year. Smears are repeated on previously screened women of all ages.
San Martin has four cytology laboratories; the principal one is located in 
Tarapoto and covers the provinces of Bellavista, El Dorado, Huallaga, 
Lamas, Mariscal Caceres, Picota and San Martin. There is one in 
Moyobamba and one in Rioja, and a fourth one in Tocache covering the 
provinces of the same names.
In October 2000, a well-known Peruvian cytopathologist visited the first 
two laboratories and complained that neither laboratory kept adequate 
records making it impossible to evaluate performance. The laboratories had 
no pathologists and only the one in Tarapoto had adequate installations, but 
even in Tarapoto, the risk of contamination needed to be eliminated.
As a consequence o f this report, technical personnel of the Tarapoto 
laboratory were sent to INEN’s cytology laboratory for retraining. DIRES 
San Martin has made efforts to hire a pathologist to be in charged of the 
pathology of the region, but they have been unsuccessful.
According to unpublished hospital statistics, a total of 93 cases of invasive 
cancer of the cervix (most in advanced stages) in women of San Martin, 
were diagnosed and treated at INEN in the period 1997-2000. If it were 
assumed that they are all the incident cases from the department of San 
Martin, then the crude incidence rate of cervical cancer would be 9 per 105 
women per year. Moreover, if  assumed that at most 30% of cases will 
reach INEN, this rate will increase up to 30, a very high one.
An under-registration rate of 52% has been estimated for mortality 
collection in the department of San Martin. This and the fact that San 
Martin does not have a cancer registry leave us with no valid statistics of 
deaths due to cervical cancer.
Gage et al 9,10 reported a study concerning the follow-up of women with 
abnormal cytology in the region. From January 1999 to April 2000, a total 
of 233 abnormal smears were registered on cytological registries of the 
region. Information recalled showed that only 46 (25% of eligible women)
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were diagnosed and treated adequately and the rest were lost to follow-up 
with or without diagnosis. Six of them died of invasive cervical cancer. 
This study confirmed that one of the main causes of failure of cervical 
screening programs in difficult settings is lack of treatment and follow-up.
In summary, even though cytological screening has been going on in San 
Martin in a routine way, it has been ineffective.
2.5. The TATI project
By the end of 1999, two partners of the Alliance for Cervical Cancer 
Prevention, PAHO and PATH, decided to run a “see and treat” 
intervention in cervical cancer somewhere in Peru (Tamizaje y Tratamiento 
Inmediato de Lesiones Cervico-uterinas, TATI project). By February 2000, 
PAHO and PATH in co-ordination with the Ministry of Health of Peru 
(MINSA) decided to set up the project in the region of San Martin.
The primary objectives of the project were:
1. To assess the accuracy, cost effectiveness, safety and acceptability of 
screening and immediate treatment of lesions of the cervix uteri.
2. To develop capacity at primary and secondary level for management of 
dysplasia and invasive cancer so that cases can be timely resolved at the 
lowest possible cost to patients and the system. The hope was to screen 
80% of the eligible population within three years.
Despite the fact that the more than 50% of the cervical cancers occur in 
women over 49 years of age in Peru, as showed by data from the cancer 
registries of Trujillo 200 (55%) and Lima 201 (58%), the gynaecological 
cancer control programme of the government states that all women aged 
30-49 should be screened at least once in their life. However in this 
intervention, because the average age at first intercourse in the region is 17 
as compared to the national average of 19 years, it was decided that women 
aged 25-29 would be included. Therefore, the target population was 91,413 
women aged 25-49 residing in San Martin. There was no population list of
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the region, but major efforts were made to invite most women in the area 
and a list of those invited that refused to participate was kept at each health 
centre involved.
Women were invited to participate during routine visits to health centres, 
or through meetings within local women’s organizations, or when health 
campaigns are carried out in their communities. Free (of cost) screening 
and treatment were offered to women who:
(i). had not been previously diagnosed with cervical cancer;
(ii). had not had a hysterectomy or conization of the cervix;
(Hi). have had sexual intercourse at any time in their life; and
(iv). were not pregnant (self-reported) at time of screening.
Women who accepted to participate signed an inform consent, in which the 
examination with visual inspection after application of acetic acid (VIA) 
and the following magnified visual inspection using an AviScope™ 
(VIAM) in case of testing positive were fully explained.
Sixteen lead health centres were designated across the 10 health networks 
(one per province) in which the region of San Martin is divided. One 
general doctor and at least one midwife were selected from each of these 
lead health centres and became a TATI team. Five lead health centres only 
included midwives. In these centres, doctors from other centres came to 
examine and treat VIA positive women, as frequently as necessary.
TATI teams were trained in a special course in Tarapoto in November 
2000. Doctors and midwives received lectures on gynaecological aspects 
related to pre-cancerous lesions and cervical cancer, on how to perform 
gynaecological exams, VIA and collecting Pap smears, and in the protocol 
to be followed in the project. Doctors were also trained to perform VIAM 
and cryotherapy and to take punch biopsies. Doctors and midwives were 
able to practice on anatomical models first, and then on a selected group of 
women, who were invited to be re-screened and were transported together 
with local health personnel into Tarapoto because of having had a positive
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cytology in the previous year. Previously developed data collection forms 
were discussed among participants during the course.
Table 2.5.1. TATI teams across the region of San M artin.
Health
Network Lead Health Centres Doctors Midwives
Bellavista HR Bellavista 1 1
DIRES C Matemo Perinatal 1 2
El Dorado HR San Jose de Sisa 1 1
HR Saposoa 0 1
Huallaga
CS Sacanche 1 0
Meal. CS La Merced 1 1Caceres
CS Jepelacio 0 1
Moyobamba CS Lluyllucucha * 1 2
CS Soritor 1 1
Picota HR Picota 1 1
CS Nueva Cajamarca * 1 1
Rioja CS Nueva Rioja 0 1
PS San Juan Soritor 0 1
Lamas HR Lamas 0 1
CS Tabalosos * 1 1
San Martin CS Pongo del Caynarachi * 1 0
CS Juan Guerra 0 1
Tocache HR Tocache 1 2
Total 16 12 19
* Doctors went to other health centres to examine/treat positive VIA 
women.
After the course TATI teams went back to their towns and put the project 
in practice. After two months, a new meeting to discuss strong and weak
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>points of the protocol was held in Tarapoto; modifications were made to 
data forms and the project continued. Midwives screened patients as part of 
their daily professional activities. Women were invited to participate when 
visiting lead health centres, or by encouragement through women’s 
community groups, or during health campaigns. Those accepting to 
participate were asked to read and sign an informed consent, where all 
procedures were explained. Midwives performed a gynaecological exam 
and VIA, and took a Pap smear before applying acetic acid. Women found 
positive on VIA, were seen by a TATI doctor who performed VIAM.
Doctors treated with cryotherapy (after taking a punch biopsy of the lesion) 
women found positive on VIAM who signed another informed consent, or 
referred them to colposcopy. Two gynaecologists especially trained, 
performed colposcopy, treated women with cold conization, LEEP, or 
hysterectomy; or referred them to INEN (if other treatment was required).
2.6. Development of protocol
2.6.1. Initial plan
In September 1999, we produced a draft protocol concerning cervical 
screening in Peru, incorporating the use of visual inspection of the cervix 
after the application of acetic acid (VIA) in combination with two other 
tests: Hybrid Capture II to detect human papillomavirus (HPV) infection 
and liquid-based cytology (LBC). Colposcopy was to be offered to every 
woman testing positive on VIA, those negative on VIA but positive either 
on LBC or HPV testing, and in a random sample of those negative in the 
three tests. The aim was to detect high-grade squamous intraepithelial 
lesions (HSIL). Histologically was considered the gold standard for 
diagnosis. The protocol was to investigate the best cervical screening 
strategy in three different areas o f Peru: a very deprived district in 
Metropolitan Lima, the province of Huamanga in Ayacucho (Sierra) and 
Iquitos in the Amazonia of Peru. This study would also compared HPV 
DNA prevalence and other risk factors for cervical cancer in the three
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geographic regions o f Peru.
2.6.2. Collaboration with PAHO and PATH
Funds were searched among different international organisations. As 
explained earlier in this document, PAHO and PATH, two partners of the 
Alliance for Cervical Cancer Prevention in co-ordination with the Ministry 
of Health of Peru, decided to run a “see and treat” intervention in cervical 
cancer in the department of San Martin (TATI project). PAHO and PATH 
decided to allow us to incorporate our protocol in the TATI project, in this 
way, we were able to use the infrastructure already in place in the region 
and the facilities implemented by the TATI project. Nevertheless, our 
original protocol was modified in order to be nested within the TATI 
project. The protocol was to be set up only in San Martin, magnified visual 
inspection was added to the screening scheme and conventional cytology.
PAHO was to be responsible for the overall “see and treat” intervention. 
PATH was to implement recruitment strategies as to achieve the screening 
goals, and we were to be in charge of the research protocol, enrolling 5,000 
women with VIA, LBC and HPV testing. Our responsibilities included 
training, implementation and monitoring of LBC and HPV testing, as well 
as, organising histology to be processed at the INEN pathology laboratory, 
and the analysis of the cohort of the first 5,000 women screened with all 
tests.
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3. OBJECTIVES
3.1. Aim of the study
To evaluate the sensitivity, specificity, acceptability and feasibility of 
various combinations of four different techniques for cervical screening.
The techniques are:
i. Visual Inspection after Acetic acid application (VIA) by a midwife (or 
nurse) without magnification;
ii. Combined use of unaided VIA and VIA by a doctor using an 
AviScope™ device (VIAM), in those judged to be positive by means of 
unaided VIA;
iii. Liquid-based cytology (LBC) using AutoCyte-Prep®>’s manual system 
(Tripath); and,
iv. Human Papilloma Virus (HPV) testing using Hybrid Capture II 
(Digene).
3.2. Main Objectives
1. To estimate the overall sensitivity and specificity of various 
combinations of screening tests in San Martin, Peru, for detection of 
high-grade squamous intra-epithelial lesions (HSIL) on histology.
2. To estimate the relative sensitivity of HPV testing (Hybrid Capture II) 
and liquid-based cytology in women with acetowhite lesions on unaided 
VIA.
3. To evaluate the effect of requiring a doctor’s AviScope™ confirmation 
of unaided VIA on the sensitivity and specificity o f this screening 
technique.
4. To train a laboratory in Lima to be able to carry out liquid based 
cytology using the manual system of AutoCyte-Prep®.
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3.3. Secondary Objectives
1. To estimate the age-specific prevalence of HSIL and occult cervical 
cancer among women in San Martin, Peru.
2. To estimate the prevalence of different types of oncogenic HPV 
infections in San Martin, Peru.
3. To establish a screening network involving the Peruvian Ministry of 
Health, the National League against Cancer, NGOs working on behalf 
of poor women, community women’s groups, the National Association 
of Midwives, colposcopists and pathologists that would be well placed 
to advise and oversee a national cervical screening program.
4. To investigate the possible role o f ethnicity, diet, smoking and 
reproductive history as cofactors in the aetiology of high-grade cervical 
lesions in women exposed to oncogenic HPV.
5. To determine the most cost-effective combination of screening tests for 
use in a developing country.
6. To ascertain the infrastructure needed to implement a national screening 
programme with a goal of 75% coverage of women before the age of 50 
years.
These secondary objectives, despite being part of the study, will not be 
assessed in this thesis.
3.4. Hypothesis
A two-stage screening process, in which all women have a VIA and those 
with any suspected lesion receive an additional test (either LBC or HC-II), 
is a cost-effective approach to cervical screening in San Martin, Peru.
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4. METHODS
4.1. Basic design
4.1.1. Population
Women enrolling into the TATI project were invited to participate in this 
study. The first 5,600 women who, after being offered additional screening 
tests (HPV testing and LBC), signed an informed consent for additional 
cervical samples, were included in the study.
4.1.1.1. Inclusion criteria
As in the TATI project women were included if:
a. They were between 25 and 49 years of age, and;
b. They have had sexual intercourse at any time in their life, and;
c. They were not pregnant (self-reported) at the time of screening, and;
d. They had not had a hysterectomy or conization of the cervix, and;
e. Signed the corresponding informed consent.
4.1.1.2. Exclusion criteria
Women were excluded if:
a. Their samples for LBC and HPV were collected but were not 
examined with VIA by a midwife,
b. They had VIA but both LBC and HPV samples were inadequate or 
missing,
c. They were first evaluated during the TATI training course in 
November 2000 (women were invited if abnormal on previous 
cytology),
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d. They were screened with VIA within previous 12 months and tested 
positive, or;
e. They came into clinics because of having severe symptoms indicative 
of gynaecological cancer; and the midwife decided they were not 
suitable for screening.
4.1.2. First part of the protocol
This is a nested screening study within the TATI project in the region of
San Martin, Peru.
The first part of the protocol is presented in Figure 4.1.2.1.
Figure 4.1.2.1. First part of the protocol.
Parti
VIA
VIAM
If cryotherapy 
was not feasible
VIAneg
VIA pos
Part IIVIAMneg
VIAM pos
Colposcopy
Suspected cancer 
Transfer to INEN
(i) GC, HPV and LBC sarrple collection
(ii) VIA
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All women participating in the study were screened with four screening 
tests. Midwives performed first a gynaecological exam and visualised the 
cervix after introducing a speculum.
A cervical sample for conventional cytology (CC) (Papanicolaou smear) 
was collected by means of an Ayre spatula, by rotating it 360 degrees in 
the area of the squamocolumnar junction, smearing and fixing the cells 
from the spatula on a glass slide. Samples were sent to cytology 
laboratories within a month of collection.
A second sample for liquid-based cytology (LBC) was collected using a
®Rovers-Cervex brush. The brush was inserted into the endocervical canal 
and rotated five times clockwise. The brush head was transferred directly 
into a vial containing CytoRich Preservative Liquid and kept in a regular 
refrigerator (4°C).
A third sample for HPV DNA testing was collected using a Digene 
cervical brush. The brush was inserted 1 to 1.5 cms. into the cervix and 
rotated three times in anti-clockwise direction. Collected samples were 
immediately stored in tubes containing Digene Sample Transportation 
Medium (STM) and kept in a regular refrigerator (4°C).
Midwives then performed VIA. They first applied a solution of acetic acid 
(nominally 5%), and after waiting for a minute, examined the cervix for 
acetowhite areas close to the squamocolumnar junction. VIA was 
considered positive if any acetowhite lesions were observed in or close to 
the transformation zone, or negative otherwise. Midwives referred women 
to the doctor if VIA was positive or directly to the colposcopist if  they 
found evidence of suspected invasive cervical cancer. However, in some 
cases midwives referred women straight to colposcopy because they 
detected large acetowhite lesions or the general doctor would not be 
available for a long period.
Doctors performed VIAM using an AviScope™ device (4x magnification, 
green light). VIAM was considered positive if acetowhite lesions were 
observed, and negative otherwise. Women testing positive were offered
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immediate treatment with cryotherapy after being asked to sign another 
informed consent to be biopsied and treated. Punch biopsies of the 
compromised areas of the cervix were first taken on those who accepted 
the treatment. If lesions covered more than 75% of the cervix, or involved 
the endocervical canal, or were clearly invasive cancer, women were 
referred to colposcopy.
Gynaecologists performed colposcopy, took biopsies and treated women 
with LEEP, cold conization or hysterectomy as appropriate, and referred to 
INEN those suspected of having invasive cancer.
Biopsies were stored in formol at 20% and sent regularly to the INEN’s 
pathology laboratory in Lima.
Women who tested positive on VIA and were screened in any of the health 
centres where a doctor was not available, were given an appointment in 
accordance with the doctor’s schedule. Women who did not attended their 
VIAM appointment, were contacted by health centre personnel and were 
given new appointments.
Women who tested negative for VIA or VIAM were told to come back for 
another screening in three years and to return or contact the health 
personnel for the other screening results in two months. If results were 
available before and one was positive, women were contacted by health 
personnel (see below).
4.1.3. Second part of the protocol
The second part of the protocol is presented in Figure 4.1.3.1.
Women who tested negative on visual methods and return to the health 
centre for their other test results, were told to come back in three years if 
they tested negative on LBC and HPV. Those who did not come back for 
results but were negative on all screening tests were not traced again; while 
those testing positive on either LBC or HPV were visited by health 
personnel, usually midwives, who explained the results and encouraged
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women to come to the health centre to discuss their management options 
with the TATI midwives.
Women who were not already treated but whose cell samples tested 
positive on either LBC or Hybrid Capture could be managed under two 
options: either to have a second screening within 6 to 12 months from the 
first one (“no colposcopy option”), or to have a colposcopy (“colposcopy 
option”), as shown in Tables 4.1.3.1.a, 4.1.3.1.b, and 4.1.3.2.
Figure 4.1.3.1. Second part of the protocol.
Part II
Second sarrples
Writ for second 
LBC and HPV results
as in Parti
HPV
negptiwHPV
positive
LBC ASCUSorLSIL
Second VIA LBC and HPV
Wbmen M A M negathe
LBC Isb^tiw  A9CUS or LSIL
Gblposccpy
and
treatment
* VIA_M negative = VIA negative or VIA positive but VIAM negative.
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As conventional cytology was not part of this study, it was only taken into 
account if  a high-grade cervical lesion was reported, when similarly to 
LBC, women were referred to colposcopy and adequate treatment.
Most women were managed under the “no colposcopy” option, since there 
were only two centres offering the exam, and those with HSIL (or worse) 
on either LBC or CC already filled the colposcopists timetables.
Table 4.1.3.1.a. Management according to results of testing first 
samples “no colposcopy option” in women with a negative VIA(M)1.
LBC
HPV testing
HPV + HPV -
HSIL2 Colposcopy and treatment Colposcopy and treatment
LSIL orASCUS 6-12 month second tests 6-12 month second tests
Negative 6-12 month second tests Screen in 3 years
1 For women not treated with cryotherapy at initial visit.
2 HSIL or more on LBC or CC.
Table 4.1.3.1.b. Management according to results of the follow-up 
sample in women with a negative VIA on following screening 
(regardless of their results from first samples) under the “no 
colposcopy option” \
LBC
HPV testing
HPV + HPV -
HSIL2 Colposcopy and treatment Colposcopy and treatment
LSIL, ASCUS, 
or NEGATIVE Colposcopy and treatment Screen in 3 years
1 For women not treated with cryotherapy at initial visit.
2 HSIL or more on LBC or CC.
Those under the “colposcopy option” were managed as presented in Table
4.1.3.2.
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Table 4.1.3.2. Management according to results of test samples taken 
on initial visit under the “colposcopy option” \
LBC
HPV testing
HPV + HPV -
H SIL2 Colposcopy Colposcopy
LSIL or ASCUS Colposcopy 6-12 month second tests
Negative Colposcopy No follow-up
1 For women not treated with cryotherapy at initial visit.
2 HSIL or more on LBC or CC.
Health personnel visited several times women requiring second screening, 
which was intended to happen within 6 to 12 months of initial screening, 
but in many cases it only took place after 12 months.
Second screening included collection of samples for CC, LBC and HPV 
testing, and a second VIA exam performed by a midwife. If this second 
VIA was positive, women were referred to VIAM or directly to 
colposcopy, following the same guidelines as in the first part of the 
protocol. If either VIA or VIAM was negative, women were told to come 
back in three weeks for their other results.
As explained on Table 4.1.3.1.b., women with HSIL (or worse) on LBC or 
HPV positive were also referred for colposcopy and further treatment. 
Those testing negative on HPV and having lesions no worse than LSIL, 
were given their results and told to come back in three years. An external 
review of LBC second samples classified as LSIL when the corresponding 
HPV test was negative was organized to ensure women with these second 
results were free of disease.
A summary of the clinical procedures applied to women according to their 
screening results is presented on Figure 4.1.3.2. In this figure, women have 
been grouped in six clinical management options according to the type of 
treatment of evaluation they required. The groups are:
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1. VIA_M cryotherapy: women VIA positive and VIAM positive who 
required cryotherapy;
2. VIA_M colposcopy: women with VIA positive referred to colposcopy, 
or referred to VIAM which was also positive and referred to 
colposcopy;
3. HSIL colposcopy: women VIA negative, or VIA positive but VIAM 
negative or missing who had HSIL on LBC or CC, and so required 
colposcopy;
Figure 4.1.3.2. Clinical management according to screening test
results.
Clinical management according to screening test results 
Initial VIA and HPV and/or LBC
VIAM
missing
VIA_M negative or 
VIAM missing
VLA_M
positive
All negative 
or just one 
Inadequate 
(missing)Cryotherapy
LBC,CC<HSILLBO=ASCUS HPV positive 
and <HSIL (no HSIL)
Colposcopy
Colposcopy VIAM
Nothing
furtherSecond screening tests 
6-12 months
Second samples 
not collected**
Second HPV and LBC
LBC2<HSIL 
or HPV2 positive and HPV2 negative
LBC2>=HSILVIA2 positive
VIAM2
ColposcopyCryotherapy
* VIA_M is a combination of VIA and VIAM screening tests.
** Or second samples were collected but results were not available at time of 
analysis.
4. Cryotherapy second screening: women VIA negative, or VIA positive 
but VIAM negative (untreated) with second screening whose second
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VIA was positive, had VIAM which was also positive and were treated 
with cryotherapy;
5. Colposcopy second screening: women VIA negative, or VIA positive 
but VIAM negative (untreated) with second screening whose second 
VIA was positive and were referred straight to colposcopy, or their 
second VIA was positive, had VIAM also positive and instead of being 
treated with cryotherapy were referred to colposcopy; or those who had 
HSIL or worse on second LBC or had their second HPV test positive; 
and,
6. No further evaluation: women testing negative in all first tests or 
inadequate in one and negative in the others; or those VIA negative or 
VIA positive but VIAM negative (untreated) whose second VIA was 
negative or positive but their second VIAM was also negative and their 
LBC was less than HSIL and their HPV was negative, and so did not 
require further evaluation.
It is worth noticing that there are two groups of women with incomplete
screening:
a. Women who were referred to VIAM after VIA, but were not examined 
with VIAM; and,
b. Untreated women VIA negative or VIA positive but VIAM negative 
who required second screening but have not had the second screening so 
far, or whose second screening tests results are not available yet.
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4.2. Laboratory techniques and data handling
4.2.1. Sample handling
4.2.1.1. Collection and storage
Collected CC slides were sent to the corresponding laboratory using the 
health network connections (sometimes courier or official cars) once a 
month, and so results were not available for 2-3 months after collection. 
Since the start of 2002, CC results are available within 3 weeks of 
collection, since slides are sent more frequently to the cytology 
laboratories.
TriPath and Digene recommend to maintain collection kits and collected 
samples at less than 30°C. But temperatures in the region can easily 
reached 36°C, especially in the dry season (July to December). LBC and 
HC-II collection kits were stored in a room with full air-condition in the 
administrative TATI office in Tarapoto. Once a month, between 50 and 
100 HPV and LBC kits were delivered to each health centre, according to 
the refrigerated storage space within their facility. Deliveries were done in 
three trips, one covering the north (usually took two days), one the centre 
and one the south of the region. Trips were done in the TATI office car, 
keeping the air-conditioning on maximum, using “The Marginal”, main 
highway that connects all provinces in the region. Unfortunately only 40% 
of the highway is asphalted and trucks get easily trapped in the middle of 
the route for hours, and in the rainy season, small lagoons are formed 
making it impossible for cars to go further, therefore a distance of 100 km 
can becomes a twelve-hour journey.
4.2.1.2. Transport of collected samples
Collected samples of LBC and HC-II samples were properly labelled, 
closed and secured with masking tape by midwives or their assistants, and 
stored in refrigerators in the lead health centres. Once a week, samples
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were sent to the administrative TATI office in Tarapoto. Adequate 
transport of samples was crucial.
Samples were arranged in termical boxes, which then were filled with ice 
and closed. Termical boxes were then labelled and secured with masking 
tape. A list (see Appendix) containing codes and names of sample owners 
was sent together with the boxes.
Samples were transported in three different ways:
a. Boxes were collected when additional empty collection kits were 
delivered to health centres, and taken to Tarapoto in the TATI car.
b. Boxes were taken by the midwife or her assistant if they were going 
into Tarapoto for some meeting, or were bringing patients.
c. Boxes were sent by courier service directly to the TATI office. Couriers 
guaranteed the arrival of boxes to their destination but not the time of 
arrival.
Once boxes arrived at the TATI office, sample tubes were immediately 
dried (depending on how long the journey was, the ice would have already 
melted), re-labelled according to the list added to the box, and stored in a 
regular refrigerator (4°C).
LBC collected samples were sent to Lima twice a month, while HPV 
samples were sent to London every two months.
LBC results were available within 2-3 weeks of screening, and the HPV 
ones after 3-4 months of screening. Results were sent by fax or personally 
delivered to the health centres.
4.2.2. Liquid-based cytology
Conventional cytology was not considered part of this study; nevertheless 
it was offered to all participants, following regulations of the Ministry of 
Health. It was processed and read in three different laboratories.
Liquid-based cytology was performed in the cytology laboratory of INEN 
using the AutoCyte-Prep® manual system (TriPath). In this process, the
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sample is thoroughly mixed and disaggregated by vortexing, and excess 
white cells, blood artifact; bacteria and debris are removed by density 
reagent centrifugation. Cell pellets are suspended in dilutent, and cervical 
material is sedimented onto specially coated slides. These slides are stained 
with the usual Papanicolaou stain used by the laboratory.
These LBC slides were then read by cytotechnicians, and reviewed by a 
cytopathologist.
Table 4.2.2.I. Classification used for LBC results.
Liquid-based cytology result
- Inadequate - ASCUS
- Normal - AGUS
Inflammation - Condyloma/HPV 
- Mild dysplasia
- Moderate dysplasia
- Severe dysplasia/ 
Carcinoma in situ
- Invasive carcinoma
- Adenocarcinoma
Results were classified using the classification show in Table 4.2.2.1. For 
the analysis condyloma/HPV and mild dysplasia were merged into low- 
grade squamous intraepithelial lesions (LSIL) and moderate dysplasia and 
severe dysplasia/carcinoma in situ into high-grade squamous intraepithelial 
lesions (HSIL).
The same classification was used for reporting CC results.
4.2.3. Hybrid-Capture II
HPV DNA testing was performed, by Dr. Philip Londesborough in Dr. 
Linda Ho’s HPV laboratory of Cancer Research UK, using Hybrid Capture 
II (HC-II, Digene Corporation). This technology is a signal amplified 
hybridisation antibody capture microplate assay that utilises 
chemiluminescent detection.
Specimens containing the target DNA are denatured and hybridised with 
HPV RNA probe cocktail (13 full-length RNA probes recognising
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oncogenic HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). 
The resultant RNA:DNA hybrids are captured onto the surface of a 
microplate well coated with antibodies specific for RNA:DNA hybrids. 
Immobilised hybrids are then reacted with alkaline phosphatase conjugated 
antibodies specific for the RNA:DNA hybrids, and detected with a 
chemiluminescent substrate. Several alkaline phosphatase molecules are 
conjugated to each antibody. Multiple conjugated antibodies bind to each 
captured hybrid resulting in substantial signal amplification. As the 
substrate is cleaved by the bound alkaline phosphatase, light is emitted 
which is measured as light units on a luminometer. The intensity of the
light emitted denotes the presence of absence of target DNA in the
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Results were given as the ratio of the relative light units given by the test 
specimen to that given by a lpg/ml HPV DNA control (RLU/CO) (number 
of RLUs for a lpg cut-off).
4.2.4. Data handling
A questionnaire was applied to all women entering the study. Age, 
ethnicity, education (years at school), province of residence, age at first 
intercourse, number of sexual partners, parity, abortion, use of 
contraceptives (method, time), number of Pap smears in life, date and 
result of the last Pap smear and smoking status (never, ex, current) were 
collected.
Seven different data forms have been used by the TATI project (see 
Appendix). The first one registers the variables mentioned above; the 
second and third one used to report VIA and VIAM results. The fourth one 
contains results from follow-up visits after cryotherapy. The fifth one is 
reports the findings during colposcopy. The sixth and seven are lists of 
collected conventional cytology samples and biopsy specimens to be sent 
to respective laboratories. For our protocol, a simple page was designed for 
the collection of additional samples. These lists contain a special sample
83
code, date of sample taking, name and age of each screened woman, and 
were stored in a Microsoft Excel file together with corresponding results.
Results from screening tests were sent to the TATI administrative office, as 
soon as they were available.
Personnel in the TATI administrative office use an information system, 
especially generated for the TATI project, to input data collected from the 
different forms. As samples were collected, the TATI information system 
periodically provided us with a database containing variables relative to 
our protocol. This database was merged with our Excel worksheet and a 
complete file with relevant information for this study was obtained.
Data was then stored in a STATA file, which has been used for analysis.
Data cleaning started as soon as data were available. This helped to point 
out problems of the main TATI database and particularly of the follow-up 
of screened women. The TATI office was informed of any inconsistency 
found.
4.3. Statistical methods
4.3.1. Definition of disease
Histology was the gold standard for comparing screening tests (Table 
4.3.1.1).
The true histology of any woman whose screening results warranted 
colposcopy or cryotherapy (according to the above tables), but who did not
•  * 207have a biopsy or colposcopy will be treated as “missing at random” 
within clinical management groups (Figure 4.1.3.2). Women who tested 
negative on all screening tests were treated as if they did not have HSIL on 
histology, even though we can not be certain of that. For this reason, 
estimates of measures of tests performance should be considered as relative 
rather than absolute measures of performance.
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Table 4.3.1.1. Definition of true positives and true negatives.
True Positives True Negatives
- Histology HSIL or worse
-  VIA_M negative and liquid-based 
cytology negative or inadequate, and 
HPV negative or inadequate (but not 
both inadequate).
-  VIA_M negative and cytology no 
worse than LSIL and on follow-up: 
VIA negative, and cytology no worse 
than LSIL and HPV negative.
-  Adequate negative colposcopy (i.e., no 
visible lesion and no biopsy taken).
-  Histology no worse than LSIL.
4.3.1.1. Women with undetermined disease status
In summary, disease status was not fully determined in:
Women with indicated VIAM, which was not performed (unless 
women had HSIL on cytology and required colposcopy);
Women referred to colposcopy (after first or second screening tests); 
which was not performed;
Women who required second samples, which were not collected, or 
women who had second samples but results were not available at 
time of analysis.
Women with cryotherapy but who were not biopsied;
Women who had inadequate biopsies (no pathology available).
These women were considered “not fully evaluated” for analysis, and 
therefore were assumed to be “missing at random”.
85
4.3.2. Variables defined from screening tests for analysis
The variables used in the analysis defined according to first screening tests
results are:
a. VIA1: positive if VIA was positive and negative otherwise.
b. VIAM1:
-  Cryo if VIA was positive and VIAM was positive and cryotherapy 
was indicated;
-  Colp if VIA was positive and VIAM was positive and referred to 
colposcopy;
-  Negative if VIA was positive but VIAM was negative; and
-  Missing if VIA was positive and women were referred to VIAM but 
this was never performed.
c. VIA_M1: a combination of results of VIA and VIAM, defined as:
-  Cryol if VIA was positive and VIA referred to VIAM, which was 
positive and indicated cryotherapy;
-  Colpl if VIA was positive and VIA referred straight to colposcopy; 
or, if  VIA was positive and VIA referred to VIAM, which was 
positive and referred to colposcopy; and,
-  Negative if  VIA was negative and VIAM was not indicated nor 
performed or VIA was positive and referred to VIAM, which turned 
out to be negative.
d. VIA_MM1: another combination of results of VIA and VIAM, defined
as:
-  Cryol if VIA was positive and VIA referred to VIAM, which was 
positive and indicated cryotherapy;
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-  Colpl if VIA was positive and VIA referred straight to colposcopy; 
or, if  VIA was positive and VIA referred to VIAM, which was 
positive and referred to colposcopy;
-  VIA neg if VIA was negative and VIAM was not indicated nor 
performed; and,
-  VIAM neg if VIA was positive and VIAM was negative.
LBC7: including LBC results divided in 7 categories:
-  Neg if LBC negative or inflammation;
-  ASCUSifASCUSorAGUS;
-  LSIL if condyloma/HPV or mild dysplasia;
-  Moderate if moderate dysplasia;
-  Severe if severe dysplasia or carcinoma in situ;
-  Cancer if carcinoma; and,
-  Inadequate if samples were insufficient for testing.
LBC6: including LBC results divided in 6 categories:
-  Neg if LBC negative or inflammation;
-  ASCUSifASCUSorAGUS;
-  LSIL if condyloma/HPV or mild dysplasia;
-  HSIL if moderate dysplasia or severe dysplasia or carcinoma in 
situ;
-  Cancer if carcinoma; and,
-  Inadequate if  samples were insufficient for testing.
. LBC4: including LBC results divided into 4 categories:
-  Neg if LBC negative or inflammation;
-  LSIL if ASCUS, AGUS, condyloma/HPV or mild dysplasia;
-  HSIL if moderate dysplasia or worse; and,
-  Inadequate if samples were insufficient for testing.
h. LBCRES: including LBC results divided into the 4 categories used to 
define women requiring second screening:
-  Neg if  LBC negative or inflammation;
-  ASCUSifASCUSorAGUS;
-  LSIL if  condyloma/HPV or mild dysplasia; and,
-  Inadequate if samples were insufficient for testing.
i. LBCLOW:
-  Pos, if ASCUS, AGUS, Condyloma/HPV, LSIL, HSIL or worse on 
LBC;
-  Neg, if negative or inflammation, 
j. LBCHSIL:
-  Pos, if  HSIL or worse on LBC;
-  Neg, if  negative or inflammation, 
k. HPV1:
-  Pos, if  HPV testing positive (>1 RLU); and,
-  Neg, if HPV testing negative.
1. HPVHVL: using a higher threshold for HC-II:
-  Pos, if HPV testing positive (>4 RLU); and,
-  Neg, if  HPV testing negative.
m. CCH_0_LB: HSIL on conventional cytology and less than HSIL on 
LBC:
-  Pos, if HSIL on conventional cytology and less than HSIL on LBC; 
and,
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-  Neg, otherwise.
n. VIA_LBCHG: interaction between VIA and high-grade disease on 
LBC:
-  Pos, if  VLA1 positive and HSIL or worse on LBC; and,
-  Neg, otherwise.
o. VIA_HPV: interaction between VIA and HPV testing:
-  Pos, if VIA 1 positive and HPV1 positive; and,
-  Neg, otherwise.
p. LBHG_HPV: interaction between high-grade disease on LBC and HPV 
testing:
-  Pos, if HSIL or worse on LBC and HPV1 positive; and,
-  Neg, otherwise.
The variables defined according to required second screening tests (after 6 
to 12 months of first samples of LBC and HPV) are:
q. VIA2, defined as:
-  Pos, if VIA positive and referred to VIAM; or,
-  Neg, otherwise, 
r. VIAM2:
-  Pos if  VIA2 was positive and VIAM2 was positive;
-  Negative if VIA2 was positive but VIAM2 was negative; and 
s. VLA_M2: a combination of second results of VIA and VIAM:
-  Cryo2 if VIA2 was positive and VIA2 referred to VIAM2, which 
was positive and indicated cryotherapy;
-  Colp2 if VIA2 was positive and VIA2 referred straight to 
colposcopy; or, if  VIA2 was positive and VIA2 referred to VIAM2, 
which was positive and referred to colposcopy; and,
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-  Negative if  VIA2 was negative and VIAM2 was not indicated nor 
performed or VIA2 was positive and referred to VIAM2, which 
turned out to be negative.
t. LBC2, defined as:
-  Pos, if HSIL or worse on second LBC; and,
-  Neg, if Negative, inflammation, ASCUS, AGUS, Condyloma/HPV, 
or LSIL on second LBC.
u. HPV2, defined as:
-  Pos, if second HPV was positive; and
-  Neg, if second HPV was negative.
v. SECSCR, defined as:
-  Cryo2, if VIA_M2 was Cryo2;
-  Colp2, if  VIA_M2 was Colp, or LBC2 was HSIL or worse, or 
HPV2 was positive;
-  Neg, if VIA_M2 was negative, LBC2 was less than HSIL and 
HPV2 was negative; and
-  Missing, if any of the three results were missing or second 
screening was required but not performed.
w. HSIL or disease status defined as:
-  HSIL, if histology was HSIL or worse;
-  No HSIL, as True Negatives are defined in Table 4.3.1.1; and,
-  Missing, if women were “not fully evaluated”.
4.3.3. Statistical analysis
All analyses were performed using STATA, version 8.0.
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4.3.3.I. Descriptive statistics
A summary of the study population characteristics is presented, including 
demographics, reproductive and sexual factors, and history of previous 
cervical screening.
4.3.3.2. Results from screening tests
Results from screening tests are tabulated; those of conventional and 
liquid-based cytology are detailed.
Positivity rates of each screening test are tabulated. The positivity rate of 
VIA_M is calculated as a weighted measure taking into account the 
corresponding VIA result. Positivity rates of CC are tabulated only for 
detecting high-grade disease, as this is the only case when they affect 
clinical management (see 4.2.2 above). Two thresholds are considered for 
LBC: ASCUS or worse (LBCLOW) and HSIL or worse (LBCHSIL) and 
two for HPV (>1 RLU and >4 RLU).
The dependence of each screening test on age and on place of screening 
(health center) is evaluated using Score tests for trends or Chi-square tests, 
as appropriate. To determine the association between VIA_M and age or 
health center, weighted proportions and trends across age groups or health 
centers are evaluated using Wald tests obtained through weighted logistic 
regression models, which account for the original VIA result.
Positivity rates of different combinations of screening tests are then 
tabulated: each of VIAM, LBC, CC (only if  HSIL or worse) and HPV 
within VIA positive women, within VIA negative women, within VIAM 
negative women (being VIA positive first), and within VIAM positive 
(being VIA positive first).
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4.3.3.3. Estimating sensitivity and specificity of screening tests
Figure 4.3.3.3.I. Algorithm used for the estimation of missing data and 
undetermined disease status.
Algorithm for estimation o f  missing data and undetermined disease status
1. “Fill in missing VIAM results”
a. Estimate the probability of different results on VIAM conditionally on results of 
other tests.
b. If a woman has VIA positive, but no VIAM or final diagnosis, replace her with 
three pseudo observations, one with each of the three possible VIAM results.
c. Assign weights to the pseudo-observations equal to the estimated probability of 
the observation given the other test results. Assign weight one to all original 
observations.
2. “Fill in missing second stage tests results ”
a. Estimate the probability of different results (discharge, treat or refer) following 
second stage testing conditional on first stage results using data from women 
who have results from all three (VIA_M, LBC, HPV) second-stage results.
(NB: Exclude women who are VIAM2 positive but HPV2 or LBC2 unknown).
b. If a (pseudo)-observation ought to have had second-stage screening, but it has yet 
not been done or the results are not yet available and if the woman has not had a 
final diagnosis, replace observation with three observations.
c. Assign weights to the new pseudo-observations equal to the estimated probability 
of the observation given the first stage results.
d. Assign weight one to all observations not created in step 2b.
3. “Fill in the missing disease status”
a. Estimate the probability of high-grade disease given the available screening 
results. This must be done taking into account the different chances of being fully 
evaluated depending on the screening results. We do this by identifying 7 
“clinical management groups” and assume that within each group, the chance of 
being evaluated is independent of the true disease status. Observations in each 
clinical group are weighted by the inverse probability of being evaluated. The 
probability of high-grade disease is then estimated from women who were fully 
evaluated.
b. If the final diagnosis is missing, replace the observation by two pseudo­
observations: one with HSIL on final diagnosis and the other without HSIL.
c. Assign weights to the observations as follows:
- weight one for any woman with known final diagnosis;
- weight equal to the estimated probability of the pseudo-observation using the 
weighted model in 3a.
d. Multiply the weights from lc, 2c, and 3c together to get a final weight.
4. Form tables o f pseudo-observations weighted by the weights from 3d.
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Overview
Sensitivity, specificity and positive predictive values could not be 
estimated directly (by usual definitions) because of missing data regarding 
screening tests and lack of disease status.
Figure 4.3.3.3.1 details the algorithm used to estimate sensitivity, 
specificity and positive predictive value of screening tests.
VIAM was not performed in a number of women who tested positive on 
VIA and were referred to VIAM; and second samples were not collected 
on women who needed them, or were collected but the results were not 
available at time of analysis. Allowance for these missing data was made 
before calculating measures of tests performance. Our approach was to 
estimate the distribution of the missing values.
Once second screening tests results were estimated, women were re­
allocated into one of seven clinical management groups (strata); six were 
described in Figure 4.1.3.2: two of women treated with cryotherapy (one 
after initial screening and the other after second screening), three of 
women referred to colposcopy (two after initial screening and one after 
second screening tests), one of women who did not required further 
evaluation (either after first screening tests or after second screening tests); 
and the seventh one composed of fully evaluated women (with histology) 
despite incomplete screening (for instance, women with pending VIAM 
who underwent colposcopy instead).
Despite the fact that women testing negative in all tests either on first or 
second samples, were considered free of disease; verification bias was 
introduced because only few women met these criteria or underwent 
colposcopy or had histology. The rest of women were considered “not fully 
evaluated”.
The probability of having been fully evaluated depended on the seven 
evaluation strata, as for instance; a woman in group 3 (needing colposcopy 
because of HSIL on cytology), was more likely to have a colposcopy that 
one requiring colposcopy after second set of screening tests. Therefore, the
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probability of disease was estimated based on the evaluation strata for 
different screening tests or combination of screening tests.
Dealing with VIAM missing data
A multinomial logistic model was fitted to estimate the possible results of 
VIAM using the other screening tests results (LBC and HC-II) (Figure
4.3.3.3.1, step 1). The predicted probabilities of having one of three 
possible results of VIAM: positive needing cryotherapy, positive needing 
colposcopy and negative were obtained. Data of women with missing 
VIAM were then expanded three times; so each of these women had one 
record with each of three possible results. Weights were then generated 
based on the predicted probabilities obtained from the multinomial logistic 
model and were assigned to each of three records of women with missing 
VIAM results. Women with complete data were given weight one. Thus, a 
woman could have three records corresponding to the three possible results 
on VIAM but sum of weights for each woman was always one.
Dealing with second screening missing data
A  multinomial logistic model was fitted to estimate the possible results of 
second screening tests using the results of first LBC and first HPV testing 
(Figure 4.3.3.3.1, step 2). All women with a second test were VIA_M 
negative. The predicted probabilities of having one of three possible 
combinations of second screening results: positive needing cryotherapy 
(VIA_M2 positive indicating cryotherapy), positive needing colposcopy 
(VIA_M2 positive referring to colposcopy, or HSIL or worse on LBC2, or 
HPV2 positive) and negative (VIA_M2 negative, less than HSIL on LBC2 
and HPV2 negative), were obtained. Data of women with missing second 
screening were then expanded three times, yielding one record for each of 
three possible results. Weights were then generated based on the predictive 
values obtained from the multinomial logistic model and were assigned to 
each of three records of women with missing second screening results.
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Again, the weights for women who needed second screening and had 
complete second screening tests and for women who did not need second 
screening tests results were the unity. New weights were defined as the 
product of the first and second set of weights. Therefore, one woman could 
have one, three or five records (five for instance if she had VIAM pending 
and LBC LSIL on the first screening test with no second results), but only 
a fraction of her had a particular second screening set of results, and so was 
counted as one person (weights from estimating VIAM results were 
combined with these ones, and their sum was the unity).
Using these estimated second screening results, the clinical management 
groups were assigned to each record and related variables were updated.
Estimating disease status
Disease status was estimated using empirical estimation and weighted 
logistic regression modelling (Figure 4.3.3.3.1, step 3).
Data of women with undetermined disease status were then expanded, so 
each had one record with high-grade disease and one with free of disease 
status. Weights were then generated based on the probability of having 
disease given a history of screening test results. The weights for women 
who were fully evaluated were the unity.
The probability of having disease on those “not fully evaluated” was 
estimated by means of:
a. Empirical estimation: using the proportion of women with high- 
grade disease (who were actually fully evaluated) within different 
combination of screening tests results (VIA_M1 x LBC x HPV 
levels). This proportion was treated as an empirical predictive value 
and was used to generate the first weight {pi) for those with 
undetermined disease status.
b. Fitting two logistic regression models using the screening tests 
results: the first on women who did not require second screening and
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the second one on those who needed second screening, the predictive 
values generated from both models were combined to obtain the 
second weight (pi) for women with undetermined disease status.
c. One logistic regression model using the screening tests results of all 
women in the study. These predictive values were used to calculate 
the third weight (pi) for women with undetermined disease status.
After these, women “not fully evaluated” had at least two records (more if  
they also had missing VIAM or second tests results) with certain weights 
and with an estimated disease status: with or without disease. The final 
weights used to estimate measures of performance were defined as a 
combination of the weights used to assign different results of screening 
tests to women with missing data and the ones obtaining from assigning 
disease status, as follows:
i=l to m 
r=l to 6 strata
m=total number of pseudo-women in stratum r 
w\= w l i* w2i
w l : weights after estimating VIAM missing 
w2: weights after estimating second stage tests missing 
Fwj= W* p i 
Fw2= W. * p2 
Fw3= W. * p3 
Where:
2>
W r =
for:
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Fwj=weight to be used for estimates of performance, for j= l, 2, or 3.
Using these final weights, the estimated number of women having disease 
was then defined as:
The estimated number of women without disease was:
N-Nhg
Where:
W=total number of women 
Definition o f  measures ofperformance
The number of True Positives for a particular test or combination of 
screening tests was the estimated number of women with disease who tested 
positive for that test or combination of tests, and the number of True 
Negatives was the estimated number of women without disease who tested 
negative for that test or combination of tests.
The sensitivity of a particular screening test or combination of several 
screening tests was estimated as the ratio of the True Positives over the 
estimated number of women with disease; the specificity as the ratio of the 
True Negatives over the estimated number of women without disease; and 
the positive predictive value as the True Positives over the total number of 
women testing positive for the test or combination of tests.
Nhg =
The screening tests or combination of screening tests, being:
(i). VIA1
(ii). V IA M 1;
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(Hi). LBC1 >ASCUS
(iv). LBC1 >HSIL
(v). HPV1;
And the combinations of:
(v). VIA1 and HPV 1;
(vi). VIA1 and LBC1 >ASCUS; or,
(vii). VIA1 and LBC1 >HSIL.
These methods yielded unbiased point estimates but bootstrapping was 
needed to estimate 95% confidence intervals.
Because of the complicated algorithm; which uses multinomial regression 
to deal with missing data and weighted logistic regression to take account 
of the fact that some groups are more likely to be fully evaluated than 
others; it was too difficult to calculate asymptotic standard errors; therefore 
we used re-sampling techniques. We choose the bootstrapping approach, in 
which samples with replacement are drawn from the original one and the 
algorithm is repeated. Based on the percentile confidence interval 
bootstrapping estimation, after 1000 replications, 95% confidence intervals 
for each measure of test performance were obtained. Bootstrapping was 
slow but results were available sooner (Stata code for algorithm and 
bootstrapping on Appendix).
4.3.4. Sample size considerations
The sample size was calculated to estimate sensitivity and specificity of 
each test and their different combinations. Assuming three different rates 
of histologically confirmed high-grade disease: 1.6%, 2% and 3% in 5,000 
women screened, then 80, 100 and 150 cases of high-grade disease would 
be expected.
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Tables 4.3.4.1 and 4.3.4.2 show the power to estimate sensitivity and 
specificity of any screening test (or different combinations of screening 
tests) assuming true sensitivities vary between 65% and 90%, and true 
specificities between 83% and 98%. The power is obtained for a one-sided 
test, using the normal approximation, for an a=0.05, and for an alternative 
hypothesis that the true minimum sensitivity or specificity equals the 
different values proposed, and the difference with the null hypothesised 
value is not more than 10%.
Table 4.3.4.I. Power for different assumed sensitivities and rates of 
high-grade disease.
Null
Hypothesis
Ho:
Alternative
Hypothesis
Ha:
Expected number of women with 
histologically high-grade disease
n=150 n=100 n=80 
Power Power Power
Sens=0.95 Sens>0.85 99% 68% 62%
Sens=0.90 Sens>0.80 97% 90% 84%
Sens=0.85 Sens>0.75 93% 83% 76%
Sens=0.75 Sens>0.65 86% 73% 65%
Sens=0.65 Sens>0.55 81% 67% 59%
A sample size of 5,000 women will guaranteed an accurate estimation of 
any specificity over 78% for any screening test or combination of tests.
Sensitivity estimation depends on rate of disease, in the worst scenario: 
only 80 cases of high-grade disease are detected, there will not be enough 
power to detect sensitivities under 75%, and the estimates will not be very 
precise. But, if  150 cases are detected, the estimation of sensitivity is 
guaranteed; assuming sensitivities are in the range of 55% to 85%.
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Table 4.3.4.2. Power for different assumed specificities and rates of 
high-grade disease (allowing for women lost to follow-up).
Null
Hypothesis
Ho:
Alternative
Hypothesis
Ha:
Expected number of women without 
high-grade disease*
n=4800 n=4500 n=4000 
Power Power Power
Spec=0.98 Spec>0.973 94% 93% 91%
Spec=0.95 Spec>0.941 87% 85% 81%
Spec=0.90 Spec>0.887 90% 88% 85%
Spec=0.85 Spec>083.5 89% 87% 84%
Spec=0.80 Spec>0.785 82% 80% 76%
* Allowing for women lost to follow-up.
Figure 4.3.4.I. Expected proportions of test results based on 
assumptions.
HC-II positive LBC positive
(4%)(17%)
1%
5.4% 0.4%
2%
.6% 0 .6%
.8%
VIA positive
(20%) 73%
The following assumptions are used to picture the number of women 
testing positives in different screening tests and their combinations, as
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shown in Figure 4.5.1. These assumptions are based in previous 
unpublished data from Peru or from the literature.
-  The positivity rate of VIA is 20%.
-  The positivity rate of HC-II is 17%.
-  The positivity rate of LBC for detecting ASCUS or worse is 4%.
In this way, for 5,000 women screened in the San Martin region, we would 
expect:
-  130 women testing positive on VIA and LBC.
-  3930 women testing negative on VIA and LBC.
-  530 women testing positive on VIA and HC-II.
-  3680 women testing negative on VIA and LBC.
-  4000 women testing negative on VIA.
4.4. Ethical considerations
Informed consent was obtained in order to perform additional screening 
tests. Reasons for testing were clearly explained to all participating 
women. A special letter of consent including explanatory figures was used 
to explain the additional screening test to participants. The advantages of 
having additional samples were explained to women by midwives, who 
were trained to answer all sort of questions regarding any of the screening 
tests used in the study. When women were illiterate, they were asked to 
stamp their fingerprints in the informed consent letter. Cervical samples for 
LBC and HPV were processed nameless. Results were given to health 
centres, where personnel incorporated them into clinical records; which are 
confidential and belong to the health facility. Women were told their 
results in private, and if  necessary, these were also explained to their 
partners.
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4.5. My contribution
Here, I state that I developed the original protocol; which after some 
amendments has been used in this study. Before this study started, I 
collaborated intensively with the TATI investigators in the 
operationalization of the project. I participated in several meetings with 
health authorities in Lima and San Martin, while setting up the project. I 
helped during the first VIA and VIAM training course. I participated in the 
elaboration of data forms, those related to this study and to the TATI 
project, including the informed consent. I also collaborated with people 
involved in the design of the TATI database (SYSTAT). I was in charge of 
the implementation of the new LBC laboratory in Lima, and of organising 
the transport of HPV and LBC samples to Tarapoto, Lima and London; 
and also of the arrangement of histology being read at INEN and its quality 
assessment. I made regular visits to the health centres involved in my study 
to personally encourage midwives to continue with recruitment; and to 
deliver sampling kits and to collect samples. I was in charge of managing 
the results of LBC and HPV testing, and I made them available as soon as 
possible for women, and helped to identify cases missed by initial 
screening with VIA. I performed several quality assessments of the data of 
the participants of my study and showed my results to the TATI office for 
their use. I carried out all the analysis. Methods for dealing with missing 
data were proposed by my supervisor. I am the sole author of this 
dissertation. I would like to thank and acknowledge midwives, doctors, 
gynaecologists, the LBC lab, the HPV lab and the pathologists for their 
contribution.
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5. RESULTS
5.1. Descriptive Statistics
Between February and December 2001, 5595 of 13426 women recruited 
by the TATI project, were also screened with LBC or HPV testing. Women 
were recruited from 16 health centres distributed across the region. If 
resources were available at the time of visit, women were offered the 
additional screening tests. Figure 5.1.1 shows a schematic summary of the 
study.
Figure 5.1.1. Schematic summary of the study
Schematic summary of the study
7830 in TATI 
but not in study protocol
30 excluded <
Sample size=5565
5595 VIA plus LBC or HPV
5539 women with VIA, LBC and HPV
7 women without LBC samples 
19 women without HPV samples’
13426 women recruited by the TATI project between February and December 2001
* one HPV sample insufficient.
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Midwives took LBC and HPV samples on 4 women but postponed VIA for 
several months. Thirty women, including these 4, were excluded from 
analysis; the reasons are explained on Table 5.1.1.
Table 5.1.1. Women excluded from analysis.
Reasons for exclusion Number of excluded
Evaluated in TATI course 2000 6
Samples collected after VIA positive 2
Samples collected after cryotherapy 17
VIA not performed 4
LBC inadequate and HPV missing 1
Total 30
Among the 5565 women considered for analysis, 7 had VIA and HPV but 
not LBC samples collected, 18 had VIA and LBC but not HPV samples 
and one HPV sample was insufficient for testing on initial screening, 
leaving 5539 (99.5%) with a complete set of screening tests. Only these 
5539 women with complete set of screening tests were used to estimate 
measures of screening tests performance (see 5.5).
5.1.1. Time and place of screening
Table 5.1.1.1 shows the recruitment period and number of women 
recruited by each health centre. A total of 1881 (34%), 2060 (37%) and 
1624 (29%) women were screened in the north, centre and south of the 
region, respectively.
Except for P.S. Juan Guerra and C.S. Jepelacio, each health centre 
recruited at least 200 women for this study. But, the Centro Matemo 
Perinatal in Tarapoto (main city of the region), the C.S. Llluyllucucha in 
Moyobamba (capital of the region) and H.R. Saposoa, contributed with 
more than 500 women each.
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Table 5.1.1.1. Number of screened women by place of screening
Recruitment Screened women
Health centre period n %
North 1881 33.8
C.S. Lluyllucucha Feb-Sep 586 10.5
C.S Soritor Feb-Oct 335 6.0
C.S. Jepelacio Jun-Aug 126 2.3
C.S. Nueva Rioja Feb-Nov 288 5.2
H.R. Nueva Cajamarca Feb-Nov 298 5.4
P.S. San Juan del Rio Soritor Feb-Sep 248 4.4
Centre 2060 37.0
Centro Matemo Perinatal Apr-Aug 618 11.1
P.S. Juan Guerra Apr-Aug 165 3.0
C.S. Tabalosos Feb-Sep 292 5.2
H.R. Lamas Feb-Aug 343 6.2
H.R. San Jose de Sisa Feb-Nov 397 7.1
H.R. Picota Feb-Aug 245 4.4
South 1624 29.2
H.R. Bellavista Feb-Aug 349 6.3
H.R. Saposoa Feb-Sep 556 10.0
C.S. La Merced Feb-Aug 321 5.8
H.R. Tocache Apr, May, Dec 398 7.1
. .
Most health centres started recruiting patients in February and completed it 
by August 2001. But, the Centro Matemo Perinatal and the P.S. Juan 
Guerra did not start until April 2001, and the C.S. Jepelacio only started in 
June. The HR Tocache, accessible only by small airplane, recruited women 
in April, May and December, when a small plane carrying sampling kits 
was especially flown into the city.
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5.1.2. Demographics
The age distribution of 5,565 women included in the analysis is presented 
in Table 5.1.2.1. Despite the fact that women between 25-49 years of age 
were invited for screening, 61 participants were younger than 25 years of 
age, while 12 were older than 49 years of age. The age range v/as 15-56 
years, and the mean (±SD) was 34.4 years (±6.5).
Table 5.1.2.1. Age distribution of screened women
Age group
Screened women 
n %
<25 61 1.1
25-29 1481 26.6
30-34 1480 26.6
35-39 1251 22.5
40-44 776 13.9
45-49 504 9.1
>50 12 0.2
Table 5.1.2.2. Education level of screened women
Education level
Screened women
n* %
No education 391 7.0
Incomplete primary school 1212 21.8
Complete primary school 1743 31.4
Incomplete secondary school 907 16.3
Complete secondary school 834 15.0
Higher education 471 8.5
* Data was not recorded for 7 women (n=5558).
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Most screened women declared themselves as literate (93%), however, 
only 24% of them had completed secondary school or had higher education 
(Table 5.1.2.2).
The majority of women were “Mestizo’5, but 264 (4.7%) belonged to 
Peruvian ethnic groups of the region (one woman was Chayahuita, 29 were 
Aguarunas, and 234 Lamas-Chachapoyas).
5.1.3. Reproductive history and sexual behaviour
Table 5.1.3.1 presents the distribution of age at first intercourse and of the 
number of sexual partners as reported by participants during screening.
Table 5.1.3.1 Age at first sexual intercourse and number of sexual
jartners.
Screened women
Characteristics n %
Age at first sexual intercourse*
<15 643 11.6
15-16 1932 34.7
17-18 1692 30.4
19-20 770 13.8
21-24 432 7.8
>25 95 1.7
Number of sexual partners
1 2893 52.0
2-3 1722 31.0
>4 950 17.0
* Data was not recorded for one woman (n=5564).
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The age at first sexual intercourse ranged between 8 and 33, and the mean 
(±SD) was 17.1 years (±2.7 years). In general, women started having 
sexual relationships early in life, 77% of participants started before 19 
years of age. There was one woman who was sexually abused at 8 years of 
age and 2 others who started sexual life at 10 years of age.
More than 50% of women had only one sexual partner in life (at time of 
screening). There was one sexual worker identified among the participants 
(>90 sexual partners).
Table 5.1.3.2 summarises the self-reported reproductive history of 
participants including the use of contraceptive methods.
Only 2% of women were nulliparous, the majority had from 2 to 5 
children, and 117 women had at least 10 children. Twenty-seven percent of 
women reported one abortion and another 17% more than one.
A total of 4214 (76%) women reported having ever used contraceptive 
methods, 58% of them specified the current contraceptive method at time 
of screening.
Hormonal methods were the most common (55%) including 567 women 
taking the pill and 761 using injectables. Sterilization had been performed 
in 584 (24%) women, and six husbands had a vasectomy. Six percent of 
participants reported using natural methods such as rhythm and 
breastfeeding. The duration of using the contraceptive method was also 
recorded but data were very inconsistent and are not presented here.
Table 5.3.1.3 summarises the previous screening history of participants as 
reported during screening.
Only 873 (16%) of women were previously unscreened, 28% had had 
cytology only once, 25% had had it twice, 18% had been cytological 
screened three times, and 13% had more than 3 previous cytologies.
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Table 5.1.3.2 Self-reported reproductive history
Screened women
Characteristics n %
Parity
0 116 2.1
1 580 10.4
2 1280 23.0
3 1182 21.2
4 890 16.0
5 533 9.6
6-9 867 15.6
>10 117 2.1
Abortions (including miscarriages)
0 3136 56.3
1 1501 27.0
>2 928 16.7
Ever use of Contraceptive Methods
Yes 4214 75.7
No 1351 24.3
Current Contraceptive Method**
None 1351 24.3
Sterilization 584 23.7
Hormonal methods 1354 55.0
IUD 172 7.0
Spermicides 30 1.2
Barrier methods 136 5.5
Natural methods 167 6.8
Other*** 19 0.8
* Data on age at first intercourse was missing for one woman (n=5564)
** Percentages based on 2462 reported current contraceptive methods 
(Percentage of None based on 5565 women).
***Including 6 vasectomies.
109
Table 5.1.3.3 Self-reported screening history
Characteristics
Screened women 
n %
Number of previous cytologies
0 873 15.7
1 1541 27.7
2 1408 25.3
3 978 17.6
>4 765 13.7
Self-reported results from last cytology*
Positive 50 1.1
Negative 3439 73.3
Does not know 1203 25.6
Self-reported year of last cytology**
2001 406 8.8
2000 2056 44.2
1999 1000 21.5
Before 1999 1186 25.5
* Percentages based on women with data (n=4692) 
** Percentages based on women with data (n=4648)
The large proportion of women previously screened is explained by the 
fact that the region of San Martin has been used to evaluate programmes of 
contraception for several years. Women seeking contraception advice were 
offered screening as part of the program. However, among those who had 
previous cytology screening, 73% reported that their last cytology was 
negative, only 50 recalled having received a positive result and 1204 did 
not know the result of their last cytology. These 50 women with a previous 
positive cytology were included in the analysis, since no record of their 
previous cytology was found in the screening centres, they were not 
previously treated and came asymptomatic into screening.
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Only 9% of women reporting previous cytology were screened in 2001, 
before participating in the project. The majority of women with previous 
cytology were last screened in 2000 (44%), 22% were screened in 1999 
and 26% before 1999.
Women were also asked if  they have ever smoked, and if  so for how long, 
97% of them had never smoked, 1.4% were current light smokers and 
1.5% were ex-light smokers (data was not recorded on 4 women).
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5.2. Screening tests
Of the 5565 women included in the analysis, 5539 (99.5%) had the three 
screening tests.
Figure 5.2.1 summarises the results of the first screening with visual 
inspection methods.
Figure 5.2.1. Results of initial screening with visual inspection 
methods.
Results of initial screening with visual inspection methods
Extra-protocol
VIAM
(45)
VIAM 
>  missing 
(102)
Negative
(4216)
Positive
(1349)
VIAM
negative
(29)
VIAM
positive
(16)
VIA
(5565)
Colposcopy
(13)
VIAM
positive
(521)
VIAM
negative
(713)
Screen in 
3 years 
(4171)
A total of 4216 women were classified as negative with VIA. However, 45 
of them were examined with VIAM outside protocol guidelines. Sixteen of 
them tested positive on VIAM and were treated or referred for appropriate 
evaluation. The remaining 4171 VIA negative women did not require 
further evaluation.
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Among the 1349 women positive on VIA, 13 were referred directly to a 
colposcopist, and the rest to VIAM. Among, 1233 women who had VIAM 
after having a positive VTA, 521 (42%) were positive and 713 (58%) were 
negative. Eleven of the 521 positive VIAM women were classified as 
“suspected neoplasia” and were referred to colposcopy. VIAM was not 
performed in 102 of 1336 women who were previously referred to VIAM 
by the midwife performing the initial VIA.
Table 5.2.0.1 summarizes the results of initial screening with conventional 
cytology (CC) and liquid-based cytology (LBC).
Table 5.2.O.I. Results of Cytology: CC and LBC.
Cytology result
CC
Screened women 
n %
LBC 
Screened women 
n %
Inadequate 620 11.1 301 5.4
Normal 4712 84.7 4311 77.5
ASCUS/AGUS 12 0.2 162 3.0
Condyloma/HPV 8 0.1 279 5.0
Mild dysplasia 30 0.5 334 6.0
Moderate dysplasia 25 0.5 97 1.7
Severe dysplasia/CIS 22 0.4 56 1.0
Invasive Cancer 3 0.1 18 0.3
Missing" 133* 2.4 7 0.1
* Including 22 collected slides that arrived broken to the laboratory.
A total of 5454 women were screened with conventional cytology (CC), 
including 22 women whose samples were broken before reaching the 
laboratory. CC samples were inadequate in 620 (11%) women. Eighty-five
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percent of women were classified as negative, only 6 ASCUS, 6 AGUS 
and 8 condylomas or HPV infections were reported. Only 30 mild, 25 
moderate, 22 severe dysplasias and 3 suspected cancers were reported (the 
three of them have been histologically confirmed).
A very different picture was that of LBC. Only 5% of LBC collected 
samples were inadequate for laboratory analysis and 7 (0.1%) women did 
not have samples collected. The majority of women (4311 of 5558) tested 
negative on LBC. Only two samples were reported as AGUS, but 160 were 
considered ASCUS. Five-percent were classified as condyloma or HPV 
infection and 334 women had mild dysplasia and 171 had high-grade 
disease, including 18 suspected cancers. Of these 18 women, 14 had 
histologically confirmed high-grade disease or worse (1 severe dysplasia, 7 
carcinomas in situ (CIS), 1 microinvasive cancer and 5 invasive cancers), 
one had a negative colposcopy (no biopsy was collected), and the other 
three have not been fully evaluated yet.
A total of 702 women (12.6%) were HPV positive on Hybrid Capture II, 
but 18 samples were not collected and one was insufficient for laboratory 
testing.
Table 5.2.0.2 presents the positivity rates of the screening tests. Two 
different thresholds are including for LBC: ASCUS or worse (including 
ASCUS, AGUS and condylomas or HPV infections, and mild or worse 
dysplasias) and high-grade disease or worse (including moderate 
dysplasias, severe dysplasias or CIS and invasive cancer). In this table, 
inadequate samples and missing tests are not counted.
The positivity rate of VIA alone was 24.2%, of VIAM in VIA positive 
women was 42.8%, and of VIA_M, i.e., combined VIA/VIAM including 
women referred straight to colposcopy instead of to VIAM, was 10.4%. 
LBC had a positivity rate of 18% for ASCUS or worse and 3% for high- 
grade disease, as compared to 2% positivity rate of CC for high-grade 
disease (as stated earlier in 4.1.3 and 4.2.2; CC positivity rates will only be 
tabulated for high-grade disease). The positivity rates of HPV testing
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(using Hybrid Capture II) were 12.7% and 10.2% for cut-off points of 1 
and 4 RLUs, respectively.
When including inadequate samples (as negative) the positivity rates of 
LBC for detecting low-grade disease (ASCUS or worse) was 17% and of 
LBC and CC for detecting high-grade disease were 3.1% and 1.8%, 
respectively.
Table 5.2.O.2. Positivity rates of screening tests
Screening test
Positive women 
n
# o f
adequate
Positivitv Rate
%
VIA 1349 5565 24.2
Combined VIA/VIAM 534 1247 10.4*
LBC > ASCUS 946 5257 18.0
LBC > HSIL 171 5257 3.3
CC > HSIL 50 4812 1.0
HPV (>1 RLU) 702 5546 12.7
HPV (>4 RLU) 568 5546 10.2
* VIAM was performed in 92% of those with positive VIA. The positivity 
rate of Combined VIA/VIAM has been corrected by the positivity rate of 
VIA.
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5.2.1. Screening tests and age
Table 5.2.1.1 shows the age distribution of women who tested positive on 
initial VIA and VIA_M.
Table 5.2.1.1. Age distribution of VIA and VIA_M positive women
Age-group
Women testing 
positive on VIA
n %
Women testing 
positive on VIA M
n
<30 385 25.0 164 11.8
30-34 380 25.7 156 11.1
35-39 318 25.4 118 10.0
40-44 168 21.7 60 8.8
>44 98 19.0 36 7.4
Total 1349 24.2 534 10.4
*Positivity rate weighted by the one of VIA alone.
The positivity rate of VIA varied according to the age of screened women. 
It increased slowly from 25%, in those less than 30 years of age, up to 26% 
in those aged 31-34, but afterwards shows a decreasing trend up to 19% in 
those older than 44 years of age (p-value for trend=0.004). There was a 
clear downwards trend of VIA_M positivity with age, the older the women 
the smaller the positivity rate of VIA_M, it was 11.8% in those less than 30 
years of age and 7.4% in those older than 44 years (Wald test=-3.21, p- 
value=0.001).
Table 5.2.1.2 shows the age distribution of women who tested positive on 
LBC (low and high-grade disease thresholds). In both cases, there is a clear 
increasing trend of the positivity rate of LBC across age groups.
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Table 5.2.I.2. Age distribution of LBC positive women
Age-group
Women testing positive on LBC 
Low-grade disease High-grade disease 
n % n %
<30 238 16.1 20 1.4
30-34 234 16.8 46 3.3
35-39 235 20.1 47 4.0
40-44 135 18.5 33 4.5
>44 104 21.8 25 5.2
. Total 946 18.0 171 3.3
When considering the low-grade disease threshold, the positivity rate of 
LBC increased from 16% in women younger than 30 years of age to 22% 
in women older than 44 years of age (p-value for trend=0.0015). This is a 
surprising result, as the number of low-grade cytological abnormalities 
usually decreases after 40 years of age.
When considering the high-grade disease threshold, the positivity rate of 
LBC increased from 1.4% in those younger than 30 to 5.2% in those older 
than 44 years of age (p-value for trend<0.001).
Table 5.2.1.3. Age distribution of HPV positive women
Age-group
Women testing positive on HC-II
n %
<30 236 15.4
30-34 183 12.4
35-39 148 11.9
40-44 89 11.5
>44 46 9.0
Total 702 12.7
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Table 5.2.1.3 shows the age distribution of women who tested positive on 
HPV. There is a decreasing trend of the prevalence of HPV infection, as 
women grow older. The positivity rate of HC-II decreases from 15.4% in 
women younger than 30 years to 9% on women older than 44 years (p- 
value for trend=0.0001). Among women screened outside the established 
age range: three aged 15-19 years, 58 aged 20-24 and 12 aged 50-56, 1 
(33.3%), 8 (13.8%) and 2 (16.7%) had a positive HPV test.
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5.2.2. Screening tests and place of screening
Table 5.2.2.1 shows the distribution of place of screening among those 
women testing positive on VIA and on VIA_M.
Table 5.2.2.I. Place of screening of VIA and VIA_M positive women
Health centre
Women testing 
positive on VIA
n %
Women testing 
positive on VIA M
n
North 441 23.4 180 11.3
C.S. Lluyllucucha 141 24.1 55 10.3
C.S Soritor 33 9.9 11 4.9
C.S. Jepelacio 70 55.6 6 6.0
C.S. Nueva Rioja 37 12.9 22 9.7
H.R. Nueva Cajamarca 95 31.9 48 19.1
P.S. San Juan del Rio Soritor 65 26.2 38 17.5
Centre 671 32.6 250 12.6
Centro Matemo Perinatal 266 43.0 73 12.0
P.S. Juan Guerra 54 32.7 14 9.8
C.S. Tabalosos 77 26.4 33 11.6
H.R. Lamas 130 37.9 47 14.1
H.R. San Jose de Sisa 115 29.0 71 18.5
H.R. Picota 29 11.8 12 5.9
South 237 . 14.6 104 6 £
H.R. Bellavista 98 28.1 18 5.3
H.R. Saposoa 40 7.2 19 3.4
C.S. La Merced 26 8.1 25 8.1
H.R. Tocache 73 18.3 42 11.0
Total 1349 100 534 100
*Positivity rate weighted by the one of VIA alone.
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The positivity rate of VIA varied greatly (Chi-square=465.8,df=15,p- 
valueO.OOOl), from 7.2% in women screened at H.R. Saposoa (in the 
south) to 55.6% in women screened at C.S. Jepelacio (in the north).
On average, VIA positivity rates were higher in the centre of the region 
(32.6%), with Centro Matemo Perinatal having the highest rate (43% of 
more than 600 screened women), while the lowest rates came from the 
south (14.6%).
The positivity rates of VIA_M also varied across health centres, but more 
moderately than those of VIA (Wald test=0.12,p-value=0.908). VIA_M 
positivity rates range was 3.4-19% (in H.R. Saposoa and H.R. Nueva 
Cajamarca, respectively).
VIA_M positivity rates were higher in the centre of the region (12.6%) and 
lower in the south (6.6%), (Wald test=-1.34,p-value=0.181).
Figure 5.2.2.1. Positivity rates of VIA M and VIA in 16 health centres.
= to
VIA positivity rate (%)
Figure 5.2.2.1 presents the positivity rates of VIA and VIA_M by health 
centre. This figure suggests that the positivity rates of both screening tests
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are weakly correlated. If the variability of VIA positivity rates was due to 
variability of disease in different health centres, this figure should show a 
significant correlation between both tests positivity rates. But it seems that 
among health centres with VIA positivity rates under 40%, there was a 
positive correlation between midwives’ and doctors’ diagnosis while the 
contrary occurred in health centres with VIA positivity rates over 40%. 
This suggests that much of the variability of VIA positivity rates is due to 
differences in VIA interpretation rather than differences in the underlying 
rates of visible lesions.
Table 5.2.2.2. LBC and CC inadequate samples by place of screening.
Health centre
Inadequate samples 
LBC CC 
n % n %
C.S. Lluyllucucha 30 10.0 33 5.3
C.S Soritor 5 1.7 9 1.5
C.S. Jepelacio 6 2.0 13 2.1
C.S. Nueva Rioja 9 3.0 89 14.4
H.R. Nueva Cajamarca 23 7.6 32 5.2
P.S. San Juan del Rio Soritor 9 3.0 75 12.1
Centro Matemo Perinatal 40 13.4 48 7.7
P.S. Juan Guerra 17 5.6 28 4.5
C.S. Tabalosos 17 5.6 59 9.5
H.R. Lamas 20 6.6 69 11.1
H.R. San Jose de Sisa 13 4.3 31 5.0
H.R. Picota 25 8.3 52 8.4
H.R. Bellavista 34 11.3 55 8.9
H.R. Saposoa 19 6.3 12 1.9
C.S. La Merced 24 8.0 3 0.5
H.R. Tocache 10 3.3 12 1.9
Total 301 100.0 620 100.0
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Table 5.2.2.2 shows the distribution of LBC and CC inadequate samples by 
place of screening. The number of inadequate samples varied from 1.7 to 
13.4 for LBC and between 0.5 and 14.4 for CC. The percentage of 
inadequate samples was roughly similar for both LBC and CC in C.S. 
Soritor, C.S. Jepelacio, P.S. Juan Guerra, H.R. San Jose de Sisa and H.R. 
Picota, larger for LBC than CC in C.S. Lluyllucucha, H.R. Nueva 
Cajamarca, Centro Matemo Perinatal, H.R. Bellavista, H.R. Saposoa, C.S. 
La Merced and H.R. Tocache, and smaller for LBC than CC in the rest.
Table 5.2.2.3 shows the distribution of place of screening among those 
women with low-grade or high-grade disease on LBC.
When considering the low-grade disease threshold, the positivity rate of 
LBC varied from 12.8% in the Centro Matemo Perinatal (centre of the 
region) to 29.4% (Chi-square, df=15, p-value<0.0001) in the P.S. San Juan 
del Rio Soritor (north).
On average, health centres in the north of the region had the highest LBC 
(low-grade) positivity rate (21.1%) while those in the centre of the region 
had the lowest (15%).
When a high-grade disease threshold was considered, the positivity rates of 
LBC varied from 1.9% in the H.R. Lamas (centre of the region) to 5.0% in 
the P.S. San Juan del Rio Soritor (north). This variation was not 
statistically significant (Chi-square, df=15, p-value=0.771).
Overall, the positivity rates of LBC for detecting high-grade disease were 
2.5% in the centre of the region, 3.6% in the north and 3.7% in the south.
LBC positivity rates of detecting ASCUS or worse were more steady than 
those of VIA across health centres; but distribution of rates was different. 
For LBC ( ^VSCUS), the positivity rates were higher in the north of the 
region (21%) while for VIA, they were higher in the centre (33%).
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Table 5.2.2.3. Place of screening of LBC positive women
Health centre
Women testing positive on LBC 
Low-grade disease High-grade disease
n % n %
North 378 21.1 65 L6
C.S. Lluyllucucha 94 17.0 15 2.7
C.S Soritor 79 23.9 13 3.9
C.S. Jepelacio 20 16.7 3 2.5
C.S. Nueva Rioja 52 18.6 10 3.6
H.R. Nueva Cajamarca 63 23.0 12 4.4
P.S. San Juan del Rio Soritor 70 29.4 12 5.0
Centre 289 15.0 49 2J>
Centro Matemo Perinatal 74 12.8 13 2.3
P.S. Juan Guerra 21 14.2 4 2.7
C.S. Tabalosos 41 14.9 8 2.9
H.R. Lamas 53 16.4 6 1.9
H.R. San Jose de Sisa 66 17.2 13 3.4
H.R. Picota 34 15.5 5 2.3
South 279 18.2 57 3J_
H.R. Bellavista 62 19.7 12 3.8
H.R. Saposoa 96 17.9 19 3.5
C.S. La Merced 42 14.1 11 3.7
H.R. Tocache 79 20.4 15 3.9
Figure 5.2.2.2 and 5.2.23 show the positivity rates LBC (ASCUS+) and 
LBC (HSIL+) positivity rates by health centre. In both cases, the positivity 
rates of LBC and VIA_M are poorly correlated.
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Figure 5.2.2.2. Positivity rates of LBC (ASCUS+) and VIA M in 16 
health centres.
20
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Figure 5.2.2.3. Positivity rates of LBC (HSIL+) and VIA M in 16 
health centres.
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Table 5.2.2.4 shows the distribution of place of screening among those 
women testing positive on HC-II.
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Table 5.2.2.4. Place of screening of HPV positive women
Health centre
Women testing positive on HC-II 
n %
North 260 13.9
C.S. Lluyllucucha 88 15.2
C.S Soritor 47 14.0
C.S. Jepelacio 15 11.9
C.S. Nueva Rioja 29 10.1
H.R. Nueva Cajamarca 45 15.3
P.S. San Juan del Rio Soritor 36 14.7
Centre 231 11.2
Centro Matemo Perinatal 80 12.9
P.S. Juan Guerra 11 6.7
C.S. Tabalosos 33 11.4
H.R. Lamas 40 11.7
H.R. San Jose de Sisa 44 11.1
H.R. Picota 23 9.4
South 211 13.0
H.R. Bellavista 46 13.2
H.R. Saposoa 72 13.0
C.S. La Merced 44 13.7
H.R. Tocache 49 12.3
The positivity rate of HPV testing varied from 6.7% in the P.S. Juan 
Guerra (centre of the region) to 15.3% in the H.R. Nueva Cajamarca (in the 
north). However, most positivity rates were between 11% and 13%, 
making the variation not statistically significant (Chi-square=T8.3,df=15, 
p-value=0.249).
Figure 5.2.2.4 shows the positivity rates of HC-II and VIA_M in the 16 
health centres participating in the study. Overall, the HC_II positivity rates
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do not vary as VIA_M positivity rates increase, and their correlation is 
very poor.
Figure 5.2.2.4. Positivity rates of HC-II and VIA M in 16 health 
centres.
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5.2.3. Combination of screening tests
Tables 5.2.3.1 and 5.2.3.2 present the detailed results of LBC and HPV by 
VIA, these results are summarised in Table 5.2.3.3 in which the positivity 
rates of VIAM, LBC, CC and HPV for different thresholds are presented.
Table 5.2.3.1 shows the results of LBC according to VIA. Among 1349 
women who tested positive on VIA, 78 (5.8%) LBC samples were 
inadequate, 999 (74.1%) were LBC negative, 3% had ASCUS, 4.7% had 
condyloma or HPV infection, 7% had mild dysplasia, and 74 (5.4%) had 
HSIL including 11 suspected cancers.
Table 5.2.3.1. LBC results by VIA.
Liquid-Based Cytology result
VIA Positive 
n %
VIA Negative 
n %
Inadequate 78 5.8 223 5.3
Negative 999 74.1 3212 78.6
ASCUS 41 3.0 121 2.9
Condyloma/HPV 64 4.7 215 5.1
Mild dysplasia 93 7.0 241 5.7
Moderate dysplasia 45 3.3 52 1.2
Severe dysplasia/CIS 18 1.3 38 0.9
Invasive cancer 11 0.8 7 0.2*
* Seven women negative on VIA did not have LBC samples.
Conventional cytology samples among women testing positive on VIA 
were inadequate in 174 women and missing in 36 (5 slides were broken 
before arriving to the laboratory), but among 1139 adequate samples, 26 
(2.3%) were reported as high-grade disease, including two suspected 
cancers.
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Table 5.2.3.2 shows the HPV testing results according VIA. Among 1349 
women testing positive on VIA, 232 (17.2%) were HPV positive, but in 
four of them HPV samples were not collected.
Table 5.2.3.2. HPV results on VIA positive women.
Hybrid Canture-II results
VIA Positive 
n %
VIA Negative 
n %
Negative
Positive (>1 RLU)
1113 82.5 
232 17.2*
3731 88.5 
470 11.5**
* Four women positive on VIA did not have HPV samples.
** Fifteen women positive on VIA did not have HPV samples.
Table 5.2.3.3 summarises the positivity rates of other screening tests 
among VIA positive women (inadequate and missing samples are not 
counted on this table).
Table 5.2.3.3. Positivity rates of VIA on women positive on other 
screening tests.
Screening tests
Women testing positive on VIA 
n _%
VIAM 534 42.8
LBC > ASCUS 272 21.4
LBC > HSIL 74 5.8
CC > HSIL 26 2.3
HPV (>1 RLU) 232 17.2
HPV (>4 RLU) 199 14.8
As presented before in Figure 5.2.1, 1349 women tested positive on VIA 
and were referred to VIAM, but 102 women have not yet been examined.
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Among 1247 VIA positive women who had VIAM, 534 (42.8%) tested 
positive on VIAM.
Among 1271 VIA positive women with adequate samples on LBC, 272 
(21.4%) had ASCUS or worse, and 74 (5.8%) had high-grade disease or 
worse. Of 1139 women with adequate samples on CC and who tested 
positive on VIA, 26 (2.3%) had HSIL or worse on CC.
Table 5.2.3.4 presents the overall positivity rates of screening tests when 
combined with VIA. The combined test is considered positive if the second 
test is positive after VIA was positive and the combination is negative 
otherwise, excluding the inadequate and missing samples. The positivity 
rates presented in this table are weighted ones, because not every woman 
who was positive on VIA had VIAM, or had adequate cytology or HPV 
samples.
Table 5.2.3.4. Overall positivity rates of screening tests among women 
testing positive on VIA.
Screening tests
Number positive among 
VIA positive women
Overall proportion 
positive on both tests
VIAM 534 10.4
LBC > ASCUS 272 5.2
LBC > HSIL 74 1.4
CC > HSIL 26 0.6
HPV (>1 RLU) 232 4.2
HPV (>4 RLU) 199 3.6
Among 1247 women who had VIAM because of being positive on VIA, 
534 were positive, giving a positivity rate of combined VIA/VIAM 
(VIA_M) of 10.4%. Of 1271 women testing positive on VIA with adequate 
LBC samples, 272 had at least ASCUS and 74 had HSIL or worse, 
yielding combined VIA/LBC positivity rates of 5.2% and 1.4%,
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respectively. Only 26 of 1139 VIA positive women with adequate CC 
samples had HSIL on CC with a positivity rate of 0.6%. As for HPV 
testing, among 1345 women testing positive on VIA with adequate HPV 
samples, 232 were positive on HC-II (>1 RLU) and 199 for a cut-off point 
of 4RLU, yielding positivity rates of combined VIA/HPV testing of 4.2% 
and 3.6%, respectively.
Table 5.2.3.5 shows the number of women testing positive on different 
screening tests according to VIA and VIAM.
Table 5.2.3.5. Positivity rates of different screening tests according to 
VIA and VIAM results.
Screening test
VIA 
negative* 
n (%)
VIA positive 
VIAM negative** 
n (%)
VIA positive 
VIAM positive*** 
n (%)
LBC > ASCUS 
LBC > HSIL 
CC > HSIL 
HPV (>1 RLU) 
HPV (>4 RLU)
674(16.9) 
97 (2.4) 
24 (0.7) 
470(11.2) 
369 (8.8)
119(18) 
24 (3.6)
5 (0.8) 
100(14.0) 
83 (11.6)
136 (26.7) 
46 (9.0) 
18(3.9) 
119(22.5) 
104(19.6)
* VIA negative = VIA neg in VIA_MM1 (see 4.3.2.d).
** VIA positive and VIAM negative = VIAM negative on VIA_MM1. 
*** VIA positive and VIAM positive = VIA_MM1 Cryo or Colp.
Among women who were negative on VIA, 674 (16.9%) had ASCUS or 
worse lesions on LBC, 97 and 24 had high-grade disease on LBC and CC, 
respectively; 470 were positive on HC-II (>1 RLU) and 369 were positive 
for a cut-off point of 4 RLUs.
Among those who were positive on VIA but negative on VIAM, 119 
(18%) had at least ASCUS on LBC, 3.6% and 0.8% had HSIL on LBC and
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CC, respectively; 14% and 11.6% were positive on HPV testing for cut-off 
points of 1 and 4 RLUs, respectively.
Among those women who tested positive in both VIA and VIAM, VIA_M 
positive, 26.7% had at least ASCUS on LBC, 9% and 3.9% had HSIL or 
worse on LBC and CC, respectively; 22.5% and 19.6% were positive on 
HC-II for cut-off points of 1 and 4 RLUs.
The positivity of each test increased across VIA and VIAM results, and 
decreased when using higher threshold definitions for cytology (ASCUS vs 
HSIL) and for HPV testing (1 vs 4 RLUs).
5.2.4. Second screening tests results
Among 646 women eligible for second screening, 477 had second VIA_M 
results, 591 had second LBC results and 563 had second HPV results 
available at time of analysis.
Table 5.2.4.I. Second screening test results.
Number of women
Second screening test Negative % Positive %
VIA_M2 448 94% 29 6%
LBC2 >HSIL 523 88% 68 12%
HPV2 418 75% 145 25%
Of the 29 being positive on second VIA_M, 12 had cryotherapy and 17 
were referred to colposcopy. Among 523 women “negative” (no worse 
than LSIL) for LBC2, 12 had inadequate LBC samples, 261 were negative, 
33 had ASCUS and 8 had AGUS, 130 had condyloma/HPV and 79 had 
mild dysplasia. Of those 68 positive, 7 women had suspected carcinoma 
and two had suspected adenocarcinoma.
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5.3. Clinical management according to screening results
The number of screened women evaluated and treated is presented 
following the clinical management groups established in Figure 4.1.3.2. 
These figures are based on original data before any estimation of missing 
values.
Group 1: Women requiring cryotherapy after testing positive on first 
VIA_M (VIA_M1).
Figure 5.3.1 presents the clinical management of women testing positive 
on VIA_M who required cryotherapy.
Figure 5.3.1. Clinical management of women testing positive on 
VIA M who required cryotherapy.
Clinical management of women testing positive on VIA M 
Group 1: W omen requiring cryotherapy
VIA_M positive1 
(534)
Group 1 
Cryotherapy 
(329)
Group 2 
Colposcopy 
(205)
No biopsy 
No cryotherapy <  
(18)
Colposcopy 
Negative (1)
Biopsy
(311)
No cryotherapy Cryotherapy
(305)
Negative Not treated yet 
HSIL (1)
1 Including 13 women referred straight to colposcopy after VIA.
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A total of 534 women were considered positive on VIA_M1. These 
included 13 women referred to colposcopy by the midwife performing 
VIA, and 521 testing positive on VIAM.
Doctors performing VIAM indicated treatment with cryotherapy in 329 
women, but in 18 cases, the treatment was postponed. There were two 
main reasons for postponement: women preferred to consult with their 
partners first, or the cryotherapy pistol had technical problems. One of 
these 18 women was referred to colposcopy that turned out to be negative 
and so no biopsy sample was collected. In other six cases, women decided 
to have a biopsy first and wait for the result before being treated. Four of 
these six women had a negative result on pathology, the other two had 
HSIL but only one of them has already been treated with LEEP. The 
remaining 305 women signed an informed consent for biopsy and 
cryotherapy, and were treated.
Group 2: Women referred to colposcopy after testing positive on initial 
VIA_M (VIA_M1).
Figure 5.3.2 presents the clinical management of women testing positive 
on VIA_M1 who were referred to colposcopy.
Doctors decided that cryotherapy was not appropriate for 205 women who 
were referred to colposcopy, 8 of these women have not been evaluated 
yet.
Of 197 women evaluated with colposcopy, 52 were not biopsied, 133 had a 
biopsy, 2 had a biopsy and were treated with cauterisation and 10 were 
treated with LEEP.
Among those women with no biopsy on the colposcopy, 44 were not 
biopsied because they were classified as negative by the colposcopist, 3 
were classified as mild dysplasia and 5 as HSIL or worse. One of the 
women with mild dysplasia on colposcopy was referred back and treated 
with cryotherapy by a general doctor, and the other two have not been 
treated yet. One of the women with HSIL was treated with LEEP, one is
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waiting to be treated, another one had a negative biopsy (on a second 
colposcopy), and two with suspected invasive cancer were referred to the 
cancer hospital in Lima (INEN).
Sixteen women who had only a biopsy on the first colposcopy were treated 
on a second or third visit (11 LEEPs, 3 cold conizations and 2 
hysterectomies), and two women with histologically confirmed carcinomas 
were referred to INEN but one of them rejected treatment. Twenty-four 
women with histologically confirmed mild dysplasia (6) or a higher 
cervical lesion are still waiting to be treated.
Figure 5.3.2. Clinical management of women testing positive on initial 
VIA M who were referred to colposcopy.
Clinical management of women testing positive mi VIA M 
Q~oup 2: Women referred to colposcopy
VIA M positive1
(534) 
. .  .
1 1
No Colposcopy 
(8)
Group 2 
Colposcopy 
(205)
— L_
Group 1 
Cryotherapy 
(329)
Golposcopy
(197)
Negative 44 
(no biopsy)
Biopsvonlv 133
Inadequate 1
Negative 90
Not treated vet 1 
(2nd biopsy=HSIL)
T
Treated 12
Cauterization* 2 
LEEP 10
Referred (ho biopsy) 8
Treated 18
LEEP 11
Cold cone 3
Hysterectomy 2
INEN 2
Not treated vet 24
T SIT 
HSIL
6
18
Treated 3
Cryotherapy 1
LEEP 1
INEN*** 2
Not treated vet 3
(Colp=LSlL 2)
(2nd biopsy = CIS 1)
1 Including 13 women referred straight to colposcopy after VIA. 
* Cauterization after biopsy.
** Negative biopsy on a second colposcopy.
*** One rejected treatment at INEN.
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Group 3: Untreated women requiring colposcopy after testing negative on 
VIA_M (or with VIAM missing) and whose cytology (LBC or CC) results 
were high-grade disease or worse.
A total of 135 untreated women who tested negative on VIA_M had HSIL 
on cytology (LBC or CC) and required colposcopy. Of them, 41 have not 
been colposcopically examined yet, 5 have had VIAM and cryotherapy 
instead, and 89 have had colposcopy.
Figure 5.3.3. Clinical management of untreated women testing 
negative on V IA M (or with VIAM missing) but HSIL on cytology.
Clinical management of untreated >vomen testing negative on VIA M but HSIL on cytology 
Q oup3: Women requiring colposcopy
Golposcopy 
Missing < -  
(41)
Group 3
VIA_Mne^tive ( a  incomplete) 
LBCorCC^tEIL 
(135)
Colposcopy
(89)
Cryotherapy
(5)
£
Negative*
(no biopsy)
Not treated \et 5 
Q>tology=HSIL
Biopsy onlv 70
Inadequate** 1
Negative*** 22
Pending 10
Treated 1
LEEP* 1
Treated 8
LEEP 7
Cold cone 1
Treated 14
LEEP** 5
Gold cone 3
Hysterectomy 2
INEN 4
Not treated \et 23
LSDL 7
HSDL*** 14
Rejected RT 2
Referred
(no biopsy) 
Negative**** 1
Treated 1
LEEP 1
Not treated \et 3 
CytologyHHSIL
* Two colposcopies classified as condyloma, one treated with LEEP.
** One severe dysplasia on second biopsy treated with LEEP.
*** One cancer and one moderate dysplasia on second biopsies not treated yet.
**** Qne metaplasia on second biopsy.
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Colposcopy was negative on six women including two classified as 
condyloma, which were not biopsied. But one of them was treated with 
LEEP on a second colposcopy.
Seventy women were only biopsied during first colposcopy; 10 of them 
were then treated (5 LEEPs, 3 cold cones, 2 hysterectomies) and 6 with 
suspected cancer have been referred to INEN (but two rejected treatment); 
two biopsies were insufficient, one of them was repeated and turned out to 
be a severe dysplasia that was treated with LEEP, the other has not been 
repeated yet. Twenty-four biopsies were negative, two of them were 
repeated, one resulted carcinoma and the other moderate dysplasia, and 
none of them have been treated yet. The other 21 biopsies were at least 
LSIL but have not been treated yet, and 10 pathology results are not 
available yet.
Eight women were treated immediately after colposcopy, seven had LEEPs 
and the other one had cold conization.
Another five women were diagnosed as HSIL on colposcopy but were not 
biopsied, one of them was treated with LEEP in a second colposcopy, 3 
have not been treated yet, and one of them had a second colposcopy with a 
negative biopsy.
Altogether, 74 have been properly evaluated and 31 (42% of those 
evaluated) had HSIL on histology.
Group 4: Untreated VIA_M1 negative with second screening who required 
cryotherapy after testing positive on second VIA_M (VIA_M2).
There were 976 untreated women who were negative on first VIA_M but 
had either ASCUS/LSIL (including ASCUS, AGUS, condyloma/HPV and 
mild dysplasia) on LBC or tested positive on HPV. So far, 12 women have 
been positive on VIA_M2 and have been treated with cryotherapy. Three 
had mild dysplasia, two had moderate dysplasia and one had severe 
dysplasia on histology (biopsy taken before cryotherapy), one sample was 
insufficient and the other five were negative.
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Group 5: Untreated VIA_M negative women with second screening, who 
required colposcopy (VIA_M2 positive or HSIL on second LBC or second 
HC-II positive).
So far, 182 women required colposcopy because of being positive on 
second screening: 17 because of VIA_M2, 31 because of having HSIL on 
second LBC, 103 because of being positive on second HPV, and 31 
because of having HSIL on second LBC and being positive on second 
HPV.
Figure 5.3.4. Clinical management of untreated women with second 
screening positive (HSIL on second LBC or second HPV positive).
Clinical management of untreated women with second screening: VIA_M2, LBC2 and HPV2 
Group 5: Women requiring colposcopy
VIA_M negative 
LBC positive <= HSIL
or HPV positive 
(n=976)
Second samples
1
Missmg/not tested yet 
1 (607)
Group 4 Group 5 Group 6
Cryotherapy Colposcopy Screen in 3 years 
(12) (182) (175)
No Colposcopy 
(156)
Colposcopy
(26)
Negative 2 
(no biopsy)
Treated
LEEP
Referred 1
INEN 
(no biopsy)
Biopsy 22
Negative 10
Pending 5
Not treated
LSIL
HSIL
Among 26 women who have had colposcopy, two were classified as 
negative and no biopsy was collected, 22 were only biopsied, one was
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immediately treated with LEEP, and another was classified as suspected 
cancer and referred to INEN (no biopsy was collected during colposcopy).
The pathology results of the 22 women with biopsy were negative on 10 
women (including one condyloma), LSIL on 4, HSIL on 3 and in five 
women the results are not available yet. None of these women have been 
treated so far.
Unfortunately, 156 women have not had colposcopy yet and therefore, are 
not fully evaluated.
Group 6: Women with first negative screening or untreated after initial 
screening who had second screening negative.
Figure 5.3.5. Clinical management of untreated women with second 
screening negative (LSIL or less on second LBC and second HPV 
negative).
Clinical management of untreated women with second screening: VIA, LBC and HPV 
Group 6: Women to be screened in three years
All first tests negative (or one of LBC1 or HPV1 inadequate/missing) 
or all second tests negative (LBC2 <HSIL and HPV2 negative) 
(n=3997)
Group 6 
Screen in 3 years 
(3997)
Cryotherapy 6
Treated
Cryotherapy 1 
LEEP 3
Colposcopy______26
No biopsy 6
Negative biopsy* 16
* One biopsy was lost before reaching the laboratory.
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Overall, a total of 3997 women were considered as negative, 3822 after 
initial screening and 175 after second screening.
Six women had cryotherapy, four of them after having a positive VIAM 
and a negative VIA (violation of protocol) and the other two after having a 
positive VIAM after an n unnecessary second positive VIA (violation of 
protocol).
Twenty-six women had colposcopy (violation of protocol), six of them 
were classified as negative on colposcopy and were not biopsied, 16 were 
biopsied but one biopsy sample was lost before reaching the pathology 
laboratory, the other 15 biopsies were negative. Four women who were 
colposcopically diagnosed with condyloma or mild dysplasia were treated, 
one was referred back to the general doctor for cryotherapy and the other 
three underwent LEEP.
5.3.1. Summary of treatment procedures
Overall 392 women have been treated, the majority with cryotherapy 
(84.2%) as it was offered as the first option to women.
Table 5.3.I.I. Summary of treatment procedures
Treatment n %
Cauterization 2 0.5
Cryotherapy 330 84.2
LEEP 41 10.5
Cold cone 7 1.8
Hysterectomy 4 1.0
Referred to INEN and treated* 8 2.0
Total treated 392 100.0
* Three other women were referred to INEN but rejected treatment.
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Forty-one LEEPs were performed, 7 cold cones and four hysterectomies. 
Eleven women were referred to INEN with clinically confirmed or 
histologically confirmed cancer, but three of them rejected the treatment 
offered (radiotherapy). One of the women who had LEEP and another one 
who underwent cold conization had hysterectomies after treatment failure 
was confirmed.
5.4. Histology results
So far, 590 women have histology results, 57 of them had two biopsies and 
8 had three different biopsies. Table 5.4.1 presents the histology results; 
when a woman has had more than one biopsy, the severest abnormality is 
reported.
Table 5.4.1. Histology results (as reported by INEN).
Histology result
Women with histology 
n %
Inadequate 16 2.7
Negative 53 9.0
Cervicitis 141 23.9
Metaplasia 71 12.0
Condyloma/HPV 155 26.2
Mild dysplasia 51 8.6
Moderate dysplasia 33 5.6
Severe dysplasia 17 2.9
Carcinoma in situ 31 5.2
Microinvasive cancer 4 0.7
Invasive carcinoma* 18 3.0
Invasive adenocarcinoma 1 0.2
Total 591 100.0
*One invasive cancer diagnosed clinically.
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Sixteen women had inadequate samples, 13 of them were treated with 
cryotherapy, and the other three were biopsied during colposcopy. All this 
women have been considered “not fully evaluated”. One woman had a 
biopsy, which was lost before reaching the laboratory, and 20 have been 
biopsied but their results have not been reported yet.
A total of 265 (45%) women had negative biopsies (normal, cervicitis, 
metaplasia), 155 (26%) had condyloma/HPV usually reported as 
koilocytotic changes, 51 (9%) had mild dysplasia and 104 (18%) had HSIL 
or worse, including 18 invasive carcinomas and one invasive 
adenocarcinoma. One of these invasive carcinomas was only clinically 
diagnosed and the patient was referred to the cancer hospital for treatment, 
but once in Lima, she refused to be examined. She has been considered as 
“with disease” for the following analysis.
Table 5.4.2. Age-specific rates of confirmed cervical lesions per 1000 
screened women.
Age
group
No.
screened
women
Rates of histologically confirmed cervical lesions
Mild
Dysplasia
n=51
Moderate
Dysplasia
n=33
Severe
Dysplasia
n=17
CIS
n=31
Cancer
n=23
<30 1542 11.7 9.1 3.2 4.5 1.3
30-34 1480 10.1 6.8 1.4 6.1 3.4
35-39 1251 9.6 2.4 4.0 4.8 6.4
40-44 776 6.4 2.6 2.6 7.7 5.2
>44 516 1.9 7.8 5.8 5.8 7.8
Total 5565 9.2 5.9 3.1 5.6 4.1
CIS: Carcinoma in situ
Table 5.4.2 presents the age-specific rates of confirmed cervical lesions per 
1000 women. Those younger than 35 years had higher rates of mild
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dysplasia and moderate dysplasia. Women over 35 years of age had higher 
rates of severe dysplasia, carcinoma in situ and cancer.
5.5. Sensitivity and Specificity
These results are based on 5539 women who had initial VIA and adequate 
first samples of LBC and HPV and are presented in three different 
sections, as estimations were performed.
5.5.1. Estimation of women with VIAM missing data
Step 1 (Figure 4.3.3.3.1):
Several multinomial logistic regression models were fitted to predict the 
missing VIAM outcomes using the initial cervical samples results. All 
these models are based on women who were positive on initial VIA and so, 
were referred to VIAM. Those who were negative on VIA but were 
examined with VIAM were excluded from this analysis (violation of 
protocol).
LBC7 (seven categories of initial LBC) and HPV1 as defined in 4.3.2 (e 
and k) were used as explanatory factors, being their reference groups: LBC 
negative and HPV negative. As for VIAM, the comparison group was 
VIAM negative.
First, a full model was fitted allowing for interactions, but none of them 
resulted significance, so a main effects model was fitted but HPV did not 
contribute to the prediction of VIAM result, and so a third model using 
only LBC7 was fitted.
The same steps were repeated considering LBC4 (four categories of LBC, 
as defined in 4.3.2g), once more the interaction was not significant and 
HPV did not contribute into the model. Table 5.5.1.1 presents a summary 
of the Log likelihood ratio test comparing the models.
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Table 5.5.1.1. Log likelihood ratio tests to assess the fitting of models 
used to predict VIAM results.
Fitted
Model
Log
likelihood
Par. Comp. LR test 
Chi-sq(df)
p-value
1(a) LBC7*HPV1 -1172.5068 22'
1(b) LBC7 HPV1 -1178.4805 14 (a) vs (b) 11.95(8) 0.1536
1(c) LBC7 -1180.6387 12 (b) vs (c) 4.32(2) 0.1155
1(d) LBC4*HPV1 -1176.8161 14
1(e) LBC4 HPV1 -1181.2604 8 (d) vs (e) 8.89(6) 0.1799
1(f) LBC4 -1183.5473 6 (e) vs (f) 4.57(2) 0.1016
Par=number of parameters. Comp=comparison.
(i). 26-4 parameters, two interactions were dropped due to collinearity.
The reference categories used in the models were VIAM negative, LBC7 
or LBC4 negative, and HPV negative.
Interactions between LBC and HPV were not significant in either models 
1(a) or 1(d), therefore only main effects models are presented.
Models based on LBC4 (Negative, LSIL, HSIL, Inadequate) fitted better 
than those with LBC7 (Negative, ASCUS/AGUS, LSIL, Moderate 
Dysplasia, Severe Dysplasia/CIS, Cancer, Inadequate), but model 1(c) is 
selected for further analysis because of being more informative (see 
Appendix, Table 5.6.1-5.6.2).
Table 5.5.1.2 presents the predicted probability of VIAM results by LBC 
expressed in percentages, using the Model 1 (c).
The doctor’s interpretation of VIAM could not be affected by the LBC 
result because the latter was not available at the time of VIAM exam. In 
women who were VIA positive, the probability of having a negative result 
on VIAM decreased with increasing severity of the result on LBC. The 
probability of needing colposcopy after VIAM was higher for women with 
high-grade disease, and the more severe LBC, the more likely women 
would need colposcopy as a result of VIAM. This is confirmed by 
estimates from model 1(c) (see Appendix at the end of the chapter).
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Table 5.5.1.2. Probability (%) of women with estimated VIAM result 
according to LBC (Model 1(c)).
LBC VIAMNegative
VIAM
Cryotherapy
VIAM
Colposcopy Total
Negative 59 27 14 100
ASCUS 50 24 26 100
LSIL 52 28 20 100
Moderate 39 32 29 100
Severe 29 24 47 100
Cancer 22 11 67 100
Inadequate 68 17 15 100
After choosing model 1(c), predictive values were obtained for the 
expanded data and used to weight the records generated after the 
expansion, assigning the estimated probability of having each result to the 
appropriate pseudo-observation for each woman with original VIAM 
missing data. Variables related to VIAM were then updated (VIA_M1, 
VIA_MM1 and clinical management group).
5.5.2. Estimation of women with second screening tests results missing
Step 2 (Figure 4.3.3.3.1):
After expanding three times the data with missing values on second 
screening tests results (SECSCR=Missing, 4.3.2 (v)), several multinomial 
logistic regression models were fitted to predict the missing outcomes 
using the initial cervical samples results. All these models were based on 
women who required second screening (negative on initial VIA_M, 
ASCUS, AGUS, condyloma/HPV or mild dysplasia on LBC or negative on 
LBC but positive on HPV). Those who had other previous initial results 
but still had second screening were excluded from this analysis 
(unnecessary second screening). Only women who had all three second 
screening results (VIA_M, LBC and HPV) were used to fit the models.
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LBCRES and HPV1 as defined in 4.3.2 (h and k) were considered 
explanatory factors, being the reference groups: LBC negative and HPV 
negative. As for SECSCR, negative was the comparison group.
First, a full model was fitted allowing for interactions, but the model was 
unstable and none of the interactions resulted significance. Then, a main 
effects model was fitted. Both LBCRES and HPV1 appeared to have an 
independent effect on the probability of having a colposcopy as a result of 
second screening but not of them affected the probability of having a 
cryotherapy after second screening (as compared with being negative on 
second screening).
A third model excluding HPV1 was fitted and as expected, the Likelihood 
Ratio test was significant, implying that HPV1 contributed to the 
prediction of second screening results and should not be taken out from the 
model.
Table 5.5.2.1 presents a summary the Log likelihood ratio test comparing 
the models. The interaction model is not included in this table, as it did not 
contribute to the analysis.
Table 5.5.2.1. Log likelihood ratio tests to assess the fitting of models 
used to predict second screening results.
Fitted Log LR test
Model likelihood Comparison Chi- p-value
2(a) LBCRES HPV1 -219.5003
2(b) LBCRES -227.7284 (a) vs (b) 16.45(2) 0.003
In general, all models have problems with estimation due to the small 
sample used, only 287 observations were considered for estimating three 
different outcomes. Because women requiring second screening were 
selected using two main combinations o f LBCRES and HPV1 results, the 
interactions are not modelled properly. Despite these problems, both 
LBCRES and HPV1 contributed to estimate the probability of having a
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certain second screening result, and model 2(a) was chosen for predicting 
second screening missing results (see Appendix: Table 5.6.3).
Table 5.2.2.2 shows the predicted probability (expressed in %) of second- 
stage results by LBC and HPV testing, using Model 2(a).
Being HPV negative on first samples increase the probability of discharge 
after second screening, the probability of treatment with cryotherapy was 
minimum (very few women with results in this category); while being 
HPV positive or having had LSIL on LBC increases the probability of 
referral to colposcopy.
Table 5.2.2.2. Probability (in %) of second-stage results by LBC and 
HPV first results (Model 2(a)).
Discharge Treat Refer
LBC HPVneg
HPV
pos
HPV
neg
HPV
pos
HPV
neg
HPV
pos
Negative 78 48 2 2 20 50
ASCUS 81 51 * * 19 49
LSIL 62 29 6 7 33 64
Inadequate 80 50 * * 20 50
* Probabilities very small (almost zero).
After choosing model 2(a), predictive values were obtained and used to 
weight the records generated after the expansion (each one with a different 
second screening result), assigning a different probability of having a 
particular result to each woman with original second screening missing 
data. Variables related to second screening were then updated (SECSCR 
and clinical management group).
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5.5.3. Estimation of disease status for women “not fully evaluated”
Step 3 (Figure 4.3.3.1):
Several survey logistic models (weighted logistic regression) were used for 
analysis.
Once more, data on observations with missing disease status 
(HSIL=Missing, 4.3.2 (w)) were expanded to create new “observations” 
for each old observation.
First, empirical predictive values (p i) of disease status were obtained by 
counting the original number of women with HSIL in each of 48 categories 
generated by three variables: VIA_MM1, LBC6 and HPV1. New weights 
were then calculated using these empirical estimates (wl); these results are 
to be present at the end of this section.
Then, weighted logistic regression models were fitted to predict the 
missing outcomes using the disease status of women fully evaluated. Two 
sets of models were used; the first one using two separate models for 
women who did not required second screening and those who needed 
second screening; and the second one using one model for all women in 
the study.
For the models on women who did not need second screening or the 
overall model (all women in the study); VIA_MM1 (four categories of 
VIA and VIAM combined), LBC6, HPV1, CCH_0_LB (HSIL on 
conventional cytology and not on LBC), and separate interactions for 
VIA1 and LBCHSIL, VIA1 and HPV1 and LBCHSIL and HPV1, were 
used as explanatory variables (4.3.2 (d), (f), (k), (m), (n), (o), (p)). The 
reference comparison outcome was “no HSIL”, and the reference levels for 
the other variables were VIA negative for VIA_MM1, LBC negative for 
LBC6, and HPV negative for HPV1. Interactions were positive if  both tests 
were positive and negative otherwise, and this negative category was used 
as the reference group when modelling. For the models on women who 
needed second screening, LBC2 and HPV2 (4.3.2 (t), (u)) were used as
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explanatory variables with LBC2 negative and HPV2 negative being the 
reference groups.
Of all models fitted, six are detailed in the Appendix of these chapter 
(Tables 5.6.4-5.6.9), two sets of models for women requiring and not 
requiring second screening, and two models for all women in the study.
Models 3(al) and 3(bl) differ only in the inclusion or not of a factor 
evaluating the effect of conventional cytology HSIL but less than HSIL on 
LBC (CC_0_LB) in predicting histologically confirmed HSIL. The overall 
results are quite similar: Women who underwent cryotherapy or 
colposcopy as a result of initial VIAM; those who ASCUS on LBC, HSIL 
on CC (only Model 3(al)) or LBC, or Cancer on LBC; and those who were 
positive on first HPV testing had a higher risk of having high-grade 
disease.
In Models 3(a2) and 3(b2) both second HPV and second LBC are used to 
estimate the probability of having HSIL in women needing second 
screening. Having a second positive result on HPV sample positive did not 
predict HSIL (p-value=0.239), while having a second positive LBC sample 
increase the probability of having high-grade disease (p-value=0.049).
Several alternative models were fitted in the subpopulation of women who 
needed second screening, VIA2, VIAM2, VIA_M2, and combinations of 
these with LBC2 and HPV2, but the small number of results available 
made models very unstable, and no good estimation of the effects of such 
factors were obtained (data not presented).
For the purpose of estimating measure of performance Model 3(al) was 
used, because of CCH_0_LB (HSIL on CC and not on LBC) being 
informative. We decided to use Model 3(a2) a priory, since the HPV result 
could only be positive or negative, while when considering a woman 
negative on a second LBC, she could have low-grade disease.
Again, Models 3(c) and 3(d) only differed in the inclusion or not of 
CC_0_LB. Women who underwent colposcopy as a result of initial
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VIAM; those who had HSIL on CC (Model 3(c)) or LBC, or Cancer on 
LBC; and those who were positive on first HPV testing had a higher risk of 
having high-grade disease.
Once again, Model 3(c) was used for estimation of measures of tests 
performance because CC_0_LB was informative enough to be included.
After selecting Models 3(al), 3(a2) and 3(c), the predictive values for each 
model were obtained. For Models 3(al) and 3(a2), the predictive values 
were combined (p2) and were used to generate another set of weights (w2). 
The predictive values (p3) from Model 3(c) were also used to generate the 
last set weights (w>3).
These two sets of weights (w2 and w3), together with those from the 
empirical estimation (wl), were combined with the previous weights 
obtained when estimating screening missing data (VIAM and second 
screening), and were used to obtain three different sets of estimates of 
measures of tests performance.
Table 5.5.3.1 shows a summary of the probability of having disease given 
the results of screening tests using the three set of predictive values p l ,p 2  
andp3  (Step 4: Figure 4.3.3.3.1).
The first two rows of the table are the observed number of women “fully 
evaluated” and the observed proportion of women with confirmed high- 
grade disease in each category according to certain combination of 
screening tests results. The third row is the estimated number of women in 
each category after allocating women with original missing screening tests 
results. The last three rows correspond to the probability of having high- 
grade disease (shown as a percentage) obtained from empirical estimation 
(pi), after fitting models 3(al) and 3(a2) (p2), and model 3(c) (p3).
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Table 5.5.3.1: Probability of detecting disease given screening test results if all women complied with follow-up evaluation.
HPV Negative HPV Positive
LBC result: Neg ASCUS LSIL HSIL Cancer Inad Neg ASCUS LSIL HSIL Cancer Inad
VIA n 3074 48 149 11 196 61 11 31 40 5 6
Negative P 0 2.1 1.3 18.2 0 3.3 18.2 6,5 45 100 16.7
72 3074 91 341 21 1 196 229 27 112 69 6 27
P i 0* 2.1 1.3 18.2 93.3 0 3.3 18.2 6.5 45 100 16.7
P2 0.1 5.7 6.9 10.4 72 0 10.2 15.3 14.4 47.9 95.3 12.1
p3 0.5 6.1 0.4 19.2 84.2 0.2 11.0 63.4 10.1 46.3 95.1 6.6
VIA n 496 5 13 2 41 9 1 2 11 2 2
Positive P 0 0 0 0 0 11.1 0 0 27.3 100 0
VIAM 72 541 19 58 5 43 51 2 24 18 2 10
Negative P i 0 0 0 0 0 11.1 0 0 27.3 100 0
p2 0 5.0 7.3 4.6 0 10.8 7.4 13.5 27.6 89.4 9.2
p3 0.2 2.4 0.1 8.2 0.1 4.5 36.9 3.1 24.6 87.9 1.9
n=Number of women “fully evaluated” in that group. Note that women testing negative on all screening tests were deemed to be fully 
evaluated even though they either did not have colposcopy or a biopsy. 
p=percentage of women with HSIL in that group.
/j=Estimated number of women in that group, after allocation of missing screening results,
p i, p2, p 3 : Estimated percentage of women with HSIL with: /H=empirical, /?2=combining models 3(al) and 3(a2),/iJ=model 3(c); 
there were 57, 113, and 96 imputed cases of HSIL (or worse) lesions under p i, p2 and p3 estimates, respectively.
* There were no cases of CIN III diagnosed in 3074 women negative on all three tests, but only 4 had colposcopy.
 Continued on Page 151
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Table 5.5.3.1: Probability of detecting disease given screening test results if all women complied with follow-up evaluation.
HPV Negative HPV Positive
LBC result: Neg ASCUS LSIL HSIL Cancer Inad Neg ASCUS LSIL HSIL Cancer Inad
VIAM n 190 9 23 4 12 30 14 14 1 1
Cryotherapy P 3.2 0 0 50 0 13.3 28.6 35.7 100 0
n 232 10 27 4 13 33 17 15 1 1
P i 3.2 0 0 50 0 13.3 28.6 35.7 100 0
p2 2.4 7.6 2.3 49 1.6 17.8 24.1 29 90.1 12.7
p3 2.3 22.6 1.6 26.9 1.0 17.8 20.0 33,9 92.0 8.3
VIAM n 113 6 13 3 5 10 2 14 15 6 5
Colposcopy P 7.1 16.7 15.4 33.3 0 50 100 35.7 60 83.3 40
n 127 9 16 4 6 11 2 16 18 7 5
p l 7.1 16.7 15.4 33.3 0 50 100 35.7 60 83.3 40
p2 6.7 19.3 6.4 73.6 4.6 43.5 67.6 44.1 54.2 96.3 40.8
P3 6.3 45.7 4.4 51.4 2.7 43.4 88.7 37.3 59,6 97.1 32.8
n=Number of women “fully evaluated” in that group. Note that women testing negative on all screening tests were deemed to be fully 
evaluated even though they either did not have colposcopy or a biopsy. 
p=percentage of women with HSIL in that group.
w=Estimated number of women in that group, after allocation of missing screening results.
p it p2, p 3 : Estimated percentage of women with HSIL with: /U=empirical, /j2=combining models 3(al) and 3(a2), /?3=model 3(c); there 
were 57,113, and 96 imputed cases of HSIL (or worse) lesions under p i, p2 and p3 estimates, respectively.
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Comparing the observed number of women in each cell (generated by 
different set of screening tests results) with the estimated one after 
allocating women with incomplete screening; for instance, among women 
who were LBC and HPV negative: 44% of women with missing VIAM 
were assigned a negative result, 42% a positive requiring cryotherapy 
result and 14% a positive requiring colposcopy result.
Women with missing VIAM or missing second screening were in general 
more allocated into categories with LBC ASCUS/AGUS and LSIL results, 
independently of HPV results.
As expected, among women with HPV positive and VIAM positive results, 
the higher the diagnosis on LBC the less number of women allocated.
With regard to the probability of having disease obtained by different 
methods, once again, in those with HPV and VIAM positive results the 
higher the diagnosis on LBC the less difference between the three 
estimates of the probability of disease, especially among those with 
carcinoma on LBC for whom almost all probabilities were over 85%.
Overall, the empirical probabilities tended to be smaller than the modelling 
ones among women with HPV negative and LBC less than HSIL results, 
and larger or similar among those being HPV positive and having HSIL or 
worse lesions.
Comparing the estimates from modelling, model 3(c) estimates were larger 
than the empirical ones and those of models 3(al) and 3(a2) combined 
among VIA_M negative women with ASCUS who were HPV positive, 
but, model 3(c) estimates were smaller than the other modelling estimates 
among women HPV negative, with LSIL and a VIAM cryotherapy results.
Because of these differences between estimates of disease status, the three 
estimates were used to calculate measures of tests performance.
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Table 5.5.3.2 presents the sensitivity, specificity, and PPV of each 
screening test and their confidence intervals for each of the three estimates 
of disease status previously obtained.
Table 5.5.3.2: Measures of performance of screening tests.
Test Sens (95%CI) Spec (95%CI) PPV (95%CI)
VIA p i 52.5 (41.1,64.0) 76.6 (76.1,78.4) 6.3 (4.9,8.2)
p2 44.0 (34.4,58.6) 76.5 (74.2,76.7) 7.1 (5.1,8.4)
p3 41.4 (30.6,59.5) 76.4 (74.2,76.6) 6.5 (4.7,7.8)
Combined P i 41.1 (32.0,52.2) 91.4 (90.6,92.1) 12.5 (9.8,15.5)
VIA&VIAM p2 30.5 (20.2,49.9) 91.3 (90.6,92.2) 12.5 (9.8,15.5)
p3 31.7 (21.7,50.1) 91.3 (90.6,92.2) 12.6 (9.8,15.5)
LBC >ASCUS P i 68.1 (57.5,79.0) 84.6 (83.6,85.7) 11.7 (9.4,14.7)
p2 68.9 (61.3,78.1) 85.2 (84.0,86.4) 15.9 (10.5,21.9
p3 64.3 (44.8,82.6) 84.9 (83.7,86.0) 14.4 (9.7,18.7)
LBC >HSIL P i 47.0 (37.9,58.3) 98.2 (97.8,98.6) 44.3 (35.2,54.5
p2 34.9 (22.5,55.8) 98.2 (97.8,98.6) 44.4 (34.1,53.3
p3 36.3 (25.4,55.9) 98.2 (97.8,98.6) 44.6 (34.4,53.7
HPV P i 77.7 (69.3,84.9) 89.3 (88.4,90.5) 17.9 (13.8,22.6
p2 72.2 (65.2,78.8) 89.8 (88.5,91.1) 22.4 (14.1,32.2
p3 79.9 (61.7,89.1) 90.0 (88.4,91.5) 23.9 (13.6,34.7
p i : empirical estimates.
p 2 : estimates combining models 3(al) and 3(a2). 
p 3 : estimates using model 3(c).
Measures of tests performance were based on 104 observed cases of high-grade 
disease (HISL or worse), and in 57,113, and 96 estimated cases from p i, p2 and 
p3, respectively.
Sensitivity depends on prevalence of disease, therefore the estimates of 
sensitivity varied according to the predictive value used (p i, p2, p3). This 
was not the case for specificity and P W  estimates. In general, the 
empirical estimates (using p i)  of sensitivity were larger than the other two, 
except for HPV, where the p3  estimate was the largest. Overall, estimates
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from modelling (p2 and p3 ) were quite similar, but because the 
bootstrapping confidence intervals obtained after combining Models 3(al) 
and 3(a2) (p2) were smaller than the others; for purposes of reporting 
results, p2  estimates would be used.
The sensitivity of VIA was 44% (Cl: 34,59), its specificity was 77% (Cl: 
74,77) and its PPV was 7% (Cl: 5,8). The sensitivity of combined VIA & 
VIAM was 31% (Cl: 20,50), its specificity was 91% (Cl: 91,92) and its 
PPV was 13% (Cl: 10,16). Incorporating VIAM after VIA, increased the 
specificity of the visual technique, but reduced its sensitivity.
The sensitivity of LBC using a low threshold (ASCUS or worse) was 69% 
(Cl: 61,78), its specificity was 85% (Cl: 84,86) and its PPV was 16% (Cl: 
11,22); and when using a high-threshold (moderate dysplasia or worse 
lesions) the sensitivity of LBC was 35% (Cl: 23,56), its specificity was 
98% (Cl: 98,99) and its PPV was 44% (Cl: 34,53). A higher-threshold for 
LBC ensured a gain in specificity and increased the PPV, but with a 
substantial loss of sensitivity.
Finally, the sensitivity of HPV testing (HC-II) was 72% (Cl: 65,79), its 
specificity was 90% (Cl: 89,91) and its PPV was 22% (Cl: 14,32).
Overall, HPV had better sensitivity than the other tests, but it had low 
specificity. Both VIA, and combined VIA & VIAM had very low 
sensitivities, VIA had also very low specificity but when combined with 
VIAM the specificity increased by 15%.
Table 5.5.3.3 presents the sensitivity, specificity and PPV of VIA 
combined with LBC or HPV testing.
The idea of combining VIA with another screening test was based on the 
assumption that VIA would have high sensitivity but poor specificity. In 
fact, the specificity of VIA combined with either LBC ^ \SCUS or 
LBC^ISIL or HPV testing, was over 95%, at least 19% improvement. 
However, in this study, VIA had very poor sensitivity; nevertheless, the 
combination of VIA with HPV yielded a sensitivity of 31% (Cl: 23,41); 
which was higher than that of VIA combined with LBC.
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Table 5.5.3.3: Measures of performance of combinations of screening
tests.
Combination of 
tests
Sens (95%CI) Spec (95%CI) PPV (95%CI)
Combined p i 31.2 (23.0,40.9) 95.9 (95.5,96.8) 18.5 (14.1,25.5)
VIA & p2 27.4 (20.3,38.3) 96.1 (95.2,96.5) 21.9 (15.1,2 6.6)
L B C ^SC U S p3 25.7 (17.0,39.2) 95.9 (95.1,96.4) 19.9 (13.6,25.1)
Combined P i 21.0 (14.4,29.6) 99.3 (99.0,99.5) 45.8 (33.0,59.7)
VIA & p2 15.8 (9.3,25.6) 99.3 (99.0,99.5) 46.4 (32.4,57.4)
LBC2HSIL p3 16.3 (10.2,26.4) 99.3 (99.0,99.5) 46.3 (32.6,57.8)
Combined P i 37.9 (28.0,48.8) 96.8 (96.4,97.7) 26.3 (20.0,37.2)
VIA & HPV p2 30.5 (22.8,41.4) 96.9 (96.2,97.3) 28.6 (20.3,34.9)
p3 29.2 (20.4,42.8) 96.8 (96.1,97.3) 26.4 (18.9,33.8)
p i:  empirical estimates.
p 2 : estimates combining models 3(al) and 3(a2). 
p3: estimates using model 3(c).
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5.6. APPENDIX: Results
Table 5.6.1 MODEL 1(b): Main effects: LBC7 and HPV1
Multinomial logistic regression Number of obs = 1243
LR chi-sq (14) = 45.56 
Prob>chi-sq < 0.001 
Log likelihood=-l 178.4805___________Pseudo R-sq = 0.0190
Coefficient St. Z P>|z| [95% Cl]
VIAM=Cryotherapy
LBCASC 0.0535 0.4122 0.13 0.897 -0.7546 0.8615
LBCJLSIL 0.0974 0.2154 0.45 0.651 -0.3247 0.5196
LBC_Mod 0.4075 0.3879 1.05 0.293 -0.3527 1.1678
LB C Sev 0.2758 0.6978 0.40 0.693 -1.0918 1.6434
L B C C a -0.1942 1.2397 -0.16 0.876 -2.6240 2.2356
LBC_Inad -0.5824 0.3220 -1.81 0.070 -1.2136 0.0487
H PV Pos 0.3365 0.1964 1.71 0.087 -0.0721 0.7214
Constant -0.8354 0.0798 -10.47 <0.001 -0.9919 -0.6790
VIAM=Colposcopy
LBC_ASC 0.8195 0.4035 2.04 0.042 0.0288 1.6103
LBCLSIL 0.4334 0.2457 1.76 0.078 -0.0482 0.9505
LBC_Mod 0.9673 0.4062 2.38 0.017 0.1711 1.7634
LBC_Sev 1.5911 0.6134 2.59 0.009 0.3889 2.7933
LB C C a 2.2197 0.8473 2.62 0.009 0.5591 3.8804
LBC_Inad -0.0941 0.3490 -0.27 0.787 -0.7781 0.5900
HPV_Pos 0.3804 0.2292 1.66 0.097 -0.0687 0.8296
Constant -1.5015 0.1022 -14.69 <0.001 -1.7019 -1.3012
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Table 5.6.2. MODEL 1(c): Main effects: LBC7
Multinomial logistic regression Number of obs = 1243
LR chi-sq (12)= 41.25 
Prob>chi-sq < 0.001 
Log likelihood—1180.6387___________Pseudo R-sq =0.0172
Coefficient St. Z P>|z| [95% Cl]
VIAM=Cryotherapy
LBCA SC 0.0546 0.4119 0.13 0.887 -0.7528 0.8619
LBC_LSIL 0.1846 0.2086 0.89 0.366 -0.2241 0.5933
LBC_Mod 0.6076 0.3690 1.65 0.097 -0.1157 1.3309
LBC_Sev 0.5786 0.6752 0.86 0.388 -0.7448 1.9021
L B C C a 0.1086 1.2272 0.09 0.927 -2.2966 2.5138
LB CInad -0.5453 0.3207 -1.70 0.092 -1.1739 0.0833
Constant -0.8018 0.0770 -10.41 <0.001 -0.9528 -0.6508
VIAM=Colposcopy
LBCASC 0.8208 0.4030 2.04 0.042 0.0310 1.6107
LBC_LSIL 0.5331 0.2372 2.25 0.025 0.0682 0.9980
LBCM od 1.1944 0.3815 3.13 0.002 0.4467 1.9421
LB CSev 1.9327 0.5786 3.34 0.001 0.7986 3.0667
LB C C a 2.5613 0.8225 3.11 0.002 0.9493 4.1733
LBC_Inad -0.0515 0.3474 -0.15 0.882 0.7323 0.6294
Constant -1.4627 0.9887 -14.79 <0.001 1.6564 -1.2689
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Table 5.6.3. MODEL 2(a): Main effects: LBCRES and HPV1
Multinomial logistic regression Number of obs = 287
LR chi-sq (8) =32.23 
Prob>chi-sq = 0.0001 
Log likelihood=-219.5022____________Pseudo R-sq = 0.0684
Coefficient St. error Z P>|z| [95% Cl]
Second screening=Cryotherapy
LBCA SC -30.3314 4346595 -0.00 1.000 -8519200 8519139
LBCLSIL 1.5592 0.9633 1.62 0.106 -0.3287 3.4472
LBCJnad -30.5802 1.4798 -0.00 1.000 -1.94e+07 1.94e+07
HPV_Pos 0.9070 0.7633 1.19 0.235 -0.5899 2.4029
Constant -3.9274 1.0521 -3.73 <0.001 -5.9895 -1.8653
Second screening=Colposcopy
LBCA SC -0.0809 0.4975 -0.16 0.871 -1.0561 0.8942
LBCLSIL 0.7271 0.3812 1.91 0.056 -0.0199 1.4742
LBC_Inad -0.0476 0.7400 -0.06 0.949 -1.4981 1.4028
HPV_Pos 1.4103 0.3578 3.94 <0.001 0.7089 2.112
Constant -1.3627 0.4192 -3.35 0.001 -2.1842 -0.5411
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Table 5.6.4. MODEL 3(al); Main effects with special interactions for
women who did not require second screening
Survey logistic regression Number of obs =4704
Population size = 5539.43 
F(13,4691) = 18.27
Subpopulation No. of obs=4372 Prob>F < 0.001
Subpopulation Size=4813.41______________________________
Coefficient St. error t P>|t| [95% Cl]
HGSIL
VIAM_neg* -0.8835 0.6522 -1.35 0.176 -2.1621 0.3951
VIAM Cryo 3.6489 0.6034 6.05 <0.001 2.4661 4.8318
VIAM_Colp 4.7121 0.5988 7.87 <0.001 3.5383 5.8860
CCHSEL 2.7837 1.3122 2.12 0.034 0.2112 5.3563
LBC_ASC 1.2027 0.5447 2.21 0.027 0.1349 2.2705
LBC_LSIL -0.0583 0.5095 -0.11 0.909 -1.0571 0.9405
LBCHSIL 5.1877 1.0986 4.72 <0.001 3.0339 7.3415
L B C C a 8.2867 1.5547 5.33 <0.001 5.2388 11.3346
LBC_Inad -0.4012 0.6380 -0.63 0.529 -1.6520 0.8496
HPV1 5.0933 1.2691 4.01 <0.001 2.6053 7.5813
VIA_LBHG -1.5343 1.2392 -1.24 0.216 -3.9637 0.8951
VIA_HPV1 -2.9270 1.2270 -2.39 0.017 -5.3324 -0.5215
LBHG_HPV -3.0205 1.0060 -3.00 0.003 -4.9928 -1.0481
Constant -7.3428 0.5016 -14.64 <0.001 -8.3261 -6.3595
* VIAM_neg includes women VIA positive and VIAM negative.
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Table 5.6.5 MODEL 3(a2): HPV2 on women who required second 
screening
Survey logistic regression Number of obs = 323
Population size = 717.02 
F(l, 322) = 1.39
Subpopulation No. of obs=323 Prob>F =0.2385
Subpopulation Size=717.02________________________________
Coefficient St. error t P>|t| [95% Cl]
HGSIL
HPV2 1.1691 0.9900 1.18 0.239 -0.7786 3.1169
Constant -2.7684 0.7838 -3.53 <0.001 -4.3104 -1.2264
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Table 5.6.6. MODEL 3(bl): Main effects with special interactions for 
women who did not require second screening (excluding CC HSIL)
Survey logistic regression Number of obs = 4704
Population size = 5539.43 
F(12,4692) =25.66
Subpopulation No. of obs=4372 Prob>F < 0.001
Subpopulation Size=4813.41______________________________
Coefficient St. error t P>|t| [95% Cl]
HGSIL
VIAM_neg -0.9328 0.6563 -1.42 0.155 -2.2193 0.3538
VIAM_Cryo 3.1733 0.5628 5.64 <0.001 2.0699 4.2767
VIAM_Colp 4.2826 0.5553 7.71 <0.001 3.1939 5.3712
LBCA SC 1.3339 0.5523 2.42 0.016 0.2511 2.4167
LBC_LSIL 0.2422 0.4558 0.53 0.595 -0.6514 1.1358
LBC_HSIL 4.1933 1.4067 2.98 0.003 1.4355 6.9510
L B C C a 7.3128 1.7852 4.10 <0.001 3.8130 10.8125
LBC_Inad -0.0976 0.6218 -0.16 0.875 -1.3166 1.1215
HPV1 6.7680 1.0671 6.34 <0.001 4.6759 8.8601
VIA_LBHG 0.1514 1.0480 0.15 0.885 -1.9032 2.2061
VIA_HPV1 -4.3414 1.1301 -3.84 <0.001 -6.5570 -2.1259
LBHG_HPV -3.9833 1.1795 -3.38 0.001 -6.2957 -1.6710
Constant -7.0066 0.4138 -16.94 <0.001 -7.8179 -6.1953
Table 5.6.7. MODEL 3(b2): LBC2 for women who required second 
screening
Survey logistic regression Number of obs =315
Population size = 706.67 
F (l, 314) =3.90
Subpopulation No. of obs=315 Prob>F = 0.0492
Subpopulation Size=706.67________________________________
Coefficient St. error t P>|t| [95% Cl]
HGSIL
LBC2 1.9364 0.9809 1.97 0.049 0.0064 3.8665
Constant -2.9371 0.7121 -4.12 <0.001 -4.3382 -1.5360
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Table 5.6.8. MODEL 3(c): Main effects with special interactions for all
women in the study
Survey logistic regression Number of obs = 4704
Population size = 5539.43
F(13,4691 =13.66
Prob>F < 0.001
Coefficient St. error t P>|t| [95% Cl]
HGSIL
VIAM_neg -0.9733 0.6023 -1.62 0.106 -2.1541 0.2075
VIAM_Cryo 1.5143 0.7658 1.958 0.048 0.0130 3.0156
VIAM_Colp 2.57 0.7624 3.37 0.001 1.0766 4.0660
CCH SIL 2.9189 0.8707 3.35 0.001 1.2119 4.6259
LBC_ASC 2.5311 1.2984 1.95 0.051 -0.0144 5.0767
LBCLSIL -3.8692 0.7270 -0.53 0.595 -1.8122 1.0384
LBCH SIL 3.8363 0.7192 5.33 <0.001 2.4263 5.2462
LBC_Ca 6.9458 1.3158 5.28 <0.001 4.3663 9.5253
LBC_Inad -0.8681 0.6659 -1.30 0.192 -2.1736 0.4374
HPV1 3.1807 1.0876 2.92 0.003 1.0484 5.3130
V IA LBH G -1.0802 0.7032 -1.54 0.125 -2.4589 0.2985
VIA_HPV1 -0.9524 1.0533 -0.90 0.366 -3.0173 1.1126
LBHG_HPV -1.8928 0.9781 -1.94 0.053 -3.8104 0.2480
Constant -5.2735 0.5574 -9.46 <0.001 -6.3661 -4.1808
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Table 5.6.9. MODEL 3(d): Main effects with special interactions for all
women in the study (excluding CC HSIL)
Survey logistic regression Number of obs =4704
Population size = 5539.43
F(12,4692) = 14.33
Prob>F <0.001
Coefficient St. error t P>|t| [95% Cl]
HGSIL
VIAM_neg -1.0174 0.5986 -1.70 0.089 -2.1909 0.1561
VIAM Cryo 1.5024 0.7665 1.96 0.050 -0.0003 3.0052
VIAM_Colp 2.5742 0.7593 3.39 0.001 1.0857 4.0628
LBCA SC 2.5560 1.2863 1.99 0.047 0.0342 5.0778
LBC_LSIL -0.0809 0.6644 -0.12 0.906 -1.4227 1,2608
LBCHSIL 3.8924 0.7154 5.44 <0.001 2.4898 5.2949
L B C C a 7.0115 1.3182 5.32 <0.001 4.4273 9.5957
LBC_Inad -0.3823 0.7226 -0.53 0.597 -1.7983 1.0336
HPV1 3.2428 1.0608 3.06 0.002 1.1632 5.3224
VIA_LBHG -1.1494 0.6865 -1.67 0.094 -2.4953 0.1964
VIA_HPV1 -0.8733 1.0459 -0.83 0.404 -2.9238 1.1772
LBHGHPV -1.9795 0.9588 -2.06 0.039 -3.8591 -0.0999
Constant -5.3011 0.5619 -9.43 <0.001 -6.4028 -4.1995
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6. DISCUSSION
6.1. Introduction
Ideally, in a screening study all participants undergo colposcopy (with 
biopsy if  indicated), so that they would be fully evaluated (those with 
disease would be histologically confirmed); in this way, no verification 
bias is introduced to the estimation of sensitivity and specificity of the 
screening tests.
The hypothesis of our study was that a two-stage process in which women 
had VIA and those positive on VIA had a second test, either LBC or HPV 
testing was a cost-effective approach to cervical screening in San Martin, 
Peru. The idea was that VIA would be highly sensitive, but that it would 
lack specificity. The hypothesised 20% of women positive on VIA would 
be told that their initial screening was positive and that should the sample 
sent to the laboratory also test positive, it would be very important for them 
to return to the clinic for treatment. It was hoped that presenting the results 
in this way would reduce the dropout rate. In the recently published HART 
study, the percentages of women declining colposcopy were 38% if they 
were negative on both HPV and cytology, 29% if they were positive on 
HPV and/or had borderline cytology, 8% if they had mild dyskaryosis, 2% 
if they had moderate dyskaryosis and 0% if  they had severe dyskaryosis or 
worse lesions on cytology. These data confirmed our prior belief that the 
rate of dropout before colposcopy is strongly related to the screening 
results presented to women. Those who are told that it is very likely that 
they have disease that needs treating will generally attend for colposcopy, 
those who are told that it is important to rule out the possibility of disease 
are more likely to dropout.
We screened 5565 women with VIA, LBC, HC-II and conventional 
cytology, but only 580 women had histological confirmation of their 
disease status. Evidence from other studies suggests that the prevalence of 
HSIL in those testing negative on all four tests will be so low as to make 
taking random biopsies unnecessary and possibly unethical. For instance,
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in a study in China, Belinson and colleagues 172 did not detect any CIN II 
or worse lesions among 1332 women who had biopsies taken and were 
later found to have tested negative on both ThinPrep Pap and HPV testing.
The design of this study, then, included the use of VIA, LBC and HC-II. 
However, due to the Ministry of Health regulations, conventional cytology 
was also carried out, so our cohort of 5565 women had in theory at least 
four screening tests (those positive on VIA had VIAM as well).
Our study population was composed of all women between 25 and 49 
years of age accepting cervical screening and willing to have additional 
cervical samples collected, in the region of San Martin. In the year 2000, 
there were 102276 women within the age-range 25-49 overspread in an 
area of 51253 square kilometres (numbers based on projections of the 
national population census of 1993). These figures show how difficult it is 
to establish a screening programme in the region. Furthermore, women will 
not accept screening or treatment without consent of their male partners, 
who in the first place, needed to be convinced.
The region of San Martin includes a university where one of the most 
popular careers is midwifery. This has contributed to the establishment of a 
good health network, where a large number of midwives lead health 
community teams, they are the ones who locate patients and convince them 
to undergo treatment. These midwives were a key part in this study, 
without them the number of women lost-to-follow-up would have been 
striking. It is worth to mention that the Program for Appropriate 
Technology in Health, PATH, established a network using these teams and 
community leaders who organised information meetings and helped to 
trace women needing rescreening or treatment.
VIA is a simple test and is easy to learn. Its major advantage is that results 
are available immediately. It was expected that women who tested positive 
on VIA, would undergo VIAM immediately. But this only happened in 9% 
of the cases, and VIAM was performed even after one year in 5% of the 
cases. The results from conventional cytology were available within 6 
months of collection (this has actually been improved since 2002).
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Additional samples for LBC and HC-II were processed outside the region; 
this generated long delays on clinical management decisions, especially in 
determining who needed second screening. LBC results were available 
within one or two months after collection and HPV testing only after 3 to 4 
months.
Another main operational problem of the study was the lack of 
colposcopists; indeed, it was one of the main reasons for not attempting to 
increase the number of women evaluated with colposcopy. At the 
beginning of the study there were only two trained colposcopists in the 
region, one in Moyobamba covering the north, and one in Tarapoto 
covering the centre and the south. But despite efforts of organising 
colposcopy clinics, long delays on being colposcopically or histologically 
diagnosed were unavoidable.
As, stated before, the fact that only positive women were colposcopically 
evaluated or treated, introduced verification biased to the study. One 
approach to overcome the lack of complete evaluation was to rescreen 
women who were positive only on Hybrid-Capture II or who were positive 
on LBC but had low-grade disease (including ASCUS, AGUS and 
condyloma/HPV). This second screening contributed to the completion of 
disease status of at least 400 women, but major efforts were required to 
recall women, rescreen them and evaluate them completely, and of course, 
there were a number of lost-to-follow-up. Nevertheless, the complete 
evaluation of these extra 400 women improved the evaluation of both 
techniques, LBC and HC-II, but complicated the design and the statistical 
analysis.
6.2. Participants
Not every woman recruited in the TATI project was invited to participate 
in this study. Between February and December 2001, only 5596 of 13426 
women recruited by the TATI project, were also screened with LBC or 
HPV testing. Women were invited to participate in this study if  resources 
were available at the time of visit, and only those who signed the informed
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consent for additional samples were recruited. A number of problems 
affected the recruitment during the study; mainly, changes in directives in 
the Health Direction of San Martin (DIRES) that meant changes in health 
policy and health priorities in the region. Midwives did their best to screen 
with VIA as many residents as possible, but were restricted by the current 
health policy. From time to time, new authorities would consider the TATI 
project, and hence this study, as the least important intervention in the 
region, and clinical midwives were told to use most of their time in 
activities other than cervical screening. Also, malaria outbreaks in the 
region meant concentration of resources to control it. In general, midwives 
tried to perform VIA once per week, screening an average of 20 women. 
But explaining the benefits of additional samples, getting written consent, 
and collecting the extra samples was time consuming; so in many cases, if 
midwives had a busy timetable, they would not offer the additional 
screening tests.
Recruitment took place in 16 health centres distributed across the region, 
and the number of women participating in this study varies greatly. But, 
between April and October 2001, the recruitment increased significantly 
due to a sub-study to evaluate VIA performance that was carried out with 
the aid of another midwife who took cervicophotographies on at least 100 
women per health centre. One would expect that women will refuse 
screening and will only attend after being absolutely sure of the benefits of 
it, especially in an area where previously screening was so bad 
implemented. Women feared to be examined and not to receive feedback at 
all, as was the case for many years. But in this study, 35 women who were 
screened only with VIA and got the news from neighbours or friends about 
cervical additional tests that identified more positive women, came back 
and asked for another complete screening; furthermore, 19 women 
attended two health centres in different parts of the region just to be sure of 
their results.
Despite distance, most women who needed second samples, further 
evaluation or treatment did come back to the health centre or travelled to
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the main hospital of their local area after being visited once by health 
workers. Transport costs were covered when required.
6.3. Health providers
One advantage of VIA is that it can be performed by a variety of health 
providers. VIA is easy to learn, and several studies have proved that good 
training and supervision would guarantee its accuracy.
1 ^ 8  1 1 *70  1 Q Q
VIA has been performed by cytotechnicians , , clinicians , , nurses
i83,187/39^ 188^  midwjves 135 and medical doctors and nurses 192. In the 
Zimbabwe study, women were interviewed and examined by a nurse- 
midwife; while in the Belinson study 172, gynaecologic oncologists were 
the examiners.
In Peru, midwifery and nursery are two different five-year-university 
careers; a university in Tarapoto offers both careers, and every year 15 
midwives (men and women) are graduated. Midwives are better trained on 
female health, they know about sexually transmitted diseases and the 
reproductive system quite well, they are in charge of taking Pap smears 
when doctors are not available, so it was easier to train them to perform 
VIA; and it is more difficult to rely on doctors who are more expensive and 
in some places not available.
Our design required that if VIA was positive it ought to be confirmed by 
VIAM performed by a general doctor using and AviScope™. Midwives 
were then in charge of cervical samples collection (CC, LBC and HPV) 
and of VIA. Doctors performed VIAM and cryotherapy whenever 
appropriate.
Midwives and doctors were first trained during a four-day course, which 
included practice with silicon models and real patients. A team of five 
specialists trained participants during the course. Three gynaecologist 
oncologists with previous experience on VIA performed VIAs, VIAMs and 
cryotherapies, one gynaecologist oncologist did the colposcopies, LEEPs 
and cold cones with anaesthesia provided by the fifth specialist. The two
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local gynaecologists previously trained in colposcopy at INEN, took part 
during colposcopies and surgery procedures.
After 3 months, trainees were reunited again, to report problems 
encountered in the field and to discuss difficult cases (or false negative 
cases detected by LBC). Afterwards, a gynaecologic oncologist visited the 
region to supervise the providers periodically.
When recruitment started, several doctors did not count with the 
AviScope™, so VIAMs were delayed. Problems with cryotherapy 
equipments were quite common, and solutions were not soon enough 
available, as a consequence, cryotherapy was almost never offered 
immediately.
Some of the first general doctors trained were in their “SERUM” year (one 
working year for the Ministry of Health in order to apply for residence 
programs), and so, they left the region within 6 months. All doctors and 
midwives took annual leave (one month) during the recruitment period, 
and moreover, some midwives also moved to different regions. Training of 
new providers had to be done regularly, and change of providers affected 
VIA and VIAM performances.
6.4. The information system
During the study, an information system for the TATI project (SYSTAT) 
was developed and used to maintain a database containing all information 
from collected data forms. A good screening programme should always 
have a reliable, up-to-date information system, which highlights the need 
for different referrals.
Despite the fact of counting with SYSTAT, information was not daily 
updated. Delays were caused because DIRES policy was to send 
information through the health network, unless extremely urgent, once per 
month. This translated into several problems.
For instance, women who knew they were positive in any screening test 
would appear in either of the colposcopy centres claiming to be examined
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by an specialist before they data forms (requiring the exam) had arrive to 
the central TATI office in Tarapoto and so, before this information was 
inputted into SYSTAT. The results from LBC and HPV testing because of 
being processed in a parallel database arrived earlier to the health centre so 
midwives recalled women as soon as possible.
A number of women were screened twice in the same health centre or 
simply by two or three different health centres. As information was so 
delayed, the only way of identifying duplicates was using SYSTAT, which 
checked similar names before accepting a new screening record. However, 
there are a large number of women with identical names in the region.
SYSTAT also helped to identify women requiring colposcopy because of 
their additional samples results (once these were inputted into the system). 
It was also used to produce monthly reports of screening targets, number of 
women with disease, number of treated women, etc.
The use of an information system in any screening programme is crucial, 
but it should be accompanied but well-kept laboratory and clinical records 
from each laboratory or health facility involved in the programme. It 
should be updated regularly in order to give precise and opportunity 
information.
6.5. Screening tests
This section assesses advantages and problems of each technique, and 
evaluates positivity rates of each screening test. After discussing the 
histology results in section 6.5, sensitivities, specificities and PPVs of each 
test are presented, compared and discussed in section 6.6.
6.5.1. VIA
The main advantage of using VIA as a screening test in a low-resource 
setting like San Martin is the ability to give immediate results to women. 
VIA is a simple, easy and fast exam, which does not require the examiner 
to be a high-qualified doctor. We expected a positivity rate of 20% for 
VIA, and we got 24%. This result is similar to those of other studies
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i80,!87^ 72^ 8^  jn particular, t0 the recent study in India, which reported a 
24.2% positivity rate of VIA for a low-threshold positivity and 15.8% 
when using a high-threshold criteria (the latter only included definite, well- 
defined acetowhite lesion in the squamocolumnar junction or close to the 
external os). In our study, midwives were taught to consider VIA positive 
if  observed acetowhite lesions were close or in the squamocolumnar 
junction.
The positivity rate of VIA varied by health centres and by time of 
screening. Table 6.4.1.1 shows the number of women testing positive by 
month.
Most of the health centres finished recruitment for our study in September. 
During October and November, women were screened in H.R. San Jose de 
Sisa (in the centre of the region) and in the north. The last 200 women 
were screened during a special campaign in Tocache in December 2001.
Table 6.4.1.1. Positivity rate of VIA by month of screening.
Women examined with VIA 
No. VIA No. women Positivitv
February 38 474 8
March 18 260 7
April 54 244 22.1
May 157 775 20.3
June 357 1026 34.8
July 329 1010 32.6
August 183 938 19.5
September 174 525 33.1
October 5 19 26.3
November 13 95 13.7
December 21 200 10.5
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During the first two months of the project the overall positivity rate of VIA 
was very small (7.5%), it seems that midwives were just getting used to the 
technique and were not enough confident to identify possible cervical 
lesions. But as time went on, positivity rates increased significantly.
Between April and September, the positivity rate of VIA varied between 
20% to 35% (Chi-square=102, df=5, p<0.0001). There is no straight 
forward explanation for this significant variation, but most probably is 
related to differences in midwives performance, and indeed to personal 
knowledge, abilities and commitment to the study.
Table 6.4.1.2 shows the number of women testing positive on VIA 
screened by each midwife before, during and after the cervicophotography 
sub-study. Unfortunately, data on midwives from H.R. Picota, H.R. 
Saposoa, H.R. Nueva Cajamarca, C.S. La Merced, C.S Nueva Rioja and 
P.S. San Juan del Rio Soritor are missing. However, based on available 
data, the positivity rate of VIA increased substantially while the 
cervicophotography sub-study was taking place, and decreased afterwards; 
except for the positivity rate of the midwife in P.S. Juan Guerra which 
continued increasing (up to 20%) after the sub-study ended.
One explanation for the increase in positivity rates during the sub-study 
could be that midwives feared to miss lesions that would appear obvious 
on the cervical photos. This suggestion highlights the weakness of VIA 
being a very subjective exam, the results depending entirely on the 
provider.
It is worth to mention that the H.R. Tocache only contributed to our 
comparative study with 400 women screened with VIA, LBC and HPV for 
the purposes of the cervicophotography sub-study during two attempts: one 
in May 2001 when the photos were damaged and one in December. When 
comparing both periods, the positivity rates of VIA were reduced from 
32.7% (midwife 1) and 20.2% (midwife 2) in May to 11% and 10% in 
December, respectively.
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Table 6.4.1.2. Positivity rate of VIA by midwife before, during and 
after Cervicophotography (CVP) sub-study.
Midwife
VIA positive women (Positivity rate %)
Before CVP CVP After CVP*
C.S. Lluyllucucha 1 39(25.5) 38(32.2)
C.S. Lluyllucucha 2 25(16) 32(25.8)
C.S Soritor 14(6.7) 21(16.5) 1(5.6)
C.S. Jepelacio 6(25) 64(63.4)
Centro Matemo Perinatal 1 4(13.3) 96(44.4) 35(37.6)
Centro Matemo Perinatal 2 16(30.2) 108(52.7) 7(36.8)
P.S. Juan Guerra 3(18.8) 44(33.3) 7(41.2)
C.S. Tabalosos 16(16.3) 45(31.7) 16(31.4)
H.R. Lamas 25(29.4) 104(44.4) 1(4.2)
H.R. San Jose de Sisa 31(15.1) 74(52.9) 10(20)
H.R. Bellavista 7(8.1) 69(39.9) 22(24.7)
* Including only midwives with more than 15 VIAMs per period.
In a recent study in Nicaragua 192, 6 medical doctors and 14 nurses 
performed VIA in 1080 patients, obtaining a VIA positivity rate of 32.7% 
and that 88.2% of women with HSIL or worse lesions had a positive VIA. 
The authors found that the percentage of women with HSIL or worse 
lesions identified by VIA was increased after performing 100 or more 
examinations from 83% (5 to 99 examinations) to 92% (100 or more 
examinations) and conclude that performance of VIA increase with 
experience. They also compared the percentage of women testing positive 
on VIA who did not had confirmed HSIL after performing a minimum of 
100 examinations obtained by doctors (77%) and nurses (75%), and found 
no statistical difference, but 83 women were classified as positive by 
doctors in comparison with only 16 women considered positive by nurses. 
Unfortunately, they do not report the positivity rates of VIA by health 
provider, but it appears as VIA positivity rates were higher among doctors.
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There is a clear need for establishing uniform criteria on VIA positivity 
and to prepare standard training material for different type of providers. 
Currently, there are several on-going studies, which are trying to evaluate 
the performance of midwives who are full-time dedicated to screening; 
unfortunately, the results of these studies would not be comparable to ours, 
nor applicable to routine practice on low-resource settings, but they should 
contribute to clarify our findings in particular those related to differences 
of VIA performance among different providers.
6.5.2. VIAM
It is possible that the sensitivity of VIA performed by a health worker 
(nurse, midwife, cytoscreener) could be improved when having a second 
opinion of the test by another health worker; or having a second opinion by 
a doctor; or when incorporating the use of a magnification device, VIAM.
This is the third study where VIAM has been added to the screening 
scheme. Denny and colleagues, also implemented VIAM in both of their 
studies in South Africa , , but their intention was to enhance the 
sensitivity of VIA, so VIAM was performed by the same nurse performing 
VIA. In their first study in Khayelitsha, they used a 2.5x magnification 
device (Edmund Scientific, NJ) and in the second one in Cape Town, an 
AviScope™ (4.5x magnification, PATH) similar to the one used in our 
study. In both studies they did not find a significant improvement in 
sensitivity of VIA when using a magnifying device.
In our study, VIAM was implemented:
1. to confirm the midwife VIA positive diagnosis;
2. to offer immediate treatment with cryotherapy if VIA positive 
diagnosis was confirmed.
During the training course, doctors did not find much advantage of using 
the AviScope™. Furthermore, in at least ten cases, they performed VIA 
instead of the midwife. After explaining the importance of following the 
protocol, this did not happen again. Doctors felt more comfortable
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Iperforming VIAM as the study went on. They only performed VIAM after 
a positive midwife diagnosis, which was confirmed in 534 women who 
were examined by a doctor using the AviScope™, reducing the referral 
rate in more than 50%.
With regard to offer immediate treatment to VIA positive women, in many 
instances, doctors were not available or did not count with the AviScope™ 
to perform VIAM or did not have the cryotherapy equipment or such 
equipment was not functioning properly at the time of treatment.
Only 329 women considered positive in VIAM were treated with 
cryotherapy, the other 205 were referred to colposcopy. Doctors were told 
to perform cryotherapy if the lesion was visible, not inside the endocervical 
canal and did not cover more than 75% of the cervix, but only 75 women 
who were referred to colposcopy had lesions with these characteristics, 
including those of 13 women referred directly to the colposcopist by the 
midwife. In some cases, doctors referred women to colposcopy because of 
their problems with cryotherapy equipment, but in general, it was hard for 
them to decide if  cryotherapy was appropriate. Among 305 women 
positive on VIA_M treated with cryotherapy, 18 (6 %) punch biopsies 
(taken before treatment) were inadequate (including one with pending 
result), 251 (82%) were negative, therefore overtreated, 18 (6 %) were mild 
dysplasias and 18 (6 %) were moderate dysplasias or worse lesions. Of 205 
women referred to colposcopy, 11 (5%) had mild dysplasia and 39 (19%) 
had moderate dysplasia or worse lesions on histology. It seems that doctors 
used the wrong threshold: they either failed to take the biopsy of the right 
place or they were overcalling.
Despite the fact that there are a number of colposcopies not performed yet, 
and some pending histology results, VIAM reduced the referral rate of VIA 
substantially (more than 50%) but doctors have problems collecting 
biopsies and deciding between treating with cryotherapy or referring to 
colposcopy.
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IOther studies are needed to evaluate the use of a second opinion by a 
health worker and a confirmatory opinion by a doctor, and if either option 
is improved with the use of a magnification device.
6.5.3. Liquid-based cytology
This is the first time LBC is used in Peru. The option of using the 
AutoCyte-Prep® manual system (TriPath) was taken because Cytic, the 
manufacturer of ThinPrep®, refused to supply sampling and processing 
kits for our study. They decided not to participate in a study where a new 
ThinPrep® laboratory was to be implemented in South America, due to the 
costs of maintenance of equipment and quality assessment implied. On the 
other hand, the manual AutoCyte-Prep® system was more affordable for 
the laboratory (very few extra equipment from standard was needed), 
sampling and processing kits were cheaper and the Peruvian/South 
American representatives of TriPath, Capricorn Technologies Inc., offered 
training for the laboratory personnel.
The laboratory was then established within the Cytology Laboratory of 
INEN, and the training took place during three days in the beginning of 
March 2001. An expert with experience in retraining cytopathologists in 
the reading and interpretation of thin layer slides, carried out the training, 
which consisted of one morning of theoretical classes and two days of 
practice, both of the slides preparation (AutoCyte-Prep® procedures) and 
reading. The first two hundred and fifty collected samples from women 
screened in Tarapoto, were processed and the slides were read using a 
multihead microscope during the course. All participants, cytotechnicians 
and cytopathologists, found it difficult to read the very first slides and 
cytopathologists found it hard to agree with the expert diagnosis in the 
beginning, but after discussion they got into agreements. Once the training 
was finished, cytotechnicians from INEN carried out the processing of 
other 400 samples and mastered the technique. Afterwards, all LBC 
samples have been processed and first read by the technicians, and 
confirmed by the lead cytopathologist of the laboratory.
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ISeveral studies have agreed that correct interpretation of LBC slides 
improves with experience, after an initial period of acclimation. It is well- 
known that AutoCyte-Prep® slides have a cleaner background (less 
inflammation, less blood and debris), have less cells (even dispersal of 
cellular material) with less overlap and better nuclear preservation 
156 1^55 1^57 1^58. m  advantage, it also tends to generate initial
overdiagnose after first training on reading LBC. And that, once 
cytotechnicians and cytopathologists become aware of their overdiagnosis, 
inversely, they start to underdiagnose 156,208,209.
In our study, the tendency to overdiagnose has been consistent. A quality 
assessment done after the first 1 ,0 0 0  samples were processed and read in 
the new LBC laboratory in Lima showed a 30% of overcalling. Seventy- 
nine LBC slides (of the first 1000) were reviewed by Dr. Vassilakos 
laboratory in Geneva. Table 6.4.3.1 presents a summary of the results.
Among 79 reviewed slides, both laboratories agreed in 53 (67%). The 
laboratory in Lima had an overcall rate of 30% (22/73). Only one LSIL 
was recognised by the Geneva laboratory, this was classified as HSIL by 
the laboratory in Lima. All HSIL or worse lesions were detected by LBC in 
Lima but one was classified as LSIL.
Table 6.4.3.I. Summary of results of quality assessment of LBC slides.
Experts from 
Geneva
Laboratory in Lima
Negative ASCUS LSEL >HSIL Total
Unsatisfactory 5 0 1 0 6
Negative 43 7 8 1 59
ASCUS 0 2 3 2 7
LSIL 0 0 0 1 1
>HSIL 0 0 1 5 6
Total 48 9 13 9 79
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The ordered kappa statistic was 0.6156 (observed agreement=91%, 
expected agreement=76%, p<0.001) using weights: 1 if complete 
agreement, 0.889 if one category apart, 0.556 if two categories apart), and 
zero if three categories apart (complete disagreement).
Cytologists in Peru and Chile proposed the classification used to report 
LBC and CC results in this study, and all investigators supported it. As the 
purpose of the study was to detect high-grade lesions, in many instances 
results are merged together in less categories, but it has been difficult to 
compare results when LBC slides have been reviewed or have been 
correlated with histology. In the future, it will be better to use the Bethesda 
system, which is widely used internationally13,14.
The positivity rate of LBC for detecting LSIL or worse lesions (including 
ASCUS, AGUS and Condyloma/HPV) was 18%, when only mild 
dysplasias or worse lesions were considered, the rate was reduced to 9.6% 
and for detecting HSIL or worse lesions was 3.3% (171/5257). These are 
the highest positivity rates ever reported in Peru. So far, 105 women of 
these 171 with at least HSIL on LBC have been biopsied, the histology 
results are as follows: one inadequate, 29 negative, 12 condylomas/HPV, 
12 mild dysplasias, 7 moderate dysplasias, 7 severe dysplasias, 22 
carcinomas in situ, 3 microinvasive cancers and 12 invasive cancers, 
confirming 23% of LSIL and 49% of HSIL or worse, and that 28% were 
wrongly classified as HSIL. These figures are far from those of Vassilakos 
laboratory 144, where among 357 patients classified as having HSIL or 
worse lesions, 89.6% were histologically confirmed, 5.6% were LSIL and 
4.5% were negative on histology.
Several studies have pointed out that the number of inadequate samples is 
reduced when using liquid-based cytology methods
145(146)209)147 148(149(15<H51;152;153;159 B e c a u s e  sa m p ]e s  ^  using  g
brush, which head is removed from its handle and immersed directly into a 
preservative vial, the smear-taker is not any more in charge of fixation, and 
so cells are unlikely to be assessed as inadequate, equivocal or borderline 
because of poor fixation 155. The percentage of inadequate samples in our
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study was 5%, most of them were not possible to evaluate because of 
haemorrhage (195 cases) or for being hipocellular (44) or acellular (4). 
One reason for so many cases of haemorrhage could be the way of 
sampling, the Rovers-Cervex® brush was rotated five times clockwise 
once inserted into the endocervical canal, this was an entirely new 
procedure for midwives who claimed that most screened women had 
severe cervical inflammation at the time of screening. The LBC laboratory 
reported 26% of slides with inflammation, and 0.5% of them with severe 
inflammation. As for infections, 519 (10%) women had an infection on 
LBC, 390 (7%) had gardnerella, 65 (1.2%) had candidiasis, 63 (1.1%) had 
trichomonas, two had herpes virus, one had chlamydia, and two had two 
infections: one chlamydia and trichomonas, and one had gardnerella and 
trichomonas. These are also the first figures regarding inflammation and 
infections detected on cytology.
As compared with conventional cytology in this study and previously in 
Peru, this is the first report of a 3.3% positivity rate of cytology for 
detecting high-grade disease in a Peruvian population, the first time the 
percentage of inadequates is below 1 0 %.
LBC collected samples were sometimes transported over 30°C of 
temperature, but were still satisfactory for evaluation. The majority of 
inadequate samples were related to bleeding processes while collecting 
samples. The Rovers-Cervex® brush may be too hard for the cervix, 
especially, if this is inflammated, and definitively, rotating it five times, 
produces bleeding in most cases.
It is clear that LBC has had more than 25% of overcalling, but further 
quality assessments are needed to estimate real values of overdiagnosis and 
underdiagnosis. However, LBC detected 51 (1%) high-grade lesions, 
including 1 2  invasive cancers.
It has been suggested that LBC slides are prepared more quickly than 
conventional cytology ones and so that laboratory productivity can 
increase 25-30% 159. This has not been evaluated properly yet, and one has 
to consider that despite the fact that several LBC slides are produced at
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once, the slide preparation is more complex and takes longer time than a 
simple Pap smear 154.
In Peru, it is not of great concern if productivity is enlarged by the use of 
LBC. If LBC were to be used greatly in Peru, two to three laboratories 
located in key localities in the country would have to be established and 
would be regulated by a central one in Lima. Currently, there are many 
conventional cytology laboratories in Peru that lack quality standards, for 
instance, the amount of slides read per day greatly exceeds the limit 
established in the UK (32 per day) and the USA (100).
In summary, further quality assessments have been planned to evaluate if 
the LBC laboratory has improved its performance with experience. The 
first results of LBC are so far very promising when compared with 
conventional cytology, but LBC laboratories need training and continuing 
education, in order to achieve quality standards and these can become very 
costly.
6.5.4. Conventional cytology
Conventional cytology was not considered as a screening option, because 
after being in place for more than 2 0  years, it showed no benefit for the 
health of women in San Martin. Conventional cytology has many problems 
in the region: often negative women are re-screened several times so the 
number of previously unscreened women covered is minimum. Sample 
collection is of bad quality, and samples can get easily lost or broken in 
their way to the laboratory. The local laboratory does not have internal or 
external quality assurance protocols, processing and reading of PAP 
smears is below quality standards. The results are not given to women 
unless they specifically asked for them, and if they are positive, no further 
evaluation or treatment is offered to them, and women have to arrange 
private health care if they can afford it.
A clear example of the conventional cytology situation in the region was 
shown during the training of midwives on VIA and general doctors on 
VIAM and cryotherapy in November 2000. A special effort was made to
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identify and visited 233 women with previous positive conventional 
cytology (LSIL or worse during 1999 and 2000) 9. These women were 
invited to participate in a special screening and treatment campaign, and 
those who agreed to participate were transported to Tarapoto, where they 
were examined by the trainers and treated as required. Before this training 
course, none of these women had been recalled for further evaluation or 
adequate treatment, and at least 1 0  of them had carcinoma in situ or 
invasive carcinoma cytology results. All these women have been treated as 
part of the TATI project.
Several attempts to improve conventional cytology in the region since the 
start of the TATI project have been carried out. Sponsored by the project, 
cytotechnicians have been retrained at INEN and have undergone 
proficiency tests. The problem of inadequate sampling has also been 
addressed; midwives with the smallest inadequate rates have standardised 
the collecting procedure and have shown it to each midwife in routine 
practice. The central laboratory in Tarapoto did not have an appropriate 
storage system of slides, the TATI project have provided with 
infrastructure to maintain slides and for keeping records.
6.5.5. HPV testing
It is a fact that HPV testing has a role in cervical screening 210,211. Several 
studies have shown the advantages of using HPV testing as a screening 
technique, but it is not been well established which role HPV testing could 
take. The most important one would be to consider HPV as an adjunctive 
to either LBC or VIA. In this study we tried to prove that HPV could be an 
adjunctive test to VIA, women testing positive on VIA could be sampled 
for HPV and if  positive then proceed to further evaluation or treatment. We 
only tested the samples collected sometime later so the assessment of 
women having high-grade disease was not based on HC-II. HPV samples 
were tested in London but ideally testing should have been carried out in
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Lima. The possibility of establishing a Hybrid Capture Laboratory in Lima 
was not feasible at the time of the study but it is now being implemented.
This is the first time that HPV collected samples are used in a very difficult 
setting. Efforts were made to keep samples under 30°C, but sometimes cars 
transporting them were trapped in dirty roads for many hours and collected 
HPV samples were exposed to temperatures over 35°C.
HPV samples were collected in third place after conventional and liquid- 
based cytology, and this did not affect its positivity rate.
The overall prevalence of HPV infection in this study was 13%, similar to 
that of other studies. The prevalence of HPV infection was 20% in a 
previous cross-sectional study in asymptomatic women in a deprived area 
from Lima using PCR to detect HPV 6 , HPV 11, HPV 16, HPV 18, HPV 
31, HPV 33 and HPV 35; after excluding women positive for HPV 6  and 
HPV 11, the prevalence was reduced to 10.4% (unpublished data). In a 
hospital-based case-control study in Lima 5, the prevalence of HPV 
infection among healthy controls was 18%, once more, after excluding 
low-risk HPV types; the prevalence was reduced to 13%. In a systematic 
review of HPV testing, Cuzick et a l 169 obtained an overall positivity rate 
of tests for high-risk HPV types (using PCR or Hybrid Capture) of 13% 
ranging from 10% for PCR using GP5/6 primers to 20% using HC-II, in 
asymptomatic populations.
Because of these consistent results, we can assume that the positivity rate 
of HC-II was not affected by high temperatures in the field or by the order 
in which samples were collected. Furthermore, there was only one 
insufficient sample for testing. This was significantly impressive if 
compared with inadequate rates observed for both cytology techniques (5% 
and 11% for LBC and CC, respectively).
HPV prevalence decreased, as women grew older, as shown in Table 
5.2.1.3 (p-value for trend<0.001). We screened women between 25 and 49 
years of age, however, 61 women younger than 25 years of age and 12 
older than 49 participated in the study.
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Table 6 .5.5.1 presents the age distribution of HPV positive women. As 
mentioned in 5.2.1, when excluding those there is a decreasing trend 
prevalence of HPV decreased with age, from 15% in women 25-29 years 
to 9% in those aged 45-49.
HPV prevalence varied between 7% (only 165 women were screened) and 
15% across health centres of recruitment (Table 5.2.2.3). After excluding 
the C.S Juan Guerra where only 165 women were screened (positivity rate 
of HC-H of 7%), the prevalence of HPV infection was consistent among 
health centres (mostly between 11% and 14%, p-value=0.249).
Overall, we considered positive women with a viral load of at least 1 RLU, 
but the prevalence of HPV infection was 10% when instead a high 
threshold ( ^  RLU) was used.
Table 6.5.5.2 presents the distribution of HPV results (RLU) obtained in 
our study, and the positivity rate of second HPV testing by RLU of initial 
testing.
Only 82 women (1.6%) had borderline HPV results (0.8-2 RLUs). Among 
702 positive women ( ^  RLU), 10% had less than 2 RLUs, 10% between 2 
and 4 RLUs, 15% between 4 and 10 RLUs, 35% between 10 and 100 
RLUs and 30% over 100 RLUs.
It has been suggested that viral load predicts persistence of HPV infection 
81,89 • hi our study, we were not able to assess this relationship, because we 
used HC-II, and according to a recent paper by Gravitt et al , RLUs do 
not predict well viral load. However, it is worth to mention, at least 50% of 
women who had 4 RLUs or more on initial HPV testing had a second 
positive HPV test.
In summary, the prevalence of HPV infection was 13% using Hybrid 
Capture II; which proved to be enough robust to be used in tropical 
conditions, had consistent results across health centres, and reported very 
few borderline results. It is worth noting that HPV testing was the only 
screening test not carried out in Peru; moreover it was performed in an 
international well-recognised HC-II laboratory.
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Table 6.5.5.2. HPV viral load distribution and positivity rate of second
HPV testin ?•
Viral load n %
%
in
positives
Second HPV testing 
No. positive/No. tested (%)
<0 .8 4821 86.9 23/300 (8 )
0 .8 -1 23 0.4 1/4 (25)
1 -2 69 1 .2 9.8 10/31 (32)
2-4 65 1 .2 9.3 8/23 (35)
4-10 104 1.9 14.8 21/42 (50)
1 0 - 1 0 0 248 4.5 35.3 49/94 (52)
> 1 0 0 216 3.9 30.8 33 /65 (51)
Total 5546 1 0 0 1 0 0 145/559 (26)
6 .6 . Histology
Punch biopsies were used before treating positive VIA_M women with 
cryotherapy. General doctors took biopsies using only the AviScope™ (not 
during colposcopy), therefore, they had difficulties in collecting a good 
sample. In addition, because women tended to bleed, treatment was 
frequently delayed or women were referred to colposcopy instead.
Local gynaecologists were trained during one or three months to perform 
colposcopy and to treat with LEEP at INEN in Lima. In the beginning of 
the study, colposcopists were not enough confident to collect biopsies of 
apparent lesions. In many cases, colposcopies were repeated even three 
times before a biopsy was collected or a woman was treated.
Table 6.6.1 shows the preliminary results of a quality assessment of 
histology performed in the UK. The results were as follows:
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Table 6.6.1. Summary of results of quality assessment of histology.
Expert in UK
Laboratory in Lima
Unsatisfactory Negative LSIL HSIL Total
Unsatisfactory 8 23 2 1 34
Negative 1 51 55 4 1 1 1
LSIL 0 3 8 7 18
HSIL 0 0 1 17 18
Total 9 77 6 6 29 181
A total of 274 pathology slides were reviewed corresponding of collected 
biopsies from 181 women. This review is still on going; some sets of 
pathology slides from a biopsy are still to be reviewed. Therefore, it is 
possible that some results coded so far as unsatisfactory change once the 
corresponding set of slides is complete.
Both laboratories agreed in 84 (46%) pathology results. The laboratory in 
Lima had an overcall rate of 45% (66/146). Only 18 LSIL were recognised 
by the UK laboratory, 3 of them were classified as negative by the 
laboratory in Lima and 7 as HSIL. Seventeen of the 18 HSIL (or worse 
lesions) were diagnosed as HSIL by the laboratory in Lima; only one was 
classified as LSIL.
The ordered kappa statistic was 0.4218 (observed agreement=79%, 
expected agreement=64%, p<0.001) using weights: 1 if complete 
agreement, 0.889 if negative in one laboratory and unsatisfactory in the 
other, and 0.556 if unsatisfactory in one laboratory and LSIL in the other 
or one category apart), and zero if unsatisfactory or negative in one 
laboratory and HSIL in the other (complete disagreement).
The level of disagreement is highly related to the number of unsatisfactory 
samples, the reviewer considered unsatisfactory or non-contributory 
samples:
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-  Those who had only endocervical tissue, failing to identify the part 
of the cervix where the SIL might have been expected and from 
where the biopsy should have been taken; and,
-  Those obtained from LEEPs, where the surface epithelium was 
completely destroyed.
Of special concern are four biopsies considered negative by the reviewer 
but HSIL by the original pathologist; three of them had an additional slide 
still to be reviewed, the other has either been overdiagnosed by the 
laboratory in Lima or misclassified by the reviewer; a third reading is 
being arranged.
As stated before, this review is yet to be continued, however, it could be 
recommended that more training and supervision of biopsy collection and 
treatment of local specialists of the region of San Martin should be 
encouraged. Regarding results, the likelihood of collecting biopsies from 
the wrong parts of the cervix might have diminished our rate of high-grade 
disease, and somehow enlarged the false positive rates of our screening 
tests. Nevertheless, the effect on tests performance would be the same for 
all screening techniques.
6.7. Statistical methods to estimate measures of performance of screening 
tests
At time of analysis, the data was incomplete. We used a very complicated 
analysis, in order to provide good estimates of sensitivity, specificity and 
positive predictive value for each screening test and for several 
combinations of them. Data will most probably be complete in six months.
One main problem of having done this estimation before data completion 
relies in the fact that it is almost impossible that HPV positive women who 
were LBC negative and VIA_M negative have had confirmed HSIL (as 
these women would have not been fully evaluated yet). More generally, the 
likelihood of definite disease status (HSIL or no HSIL) is heavily 
depending on screening tests scheme.
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Whereas other similar studies have used a direct calculation of the 
proportion of evaluated women and applied it to the general group; in 
addition to the proportion of women not fully evaluated within groups, we 
had a very large proportion of women with missing VIAM or second 
screening results. There may be other ways to handle these difficulties, but 
we decided to estimate the distribution of the missing values and used for 
estimation.
The algorithm used to estimate sensitivity, specificity and positive 
predictive values yielded unbiased estimators, but we needed to use 
bootstrapping to calculate confidence intervals.
6.8. Measures of performance of screening tests
HPV testing (HC-II) had the highest sensitivity of the screening tests (72%, 
Cl: 65,79), but moderate specificity (90%, Cl: 89,91) for detecting high- 
grade disease. LBC (considered positive if ASCUS or worse lesions were 
diagnosed) had the second highest sensitivity (69%, Cl: 61,78) and lower 
specificity (85%, Cl: 84,86) than HPV testing. The most unexpected 
results were those of VIA which had an extremely low sensitivity (44%, 
Cl: 34,59) and a poor specificity (77%, Cl: 74,77). Combining 
VTA/VIAM, reduced the sensitivity to 31% but increase the specificity to 
91% (Cl: 91,92).
Overall, these results are very disappointed as compared with other of 
similar studies in the literature.
The sensitivity of HPV testing (using HC-II) has been consistently reported 
over 80% 75>173j171>170 anci over 950^  jn more recent studies 174>172>161. HC-II 
missed 26 high-grade lesions: zero cancers, 3 carcinomas in situ (in women 
aged 26, 35, and 43), 4 severe dysplasias (in women aged 28, 29, 39, 45) 
and 19 moderate dysplasias. Of these 26 lesions missed, 6  were detected by 
VIA and LBC, 14 were identified only by VIA, 5 only by LBC, and one 
was detected during a non-indicated second screening. In contrast, HC-II 
specificity was higher than that previously reported by other studies except 
for the Cuzick study 75 in women older than 35 years of age. It is clear that
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if moderate dysplasia were excluded from our definition of HSIL, the 
sensitivity of HC-II would be much better. It remains to see how many of 
the missed cases of HSIL are recoded to LSIL on review by the expert 
pathologist.
The sensitivity of conventional cytology has been reported to vary between 
40% and 80% 134)138>135j139> Belinson et a l 172 reported a sensitivity of LBC 
of 77% using ThinPrep at a high threshold ( >HSIL), and Vassilakos and 
colleagues 142 a sensitivity of 99% using AutoCyte-Prep® (low threshold >  
ASCUS). In our study, the sensitivity of LBC using AutoCyte-Prep® at a 
low threshold was not as high as that from Vassilakos group, but at least 
was higher than 65%. LBC was inadequate in one microinvasive and two 
invasive cancers and negative in other 27 HSIL lesions (including one 
invasive adenocarcinoma); 9 of these lesions were detected by VIA and 
HC-II; 14 were identified only by VIA, 3 only by HC-II, and one during a 
non-indicated second screening. The three inadequate LBC samples that 
resulted in cancers were detected by HPV, and only the microinvasive 
cancer was missed by VIA. It is worth mentioning that conventional 
cytology (CC ^ASCUS) only considered positive 30 of 75 (40%) high- 
grade lesions detected by LBC. But CC also identified two of the cancers 
whose LBC samples were inadequate and another high-grade lesion missed 
by LBC.
The specificity of LBC was low; this is not surprising, as it was cleared 
throughout the study that LBC was overcalling lesions regularly.
The most striking results as those of VIA (and combined VIA/VIAM). 
This study was designed based in the assumption that VIA would have a 
high sensitivity but poor specificity as shown in several other studies, and 
that HPV testing or LBC could be used as an adjunctive screening test to 
improve low specificity. But VIA (and combined VIA/VIAM) had the 
lowest sensitivity of all screening tests. VIA missed 23 high-grade lesions, 
3 microinvasive cancers and 10 invasive cancers (including one 
adenocarcinoma); 27 of which were identified by both LBC and HPV 
testing, 5 only by LBC and 2 only by HC-II, and one during a non­
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indicated second screening. However, VIA was able to identify 25 and 20 
additional cases missed by LBC and HPV testing, respectively.
As expected combinations of VIA with other screening tests improved VIA 
specificity with a loss in the already so poor sensitivity.
The highest positive predictive values was that o f LBC ( >HSIL) had the 
highest positive predictive value (44%, Cl: 34,53), followed by HC-II 
(2 2 %, Cl: 14,32).
Overall, HC-II did not miss any invasive carcinoma; LBC missed one 
invasive adenocarcinoma and was unable to identify three cancers because 
cervical samples were inadequate; and VIA was unable to identify 10 of 18 
detected cancers (56%).
Glandular abnormalities are not readily detected by cytology 213j214> but it 
is accepted that invasive and preinvasive lesions would be found in 40% 
and 20-28% of abnormal glandular smears 2159216. Being the LBC 
laboratory recently established, it is not surprising that it failed to identify 
one invasive adenocarcinoma.
A critical case is that of VIA, it is unacceptable that it missed 10 invasive 
carcinomas. One possible explanation but not justification for such failure 
could lie on the fact that women coming into screening frequently suffered 
of severe cervicitis, and this must have hide lesions even after acetic acid 
was applied. Nevertheless, we are in the process of reviewing the clinical 
data forms, investigating the stage of these cancers, and arranging the 
correspondent histology review.
In summary, HPV testing had higher sensitivity than all the other screening 
tests, LBC had moderately low sensitivity and specificity but its results 
were improved as the new LBC laboratory gained experience. VIA had 
very poor sensitivity and specificity, but was able to identify additional 
high-grade lesions missed by either HC-II or LBC. This is the first 
screening study within an organised intervention to be reported for Peru, in 
any case, the number of preinvasive lesions and invasive carcinomas
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identified by each screening test suggest that each of them is better than 
previous opportunistic cytology.
6.9. Future of cervical screening in Peru
Given the results of this study, it is not clear yet which should be the best 
approach to cervical screening in Peru.
The lack of facilities in different parts of the country as in the San Martin 
region makes it very difficult to establish a well-organised programme. 
The need for decentralization has become obvious after this study, without 
a pathology laboratory, without well-trained colposcopists and 
gynaecologists capable of treating high-grade lesions, any effort to screen 
is useless, since it is critical to treat all lesions found and this, has not 
happened in Peru for decades.
Different approaches would need to be put in practice depending of the 
screening target population and the health facilities available for such 
population.
Despite the poor results of VIA, the advantages of this test over 
opportunistic cytology are clear. In rural areas of Peru, the modality of 
health campaigns is very common: a group of health providers go into one 
locality and apply a complete basic health package which includes 
vaccination, screening, reproductive health advice counsel and immediate 
treatment of minor diseases. VIA can easily be used within health 
campaigns; a team consisting of a midwife, one doctor with cryotherapy 
equipment and one gynaecologist with a colposcope could travel to 
different areas, screen and treat (if appropriate). This scheme has already 
been in place within the TATI project and has allowed the screening of 
women living in very remote areas.
The possibility of using VIA as a primary cervical screening method is 
promising; but first, definition standards of VIA positivity, and well- 
documented training material should be developed and used to train VIA
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providers. Because midwifery is offer in most universities in Peru, VIA 
could be taught initially at undergraduate levels and midwives could be 
retrained once in clinical practice. In this way, better and more consistent 
performance of VIA could be ensured; with no extra cost.
For urban areas, more sophisticated schemes can be applied where the use 
of HPV testing should be the first choice. Cuzick 217 have recently 
proposed that HPV could be used as a primary screening test, although this 
approach needs more evaluation, our results in very difficult conditions 
support this suggestion, and it would be expected that HPV testing would 
perform significantly better in less difficult conditions. However, ways of 
dealing with the anxiety to be generated in women testing positive on HPV 
should be proposed, discussed and normalised.
Another main problem is the fact that even in areas where health networks 
work quite well, information is not given the relevance it should, causing 
delays in the clinical management of positive women. Efforts need to be 
made in order to ensure that positive women receive adequate treatment 
within a reasonable time after diagnosis; and the first step to do so, is by 
ensuring that precise information is available when necessary; without 
trespassing ethical issues of anonymous records.
6.10. Screening developments
A number of new screening techniques for cervical cancer are currently 
under investigation.
Visual inspection after the application of Lugol’s Iodine (VILI) is a 
promising one. In a study of 4444 women in India 193, the sensitivity of 
VILI to detect high-grade lesions was 87% and its specificity 85%, while 
those of VIA were 89% and 78% (for a high-threshold positivity 
definition).
Several studies have described biomarkers to be used in the detection of 
cervical neoplasia; of special interest are those related to the detection of 
p i 6  overexpression in HPV-related lesions . HPV types have been 
subdivided into high- and low-risk categories based on their association
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with invasive cervical carcinoma. This association is as well, based on the 
relative affinity that the HPV-type specific oncoproteins E6  and E7 bind to 
cellular regulatory proteins, specifically, the p53 tumour suppressor protein 
(Rb). Inactivation of these factors leads to disruption of the cell cycle and 
to overexpression of p i 6  levels in HPV-related lesions. High degree of 
correlation between the immunohistochemical detection of p l 6  in tissue 
sections and the presence of oncogenic-risk HPV-induced SIL lesions have
910  990been reported when using antibodies to p i 6  , .
Cervical cancer and CIN express high levels of the cyclin-dependent 
kinase inhibitor p i 6 , suggesting that staining for this marker could help to 
more precisely identify CIN in tissue sections and therefore reduce
991variation in interpretation of cervical lesions. Klaes R et al stained 
biopsy sections with hematoxylin and eosin, and with a p i 6  -specific 
monoclonal antibody; and obtained 91% agreement in the interpretation of 
p i 6  expression between five experienced pathologists; p l 6  was expressed 
in CIN 2, CIN 3, and CIN 1 associated with HPV or cervical cancer. Even 
small CIN or cervical cancer lesions in biopsy sections were identified 
after p i 6  immunostaining. The authors concluded that p l 6  
immunohistochemistry could reduce false-negative and false-positive 
biopsy interpretation.
In a more recent study, Agoff and colleagues 222 performed 
immunohistochemistry for p lb 1^ 4* and Ki-67 on 569 and 432 biopsy 
samples, respectively. The degree of p l 6 INK4a and Ki-67 expression 
correlated with degree of cervical neoplasia, and p lb 11^ 4* was less likely to 
be positive in samples from women with negative, reactive, and atypical 
biopsies. The authors conclude once more that of p lb 11^ 43 has potential as 
a screening marker for cervical neoplasia. The use of a p i 6  
immunohistochemistry test; which can give results within the same day of 
screening or even as a deep-stick test could change the future of cervical 
screening.
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Although screening studies using p lb 11^ 4* need to be carried out, and more 
studies should evaluate the performance of VILI; the use of p lb 11^ 4* and 
VILI appear as promising cervical screening alternatives.
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7. CONCLUSIONS AND RECOMMENDATIONS
7.1. Conclusions
In summary, the conclusions of this thesis are:
1. VIA is a cheap, easy screening test that gives immediate results, and 
can be easily implemented in routine midwifery clinics. VIA 
performance improves with experience and requires periodic 
retraining. Standard definitions of positivity and measures of 
proficiency on VIA and a minimum number of VIAs performed per 
week should be established. Well-documented manuals and updated 
literature on the technique should be available for VIA providers. 
With such quality assurance measures in place, VIA should provide a 
sensitive, but non-specific test for HSIL. However, in this study, the 
lack of supervision resulted in poor sensitivity emphasising the 
difficulties that must be overcome if VIA is to be used in mass 
screening programmes in developing countries.
2. VIAM reduced VIA referral rate in more than 50%. However the 
improved specificity was associated with a reduced sensitivity (from 
44% to 31%). Additionally, doctors were not confident enough to 
discriminate between women suitable for immediate treatment and 
those needing colposcopy.
3. The advantage of VIA is that the result is available immediately. 
Hence, if  screening is properly organised it should be possible to 
treat women at the same visit thus eliminating dropout associated 
with recall for treatment. The disadvantage is that its poor specificity 
would result in over-treatment and without adequate post-treatment 
surveillance, recurrence is likely 223)224. For instance, in a study by 
Benedet et al 223, among 1675 patients eligible for assessment at one 
year after being treated with cryotherapy, 6 % had recurrence for CIN 
and 5.6% were lost to follow-up. Soutter et al 224, using data from 
four UK centres, reported 2.6% annual recurrence after treating CIN
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with laser vaporisation, cold coagulation, laser cone or loop 
diathermy. Currently, it is not possible to carry out cytology or HPV 
testing during a single visit.
HC-II and AutoCyte-Prep® samples appeared to be robust to the 
high temperature of San Martin; and can be used in difficult resource 
settings even if not possible to comply with manufacturer’s 
recommendations for storage.
The percentage of inadequate LBC samples was high but half that of 
conventional cytology. The positivity rates of LBC for low and high 
threshold of disease, and those of CC are the highest ever reported in 
Peru. LBC detected biopsy confirmed HSIL cases missed by VIA 
and VIA_M; and detected twice the number of histologically 
confirmed HSIL or worse lesions detected by CC.
HC-II is an objective test, had the highest sensitivity of all screening 
tests used in this study, and proved to be robust enough to be used in 
tropical conditions. But it is still significantly more expensive than 
VIA. However, if HPV testing could guarantee longer screening 
intervals, its use could be certainly justified, as the increase in cost 
will reduce the cost of several visits and of false positive referrals. 
HC-II would definitively have a place in organised cervical screening 
programmes in less difficult conditions within developing countries.
More studies using existing infrastructure, but with organised quality 
assurance should be carried out to evaluate the performance of VIA 
in routine clinical practice.
7.2. Recommendations:
1. Efforts should be made to train midwives on VIA while they are at 
undergraduate level.
2. Midwives should performed certain number of VIA examinations, 
receive regular training and have proficiency tests, in order to ensure 
better performance.
3. Better effort should be made to guarantee the performance of 
cryotherapy equipment before implementing the treatment in a large 
scale.
4. Training of colposcopists should be done under a standard 
curriculum and regular test of proficiency should be established.
5. The ideal “single-visit” scheme is not feasible in settings where 
qualified specialists are not available. Using external gynaecologists 
and other high-qualified health professionals is not practical in low- 
resource settings. Instead, a combination of VIA with another 
screening test such as LBC or HPV testing should be considered for 
low-resource areas; while HPV testing in combination with LBC is 
possibly more appropriate for areas with better facilities. The use of 
“health campaigns” both to screen and treat women once laboratory 
results are available (if applicable) is strongly recommended.
6 . Decentralization of health resources is recommended before 
establishing a mass screening programme. Nevertheless, different 
approaches should be implemented depending on target population 
characteristics and health services available.
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APPENDIX:
Code used to calculate sensitivity, specificity and PPV after estimating screening tests 
results and disease status in women with imcomplete screening or women not fully 
evaluated.
prog def cal_eff, rclass 
version 8.0
xi:mlogit viaml i.lbc7 if  v i a l= l  
predict fitvO fitvl fitv2
expand 3 if v ia m l= . & v i a l = l  & eval= 0 
sort codigomu 
gen pviaml=viaml
qui by codigomu:replace pviaml=_n-l if pviaml==. & v i a l = l  & eval= 0  
gen wviaml=l
replace wviaml=fitvO if p v iam l= 0  & viaml= .  
replace wviaml=fitvl if p v ia m l= l & viaml= .  
replace wviaml=fitv2 if pviaml ==2 & v ia m l= .
lab var pviaml "New VTAM after estimating VIAM pending result" 
lab def pviaml 0 Neg 1 Cryo 2 Colp
/*New management groups after estimating VIAM pending*/
/*Combined results from first samples VIA and VIAM (pviam)*/ 
drop via_ml
gen via_ml=0 i fv ia l= 0  | ( v ia l= l  & p v iam l= 0 )
replace via_m 1=1 ifp v ia m l= l
replace via_ml=2 if pviam 1 = 2
lab drop via_ml
lab var via_ml "VIA_M"
lab defvia_ml ONeg 1 Cryo 2 Colp
lab val via_ml via_ml
drop via_mml
gen via_mml=0 if vial==0
replace via_mml=l i f v i a l = l  & pviam 1 = 0
replace via_mml=2 if v i a l = l  & pviaml= 1
replace via_mml=3 if v i a l = l  & pviam 1 = 2
lab drop via_mml
lab varvia_mml "VIA_M"
lab def via_mml 0 "VIA neg" 1 "VIAM neg" 2 Cryo 3 Colp
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lab val via mml via mml
capture drop via_lbhg 
gen via_lbhg=0
replace via_lbhg=l if via_ml~=0 & lbchsil= l
capture drop vialbhg 
gen vialbhg=0
replace vialbhg=l if  v i a l= l  & lbchsil==l
capture drop vialblo 
gen vialblo=0
replace vialblo=l if v ial— 1 & lbclow==l
capture drop viahpv 
gen viahpv=0
replace viahpv=l if  v i a l = l  & h p v l= l
capture drop via_lblo 
gen via_lblo=0
replace via_lblo=l if via_ml~=0 & lbclow = l
capture drop via_lbhs 
gen via_lbhs=0
replace via_lbhs=l if via_ml~=0 & (dxlbc=8 | dxlbc=9)
capture drop via_lbca 
gen via_lbca=0
replace via_lbca=l if  via_ml~=0 & dxlbc=10
capture drop via_cchg 
gen via_cchg=0
replace via_cchg=l if via_ml~=0 & cch sil= l
capture drop via_hpv 
gen via_hpv=0
replace via_hpv=l if  via_ml~=0 & h p v l= l
capture drop lbhg_hpv 
gen lbhg_hpv=0
replace lbhg_hpv=l if lb ch sil= l & h p v l= l
capture drop cch_o_n 
gen cch_o_n=0
replace cch_o_n=l ifc c h s il= l & lbchsil~=l & hpvl~=l & via_ml~=l 
lab var cch_o_n "Only CC HSIL, others neg"
capture drop cch_o_lb 
gen cch_o_lb=0
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replace cch_o_lb=l if c ch s il= l & lbchsil~=l
lab var cch_o_lb "CC HSIL & LBC<HSIL, others not consid"
capture drop hpv 1020 
gen hpv1020=0
replace hpv1020=1 i fh p v l= 0  & hpv2= 0
capture drop hpv 1021 
gen hpv 1021=0
replace hpv 1021=1 i fh p v l= 0  & h p v 2 = l
capture drop hpvl 120 
gen hpvl 120=0
replace hpvl 120=1 i f h p v l= l  & h pv2= 0
capture drop hpvl 121 
gen hpvl 121=0
replace hpvl 121=1 i f h p v l= l  & h p v 2 = l
capture drop rescreen 
gen rescreen=0
replace rescreen=l if  (v ia_m l= 0) & ((dxlbc>=4 & dxlbc<8)| ((dxlbc<4| dxlbc>90) & 
dx h p v = l)) & (dxpap<8 | dxpap=98 | dxpap=99 | dxpap= .) 
lab var rescreen "Need rescreening"
capture drop norescr
gen norescr=l -rescreen
lab var norescr "Not need rescreening1
xi:mlogit dxscreen i.lbcres i.hpvl if rescreen= l & via_m2~= & lbc2~=. & hpv2~=,
basecategory(O)
predict fitsO fitsl fits2
sort codigomu 
gen codi2=_n
expand 3 if  dxscreen==. & rescreen==l & eval==0 
sort codi2
gen prescr=dxscreen
qui by codi2:replace prescr=_n-l if p rescr= . & rescreen= l & eval==0 
gen wrescr=l
replace wrescr=fits0 if p rescr= 0  & dxscreen==. & rescreen= l 
replace wrescr=fitsl if prescr==l & dxscreen=. & rescreen= l 
replace wrescr=fits2 if prescr==2 & dxscreen==. & rescreen= l
gen fmwe=wviaml*wrescr
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local clgp6 "via_m 2=0 & ((foldxlbc>=l & foldxlbc<=3 & foldxhpv=0) | 
(foldxlbc— 99 & foldxhpv=0) | (foldxlbc>=2 & foldxlbc<=3 & foldxhpv>90 & 
foldxhpv<100))"
local clgp5 "via_m 2=2 | (((foldxlbc>7 & foldxlbc<20)| foldxhpv=l) & 
clingroup=.)"
/*Clinical management groups*/ 
drop clingroup
gen clingroup=l if v ia _ m l= l 
replace clingroup=2 if  v ia_m l= 2
replace clingroup=3 if (via_ml==0 | viaviam =9) & ((dxlbc>7 & dxlbc<20) |
(dxpap>7 & dxpap<20))
replace clingroup=6 if  v ia_ m l= 0  & (dxpap<8 | dxpap=98 | dxpap=99 | dxpap=.)
& ((dxlbc>=l & dxlbc<=3 & dxhpv=0) | (dxlbc==99 & dxhpv=0) | (dxlbc>=2 &
dxlbc<=3 & dxhpv>90))
replace clingroup=4 if  clingroup=. & prescr==l
replace clingroup=5 if  clingroup=. & prescr=2
replace clingroup=6 if  clingroup=. & prescr=0
replace clingroup=10 if  e v a l= l & clingroup=.
lab var clingroup "Clinical management groups" 
lab drop clingroup
lab def clingroup 1 Cryo 2 Colp 3 "HSIL Colp" 4 "Cryo aft 2nd sa" 5 "Colp aft 2nd sa" 
6 Neg 10"Full eval/incomp screen" 
lab val clingroup clingroup
egen n_cg=sum(finwe), by(clingroup) 
egen n_eval=sum(finwe*eval), by(clingroup) 
gen ipeval=n_cg/n_eval
svyset[pw=ipeval]
sort codigomu 
gen codi3=_n 
expand 2 if eval~=l 
sort codi3 
gen hg=hgsil
qui by codi3:replace hg=_n-l if eval— 0 
gen wei=eval 
gen nohg=l-hg
egen fit3=mean(hgsil), by(via_mml lbc6 hpvl) 
egen fit30=mean(hgsil) if  lbc6=4, by(lbc6) 
replace fit3=fit30 if f it3 = .
gen wei3=l
replace wei3=fit3 if eva l= 0  & h g = l
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replace wei3=(l-fit3) if eval= 0  & hg=Q  
gen peso3=finwe*wei3
xiisvylogit hgsil i.via_mml i.cch_o_lb i.lbc6 i.hpvl i.via_lbhg i.via_hpv i.lbhg_hpv,
subpop(norescr)
predict fitnor if  norescr==l
count if fitnor= .
egen fitnorO=mean(hgsil), by (clingroup via_ml) 
replace fitnor=fitnorO if fitnor= .
xiisvylogit hgsil i.hpv2, subpop(rescreen) 
predict fitres if  rescreen= l 
count if fitres==
egen fitresO=mean(hgsil), by (clingroup via_ml) 
replace fitres=fitresO if fitres= .
gen fitfin=cond(norescr==l, fitnor, fitres)
replace wei=fitfin if eva l= 0  & h g = l  
replace wei=(l-fitfin) if  eval= 0  & hg==0
gen pesol=finwe*wei
gen wei2=eval
xiisvylogit hgsil i.via_mml i.cch_o_lb i.lbc6 i.hpvl i.via_lbhg i.via_hpv i.lbhg_hpv 
predict fit 
count if  f i t= .
egen fitO=mean(hgsil), by (clingroup vial) 
replace fit=fitO if f i t= .
replace wei2=fit if eva l= 0  & hg==l 
replace wei2=(l-fit) if eva l= 0  & h g = 0
gen peso2=finwe*wei2
global rlist ""
foreach i of numlist 1/3 { 
sum hg [iw=peso'i'], mean 
scalar nhg=r(mean)*r(sum_w) 
sum nohg [iw=peso'i’], mean 
scalar nonhg=r(mean)*r(sum_w)
foreach test in vial viamcom lbclow lbchsil hpvl vialbhg vialblo viahpv{ 
sum 'test' [iw=peso'i'] if h g = l ,  mean 
scalar se'i'_'test-(r(mean)*r(sum_w))/nhg
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sum 'test' [iw=peso'i'] if h g = 0 , mean 
scalar sp 'i'_ 'test-1 -(r(mean)*r(sum_w)/nonhg) 
sum hg [iw=peso'i'] if 'test!= l ,  mean 
scalar p'i'_'test'=r(mean) 
global rlist ,f$rlist se'i'_'test,=r(s'i'_'tesf) s p 'i '^ te s f^ s p 'i '^ te s f )
p 'i ,_'tesf=r(p'i'_'test,)M
}
}
end
drop all
use sens
Code used to calculate confidence intervals of sensitivity, specificity and PPV after 
estimating screening tests results and disease status in women with imcomplete 
screening or women not fully evaluated.
prog bootests 
version 8.0 
tempname sim
postfile 'sim* $rlist0 using results3a, replace 
set seed 123456 
quietly {
forvalues i =1/10 { 
u simul, clear 
bsample 
cal_eff4
post 'sim* $rlistl
}
}
postclose 'sim* 
end
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